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ABSTRACT
The new paradigm is that cancers may originate from stem cells, and that terminal
differentiation of stem cells is a possible treatment for cancers. Understanding the origin of
cancers requires elucidation of factors causing genetic rearrangements. The first part of this
thesis explores the effects of NO' on homologous recombination in embryonic stem cells.
Using terminal differentiation of stem cells as a therapy for cancer necessitates an
understanding of factors governing their differentiation. The second part of this thesis
explores the effects of heparan sulfate glycosaminoglycans (HSGAGs) on stem cell
differentiation.
Inflammation is increasingly recognized as an important risk factor for cancer. During
inflammation, macrophages secrete NO', which reacts with superoxide or oxygen to produce
ONOO- or N20 3, respectively. Although ONOO- and N203 are potent DNA damaging agents,
little was known about the ability of these agents to induce homologous recombination in
mammalian cells. Homologous recombination events are a significant source of mutations
that are likely to contribute to initiation and progression of some cancers. In the first part of
this thesis, the recombinogenic potential of ONOO- and N20 3 was characterized by sister
chromatid exchanges, chromosomal direct repeat substrate and interplasmid recombination
assays. Our results show that on a per lesion basis, ONOO--induced oxidative base lesions
and single strand breaks are more recombinogenic than N20 3-induced base deamination
products. These results are in accordance with the model that ONOO-induced recombination
may contribute to inflammation-induced cancer.
Directed differentiation of stem cells holds an immense potential for regenerative medicine
as well as cancer therapy. Such therapeutic approaches require an understanding of the
mechanisms regulating stem cell differentiation. The second part of this thesis investigates
the role of HSGAGs in embryonic stem cell differentiation into endothelial cells.
Differentiation of stem cells was accompanied by increases in the transcript levels of key
HSGAG-biosynthetic enzymes, and the quantity of cell surface HSGAGs. Differentiation
into endothelial cells was inhibited by ablation of the HSGAG-biosynthetic machinery by
chlorate treatment, or by the enzymatic degradation of the HSGAGs. Exogenous addition of
heparin to chlorate-treated cells partially restored differentiation into endothelial cells. These
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effects were mirrored in phospho-ERK levels, suggesting the involvement of the MAPK
pathway. These results suggest that stem cell differentiation can be regulated by modulating
the HSGAG moiety and this opens up new treatment modalities for cancer therapy and
regenerative medicine.
Thesis Co-Supervisor: Bevin P. Engelward
Title: Associate Professor of Biological Engineering
Thesis Co-Supervisor: Ram Sasisekharan
Title: Professor of Biological Engineering
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CHAPTER 1
Introduction
1.1 Inflammation and Cancer
More than a century ago, in 1863, Rudolf Virchow for the first time made a
connection between inflammation and cancer by hypothesizing that the origin of cancer was
at sites of inflammation (1). Today, it is widely believed that increased risk of malignancy is
associated with chronic inflammation (2, 3). It is estimated that -15% of cancer cases
worldwide are attributable to infectious diseases, many of which induce chronic
inflammation (4, 5). Some examples of strong epidemiological associations of chronic
inflammation and cancer include the association between colon carcinogenesis and
inflammatory bowel disease, the association between liver carcinoma and Hepatitis C
infection, and the association between bladder and colon carcinoma and schistosomiasis (6).
Moreover, Helicobacterpylori infection is demonstrated to be a carcinogen of gastric cancer
and it is known to be the leading cause of stomach cancer. More examples of epidemiological
associations of chronic inflammation and cancer are presented in Table 1.1.
In inflamed tissues, a variety of immune system cells, including basophils,
eosinophils, lymphocytes, neutrophils and macrophages are recruited and are activated to
produce potent cytotoxic agents, primarily to destroy the invading pathogens and foreign
bodies and tumor cells. These cytotoxic agents include various reactive oxygen and nitrogen
species such as superoxide, hydrogen peroxide, nitric oxide (NO), and the secondary
products that result from the reaction of NO with oxygen and superoxide (discussed in detail
below). Under some circumstances, inflammation lasts for prolonged periods of time,
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extending to months and sometimes to years, during which time not only the invading
pathogens and foreign bodies, but also the host cells are exposed to high levels of cytotoxic
reactive oxygen and nitrogen species. These reactive oxygen and nitrogen species have been
shown to induce DNA lesions and mutations under various experimental conditions (e.g., see
references (7-13). Although the underlying mechanism of inflammation-induced cancer is
not yet fully understood, it has been proposed that the DNA damage and mutations produced
by these reactive oxygen and nitrogen species are one of the main causes of initiation and
progression of cancer (14-1 7). One example is gastric cancer caused by Helicobacterpylori,
where DNA damage resulting from chronic inflammation is believed to be a major
mechanism of induction and progression of disease (18). Much work has been focused on
understanding NO' induced DNA damage and mutations.
1.2 Nitric Oxide
NO' is a free radical gas with multiple biological functions. With its electrically
neutral charge and small size, it can freely diffuse through cell membranes and act as a
signaling molecule in diverse biological processes. On the other hand, it is a radical with an
unpaired electron, and it readily reacts with various molecules to form products that are toxic
to a cell (for reviews see (19-22)). For example, NO' can react with oxygen or superoxide to
form nitrous anhydride (N203) or peroxynitrite (ONOO-), respectively, which have been
shown to be genotoxic agents (for reviews see references (23,24)). The fate of NO and its
biological effects are determined by many factors, which include (1) the physicochemical
factors such as the rate of NO' production, the rate of NO diffusion and the distances
between NO' generator cells and the target cells; and (2) the chemical and biochemical
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factors, such as the concentration of oxygen and superoxide, the concentration of catalase
and superoxide dismutase, and the levels of antioxidants such as glutathione (25, 26).
Depending on the combination of all these factors, NO' acts either as a signaling molecule,
facilitating inter-cellular and intra-cellular signaling events in various biological processes, or
as a cytotoxic agent, used by the immune cells in host defense.
NO' is synthesized from L-arginine by a family of isoenzymes called NO' synthases
(27). In mammals, there are three known types of nitric oxide synthases, nNOS (neuronal
NOS), eNOS (endothelial NOS), and iNOS (inducible NOS). eNOS and nNOS are
constitutively expressed enzymes, and the low concentrations of NO' (-nM) released by
these enzymes are known to play important roles in cellular signaling in cardiovascular and
nervous systems, including processes such as vasodilation and neurotransmission and blood
pressure regulation. In contrast to eNOS and nNOS, iNOS is an inducible enzyme. Under
immunological stimuli, iNOS is induced, and NO' is released for potentially long periods of
time, resulting in high concentration of NO (steady state levels of -1 gM) in the surrounding
tissue (28-30). At these high concentrations, NO' has been shown to be a cytotoxic agent.
iNOS was initially discovered in macrophages, which are among the cells of
mammalian immune system. Consistently, NO' plays a particularly important role in host
defense. During an immune or inflammatory response, iNOS is induced by interferon-y (31),
leading to continuous production of NO' by macrophages for days or weeks (32-35). In
addition to NO', macrophages also secrete various other species, such as reactive oxygen
species (i.e., superoxide and hydrogen peroxide), FAS ligand, tumor necrosis factor, and
various cytokines and chemokines (e.g., interleukins and interferon-y) (6, 17, 23, 26). Among
these species, NO' is believed to be a key mediator of macrophage-induced cytotoxicity,
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based on the observation that NO' scavengers inhibit the cytotoxic effects of macrophages
(33, 36). In some cases, inflammation continues for prolonged periods of time, extending to
months or years. Under these circumstances, the host tissue inevitably gets exposed to
cytotoxic levels of NO' and reactive oxygen species. Under these circumstances, significant
levels of tissue damage are generated by high levels of NO' and reactive oxygen species.
Interestingly, formation of high levels of NO' in the presence of reactive oxygen species has
been associated with a variety of human pathologies, including atherosclerosis, rheumatoid
arthritis, neurodegenerative diseases and cancer (37).
1.3 Nitric Oxide induced DNA Damage and Mutagenesis
NO' chemistry in biological systems is extremely complex due to the large number of
the chemical species formed. Although NO' itself is a reactive radical gas and it may be
involved with Fenton chemistry and hydroxyl radical induced DNA damage (24), the
genotoxicity of NO' predominantly arises from its derivatives, nitrous anhydride (N2 0 3) and
peroxynitrite (ONOO-), which are the dominant reactive nitrogen species formed under
physiological conditions (23, 26). The predominant types of DNA damages and point
mutations produced by N20 3 and ONOO- (and ONOOCO2-) are summarized in Figure 1.1
and are explained in more detail below.
1.3.1 Nitrous Anhydride (N203)
N20 3 is formed from the oxidation of NO' with molecular oxygen at physiological pH
(38). The rate of formation of N203 has been shown to be second order in NO' concentration
and first order in oxygen, with a rate constant of 8.4 x 106 M 2 s- at 370 C (28). Thus, the half
life of NO' is inversely proportional to its concentration, such that as the NO' concentration
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increases, the rate of its turnover to N 203 increases proportionally in a second order manner.
Hence, under conditions such as chronic inflammation, where elevated level of NO are
secreted by the immune system cells for prolonged periods of time, NO' rapidly reacts with
oxygen to form N20 3.
N203 is a potent DNA deaminating agent and a minor DNA crosslinking agent. At
physiological pH, it is involved in conversion of cytosine to uracil, guanine to xanthine,
adenine to hypoxanthine, 5-methylcytosine to thymine, and there is evidence that N20 3
generates low levels of G-G cross-links (15, 26, 39-43). Studies conducted under
physiological conditions suggest that uracil, guanine to xanthine constitute most of the DNA
damage induced by N20 3 (25-35% each) in an inflamed tissue. Only 4-6% of the total
damage is made up of abasic sites and -2% is made up of G-G cross-links (7, 23, 43).
The deamination of DNA bases with N203 has potential mutagenic consequences. For
example, mispairing of xanthine can cause G:C A:T transition mutation. Alternatively,
xanthine can depurinate and can lead to non-informative mutagenic lesions. For example, an
adenine may be inserted opposite to the abasic site, leading to a G:C T:A transversion
mutation. In addition, mispairing of uracil can cause a G:C A:T transition mutation, and
mispairing of hypoxanthine can cause A:T G:C transition mutation. All these mutations
have been detected in various mammalian cells exposed to conditions in which N203 was
generated (44-47).
1.3.2 Peroxynitrite (ONOO)
During inflammation, activated macrophages generate superoxide in addition to NO'.
These two radicals react rapidly with one another to generate ONOO-. The rate constant of
this reaction is known to be between 6.6-19 x 109 M l s ' at 370 C, which is in the range of
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diffusion-controlled limit (48-50). In the presence of bicarbonate, such as in physiological
systems, ONOO- further reacts with bicarbonate, in a bimolecular reaction with a rate
constant of 3-6 x 104 M -1 s 'l, to form nitrosoperoxycarbonate (ONOOCO2-) (51-53). Both
ONOO- and ONOOCO2- are capable of conducting 1- and 2-electron chemistry, including
oxidations and nitrations (51, 52).
ONOO- is a potent DNA oxidizing agent, which is primarily involved in oxidation of
guanine and oxidative breakdown of deoxyribose. The reaction of ONOO- with guanine
produces a variety of primary and secondary base lesions. The primarily lesions created
include 8-oxoguanine (8-oxoG) and 8-nitroguanine (8-nitroG) (15, 26, 54, 55). Formation of
oxazolone (56), 5-guanidino-4-nitroimidazole (57), and 4,5-dihydro-5-hydroxy-4-(nitrooxy)-
2'-deoxyguanosine (58) has also been reported. It is has been shown that ONOO- is at least
1000-fold more reactive with 8-oxoG than guanine itself (61), and further reaction of 8-oxoG
with ONOO- leads to the formation of a variety of secondary products, including
spiroiminodihydantoin, guanidinohydantoin, 3a-hydroxy-5-imino-3,3a,4,5-tetrahydro-lH-
imidazo[4,5-d]imidazol-2-one, 5-iminoimidazolidine-2,4-dione, 2,4,6-trioxo-[1,3,5]-
triazinane- 1-carboxamidine, parabinic acid, oxaluric acid cyanuric acid, and others (for
reviews see (23, 26)). In addition to these primary and secondary oxidative base lesions,
ONOO- also induces direct single strand breaks in DNA via the oxidative breakdown of
deoxyribose (54, 59, 60).
It has been shown that the proportions of base lesions to strand breaks induced by
ONOO- depends on the presence of bicarbonate (60, 62). For example, in the absence of
bicarbonate, ONOO- predominantly causes strand breaks. However in the presence of
bicarbonate, ONOO- is converted into ONOOC02-, and ONOOC02- predominantly causes
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base damage with a significant increase in 8-nitroG. Although, bicarbonate shifts the
proportion of strand breaks to base damage, the total quantity of lesions remains constant.
ONOO- has been shown to be mutagenic both in bacterial and mammalian systems (9,
63). In previous studies, most of the mutations have been shown to occur at the G:C base
pairs, leading predominantly to G:C T:A transversion mutations. However, G:C C:G
transversion mutations and G:C A:T transition mutations have also been also detected. In
addition to these point mutations, ONOO- has also been shown to cause deletion and
insertion type mutations (63).
In short, both N203 and ONOO- have been shown to be mutagenic in mammalian
cells, and the DNA damage and the resulting mutagenecity of reactive nitrogen species
generated during inflammation has been proposed to be a mechanism of induction and
progression of cancer. While NO'-induced point mutations have been studied extensively, as
described above, very little is known about the ability of NO' to induce other classes of
mutations, such as sequence rearrangements that are mediated by homologous
recombination.
1.4 Homologous Recombination
Mitotic homologous recombination (HR) is one of the most important mechanisms
that cells use to defend against DNA damage-induced toxicity. During HR, missing sequence
information is extracted from a sister chromatid or from a homologous chromosome (64-67).
HR is used to repair double-strand breaks (DSB), especially during the S and G2 phases of
cell cycle (68-70). Importantly, it has been shown that in mammals, proteins that are key for
homologous recombination are essential for life itself (71-73).
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1.4.1. Classes and Sources of Lesions that Induce Homologous Recombination
Homologous recombination is best characterized for repair of DSB. A DSB in DNA
may be formed via replication independent or dependent mechanisms.
Replication independent DSBs are two-ended (Figure 1.1A), such as those formed by
ionizing radiation. Alternatively, replication-independent DSBs can be formed from
proximity of two single strand breaks on the opposing strands of DNA. For example, single
strand breaks are created enzymatically, as repair intermediates, during base excision repair
(BER). Consequently, if DNA glycosylases initiate BER of closely opposed lesions,
recombinogenic DSBs can be formed (74, 75) (Figure 1.lB).
Replication-dependent DSBs are one-ended. One of the mechanisms by which one-
ended DSBs are formed is via collapse of a replication fork at a nick in the template DNA
(Figure 1.1C). Nicks in the template DNA can be formed directly by strand break-inducing
agents or as intermediates of DNA repair pathways. For example, during base excision repair
(BER), single strand breaks may be created as repair intermediates, and when encountered by
a replication fork, they may form highly recombinogenic one-ended DSBs. Such BER
intermediates have been shown to be highly recombinogenic in S.cerevisiae (76-78) (Figure
1. D). One-ended DSBs may also be formed when a replication fork encounters a blocking
DNA lesion in the leading strand (Figure 1. E). It has been shown in E.coli that inhibition of
replication fork progression induces one-ended DSBs that are repaired by homologous
recombination (65, 79). Alternatively, a blocking lesion could be formed in the lagging
strand. It has been proposed that a blocking lesion in the lagging strand would result in the
formation of a single strand region called a daughter strand gap (Figure 1. F). Although not
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completely understood, daughter strand gaps are thought to be repaired by homologous
recombination.
1.4.2 Mechanisms of Homologous Recombination
Much of what we know about the mechanisms of recombination in eukaryotes comes
from studies of S. cerevisiae (for extensive reviews see (80-82)). Mechanisms of homologous
recombination are thought to be conserved from yeast to mammals (69, 83). Repair of DSBs
is thought to happen through three classes of recombination events: single strand annealing
(SSA), gene conversion (GC), and break-induced replication (BIR).
When a two-ended DSB is flanked by homologous sequences, it can be repaired via
SSA. For SSA, initially the ends of the double strand breaks are resected 5'-to-3'. Following
resection, the homologous 3' overhangs anneal and the gaps are filled (Figure 1.2A). This
way, the DSB is repaired, albeit with the loss of significant genetic information, including
one of the repeats (80).
Most homologous recombination events are GC events where information is
transferred from one molecule to another in a non-reciprocal fashion without loss of
sequence information (reviewed in (68)). In the prototypic recombinational repair model, as
originally proposed by Szostak (84), initially the ends of the DBS are resected 5'-to-3'
forming 3' overhangs. The 3' overhang then invades a homologous sequence (e.g., from a
sister chromatid or a homologous chromosome), and are extended by the initiation of new
DNA synthesis (Figure 1.2B). This leads to the formation of two Holliday junctions, which
can then be resolved in two different ways. Depending on which strands are cleaved, a GC
event occurs either with crossing over or without crossing over of the flanking sequences.
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This model predicts an equal number of crossing over and non-crossing over events.
However, it is now known that most GC events occurs without crossing over events, which
can not be explained with the traditional Szostak model (85). More recently, synthesis
dependent strand annealing (SDSA), has been proposed to explain GC events that are not
associated with crossing over of flanking sequences (80). SDSA is initiated similarly to the
prototypic Szostak model. The main difference is that, in SDSA only one end of the resected
double strand break end is required to invade the homologous DNA to form the D loop
(Figure 1.2C). The second end does not necessarily bind to the D loop. Instead, once the
missing sequence is restored, the Holliday junction is moved to release the first end, which
then anneals to the 3' overhang of the non-invading double strand break end via a process
similar to SSA. In this model there is no cleavage of the Holliday junction, thus crossing over
events are prevented.
Both SSA and GC mechanisms are used to repair two-ended double strand breaks. A
third pathway of homologous recombination exists, which is used to repair one-ended DSBs
that are formed from broken replication forks. This mechanism is known as break-induced
replication (BIR) (66). As is the case for SSA and GC mechanisms, in BIR, the initial step is
again the 5'-to- 3' recession of the DSB. The 3' overhang then invades the homologous
DNA, forming a Holliday junction (Figure 1.2D). This leading strand is then extended by
synthesis of new DNA using the homologous sequence as a template. This is followed by the
resolution of the Holliday junction to complete the process of restoring the broken replication
fork.
Although homologous recombination takes place via all three pathways described
above, it is noteworthy that in mammals, most two-ended DSBs are repaired by non-
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homologous end joining (NHEJ). In NHEJ, the two broken ends are processed and rejoined
to each other with some loss of sequence information (86, 87). Unlike two-ended DSBs, one-
ended DSBs can only be repaired via the BIR pathway. Thus, homologous recombination is a
particularly important and indispensable repair pathway for mammals, especially in the
context of DSBs induced during replication.
1.4.3 Proteins involved in Homologous Recombination
Most of the proteins involved in homologous recombination were first identified by
their requirement for the repair of ionizing-radiation-induced DNA damage in
Saccharomyces cerevisiae. In yeast these proteins belong to the RAD52 group genes, which
include, RAD50, RAD51, RAD52, RAD54, RDH54, RAD55, RAD57, RAD59, MRE11, and
XRS2 (88). This repair pathway is thought to be evolutionarily conserved in higher
organisms, as indicated by the fact that homologs of these genes can be found in mammals
(for reviews see references (67, 83)). Mammalian homologues of essentially all these genes
have been described (89), and these include Rad51, Rad52, Rad54, Rad5O, Nbsl(Xrs2) and
Mrel 1, as well as the five Rad51 paralogs, Xrcc2, Xrcc3, Rad51B/Rad51L1,
Rad51C/Rad51L2, and Rad51D/Rad51L3 (88, 90).
The role of the Rad52 epistasis group proteins in homologous recombination has been
reviewed in great detail (68, 69, 88, 91, 92) and the current understanding that has emerged is
briefly summarized here. In all of the mechanisms of homologous recombination described
above, repair of the double strand breaks is initiated with the re-dissection of the double
strand break to generate 3' overhangs. In mammals, this process is initiated by the Mrel 1/
Rad50/ Nbsl complex, and an as yet unidentified exonuclease ressects the break to generate
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a single strand 3' overhang (93, 94). The single stranded DNA is then bound with Rad51
which forms proteo-filaments around the single-stranded DNA. The binding of Rad5 1 is
stimulated by the initial binding of Replication Protein A (RPA) and Rad52 to the single
stranded DNA (95-98). RPA is thought to stabilize the single stranded DNA, while Rad52
helps load Rad5 1 (99). Rad5 1 catalyzes homology searching, strand invasion and strand
exchange (100). Strand exchange is enhanced by Rad54, which is a member of the Swi2/Snf2
family of chromatin-remodeling protein and is thought to move nucleosomes to assist in
homology searching and strand displacement to form a D-loop (101). Although the Holliday
junctions are thought to be cleaved by resolvases, the proteins involved in branch migration
and resolution have yet not been identified in eukaryotes. However, a role for Mus81
endonuclease complex in cleaving Holliday junctions was proposed (65), and Rad5 1C was
recently shown to play a role in junction resolution (102).
Studies of mouse models with defective recombination genes and studies of
mammalian cell lines also support the significant role of the above mentioned proteins in
mammals. For example, Rad5 1 appears to be one of the most critical protein in mammals,
based on the observation that Rad51 /' mutant mice die early during embryonic development
(71). Moreover, Rad51 deficient cells accumulate chromosomal breaks when cultured and do
not survive more than a few cell divisions (103). Similar to Rad51, Rad50 and Mrel 1 genes
also seem to be critical for mammals, since RadSO/ is embryonic lethal in mice and RadSO/
Mrel 1-/ mouse cells do not survive in culture (69). In Rad54 /' mouse embryonic stem cells,
a 30% decrease in sister chromatid recombination was observed showing that Rad 54 plays a
significant role in recombination (104). Finally, it has been shown that cell lines that contain
defects in the Rad5 1 paralogs, Xrcc2 and Xrcc3 have significantly lower levels of
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recombination and a high level of genomic instability, showing the involvement of these
proteins in homologous recombination and genomic stability (105-108).
1.5 Homologous Recombination and Cancer
Although homologous recombination is generally accurate and important for genomic
stability, transfer of genetic material carries with it a certain amount of risk. Approximately
one-third of the mammalian genome is composed of highly repeated DNA sequences (for
review see (109, 110)), and recombination between misaligned sequences can lead to genetic
rearrangements such as insertions, deletions, inversions and translocations (Figure 1.3A). In
addition, exchanges between homologous chromosomes are responsible for causing most
spontaneous loss of heterozygosity events in mammals (111-115) (Figure 1.3B). These
genetic rearrangements may contribute to the development of diseases and put cells at risk of
developing diseases such as cancer.
Several associations with cancer and homologous recombination have been made.
Nearly all tumors show LOH and other types of sequence rearrangements that are likely to
result from mitotic homologous recombination. For example, cancers including chronic
myelogeneous leukemia, Ewing's sarcoma and breast cancer have been associated with
mitotic recombination events involving misaligned Alu sequences (116, 117). In addition, it
is known that one of the causes of acute myeloid leukemia is the partial duplication of the
ALL-1 gene that results from a misaligned recombination event between repetitive Alu
sequences (118). Moreover, it has been shown, in yeast, human cells and mice that many
known carcinogens are also recombinogens (for a review see references (119, 120)).
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Consistent with the association between tumor cells and recombination events,
patients whose cells have an increased frequency of recombination have an elevated
frequency of cancer (reviewed in ref (121, 122)). For example, people with Bloom's
syndrome are defective in the BLM helicase. A defect in BLM helicase results in elevated
levels of sister chromatid exchanges, hyper recombination and chromosomal aberrations
(123). These patients are prone to cancer and it has been indicated that one in nine Bloom's
patients develop malignancies by the age of 20 (124). Another example can be provided by
ataxia-telangectasia (AT) syndrome which is caused by a mutation in ATM. Patients of AT
show a predisposition to cancer. Cells from these patients show an increased susceptibility to
homologous recombination, which may contribute to their predisposition to cancer (125,
126). Lastly, Li-Fraumeni syndrome patients that carry a recessive mutation in TP53 have
been shown to have an early onset of cancer such as carcinomas of breast, sarcomas, brain
tumors, leukemia and lymphoma (127). Although the relationship between p53 and
homologous recombination is yet not clearly understood, many studies show that cells
lacking p53 have higher frequency of homologous recombination (128-130).
In summary, all the above examples suggest that, whether by exposure to endogenous
and environmental recombinogens, or by inherited predisposition, conditions that lead to
increased levels of homologous recombination are associated with an increased risk of
cancer.
1.6 NO' and Homologous Recombination
At the time when this work was begun, there were almost no studies exploring the
recombinogenicity of NO' in mammals. However, there were a few studies suggesting that
30
NO' may induce recombination in mammalian cells. For example, patients who suffer from
chronic inflammation associated with Crohn's Disease have increased levels of sister
chromatid exchanges (SCEs) in their lymphocytes (131), though it is not known to what
extent NO' is responsible for this effect. In addition, two studies have shown that mammalian
cells exposed to chemicals that give rise to NO' ('NO' donors') suffer increased levels of
SCEs (132, 133), though the NO' donors used in these studies also give rise to additional
potentially recombinogenic radical species. The observation that mammalian cells exposed to
NO' have an increased susceptibility to LOH provides additional support for the possibility
that NO' induces recombination (10). Taken together, these observations suggest that NO'
may induce homologous recombination in mammalian cells.
Although double strand breaks are thought to be critical for inducing homologous
recombination, in vitro studies using purified DNA have shown that neither N203, nor
ONOO- efficiently creates double strand breaks by direct reaction with DNA (59, 134, 135).
However, as described in the previous sections, base lesions, abasic sites, and single strand
breaks can be converted into double strand breaks by enzymatic processing or when they are
encountered by the replication fork. For example, during base excision repair (BER), single
strand breaks are created as repair intermediates. Consequently, if DNA glycosylases initiate
BER of closely opposed lesions, recombinogenic double strand breaks can be formed (74,
75). Alternatively, DNA lesions that inhibit replication fork progression, such as BER
intermediates, are highly recombinogenic (e.g., references (76-78, 136)). Indeed, previous
work has demonstrated that NO' induces recombination in E. coli, and DNA glycosylases
promote this NO'-induced recombination in E. coli, presumably by converting base lesions
into recombinogenic BER intermediates (137, 138). These results suggest that, as
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demonstrated in E. coli, N20 3 and ONOO- created DNA lesions may also be converted into
recombinogenic double strand breaks and cause induction of recombination in mammalian
cells.
1.7 Specific Objectives
It is well established that there is an association between inflammation and increased
risk of cancer, and it is proposed NO' induced DNA damage plays a key role in initiation and
progression of cancer. It is also well established that there is an association between elevated
levels of homologous recombination and increased risk of cancer, and it has been shown that
most known carcinogens are also recombinogens. While NO'-induced point mutations have
been studied extensively, very little was known about the ability of NO' to induce other
classes of mutations, such as sequence rearrangements that are mediated by homologous
recombination in mammalian cells. Thus, the aim of this work has been to reveal the
relationship of NO' and homologous recombination in mammalian cells. Specifically, tools
were developed to study homologous recombination in mammalian cells and these tools were
used to dissect the relative recombinogenicity of reactive nitrogen species. Furthermore, we
set out to delineate the classes of recombinogenic DNA lesions. Our results show that NO'
generated peroxynitrite is a potent inducer of recombination in mammalian cells, which
suggest that ONOO-induced recombinogenic DNA damage may play an important role in
inflammation-induced cancers. The next chapter explains the strategy, results and the impacts
of our findings in more detail.
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Figure 1.1. Schematics of the types of DNA lesions and point mutations induced by Nitric
Oxide. Under physiological conditions Nitrous Anhydride and Peroxynitrite/ Nitroso-
peroxycarbonate are the two predominant reactive nitrogen species (RNS) formed from NO'.
The major classes of DNA lesions and the point mutations formed by these RNS are shown.
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Strand Break
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Figure 1.2. Classes of DNA lesions that induce homologous recombination. Replication
independent mechanisms (A-B). Replication dependent mechanisms (C-F). (A) Two-ended
double strand break can be directly formed, or can be formed from the proximity of two
single strand breaks. (B) Two-ended double strand break can be formed from base excision
repair intermediates. (C) Nicks can be converted to a one-ended double strand break when
encountered by a replication fork. (D) Base damage can be converted into a nick as an
intermediate of base excision repair, which can then be converted to a one-ended double
strand break when encountered by a replication fork. (E) Inhibition of leading strand
synthesis by a blocking lesion causes replication fork collapse forming a one-ended double
strand break. (F) Inhibition of lagging strand synthesis by a blocking lesion leads to the
formation of a daughter strand gap.
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Figure 1.2. Mechanisms of Homologous Recombination. (A) Single Strand Annealing. The
end of the double strand breaks are dissected till overhangs with significant sequence
homology is reached. The homologous 3' overhangs are then annealed to restore intact
duplex DNA. (B) Szostak Model. The ends of the DBS are resected forming 3' overhangs
which then invade a homologous sequence. New DNA synthesis from the 3' overhangs leads
to the formation of two Holliday junctions. Depending how these junctions are resolved, a
GC event occurs either with crossing over or without crossing over. (C) Synthesis Dependent
Strand Annealing (SDSA). The ends of the DBS are resected forming 3' overhangs. One of
the overhangs invade the dublex initiating synthesis of new DNA. Once the missing
information is restored, the invading strand is displaced and anneals to the 3' overhang of the
other end enabling the synthesis of the missing information. No crossover events are
associated with SDSA. (D) Break Induced Replication (BIR).The initial step is again the
recession of the DSB end. The 3' overhang then invades the homologous DNA, forming a
Holliday junction and enabling the synthesis of new DNA. The holliday junction is then
resolved to complete the process. Figures are adapted from (80,81).
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Figure 1.3. Some examples of Gene Rearrangements that may result from homologous
recombination. (A) Deletions and insertions may result from misaligned BIR pathway.
(B) Schematics of how a crossover event during homologous recombination can lead to loss
of heterozygosity (LOH). If the crossover event takes place between a mutant and a WT
version of a gene, one of the daughter cells may end up with two copies of the mutated gene.
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Neoplasm Aetiologic agent
Bladder, liver, rectal carcinoma, Schistosomiasis
follicular lymphoma of the Spleen
Cervical carcinoma Papillomavirus
Ovarian carcinoma Pelvic inflammatory disease
Gastric adenocarcinoma, mucosa Helicobacterpylori
associated lymphoid tissue lymphoma
Mesothelioma carcinoma Asbestos
Lung, bronchial carcinoma Silica, asbestos, smoking
Kaposi's sarcoma Human herpesvirus type 8
Colorectal carcinoma Inflammatory bowel disease, Crohn's disease,
chronic ulcerative colitis
Oesophageal carcinoma Barret's metaplasia,
Hepatocellular carcinoma Hepatitis virus B and /or C
Cholangiosarcoma, colon carcinoma Liver flukes, bile acids
Modified from (1,6)
Table 1.1. Examples of associations between
conditions and Neoplasms
Infectious and Chronic Inflammatory
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CHAPTER 2
Delineation of the Chemical Pathways Underlying
Nitric Oxide-Induced Homologous Recombination
in Mammalian Cells
Synopsis: Inflammation is an important risk factor for cancer. During inflammation,
macrophages secrete NO', which reacts with superoxide or oxygen to create ONOO- or N203,
respectively. Although homologous recombination causes sequence rearrangements that
promote cancer, little was known about the ability of ONOO- and N203 to induce
recombination in mammalian cells. Here, we show that while ONOO- is a potent inducer of
homologous recombination, N20 3 is at most only weakly recombinogenic. Furthermore, on a
per lesion basis, ONOO-induced oxidative base lesions and single strand breaks are far more
recombinogenic than N20 3-induced deamination products. Similar results were observed in
mammalian cells from two different species, suggesting that the relative recombinogenicity
of ONOO- and N203 is highly conserved in mammals. These results suggest that ONOO--
induced recombination may be an important underlying mechanism of inflammation-induced
cancer.
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CHAPTER 2
Delineation of the Chemical Pathways Underlying
Nitric Oxide-Induced Homologous Recombination
in Mammalian Cells
2.1 Introduction
Nitric oxide (NO) is a key mediator of diverse biological processes, including
vasodilation, neurotransmission, endotoxic shock, cerebral ischemia, and inflammation (1-3).
At low concentrations, NO' is involved in intra- and inter-cellular signaling, while at high
concentrations NO' is toxic (4-6). As a cytotoxic agent, NO' is secreted by activated
macrophages, along with oxygen radicals and other cytotoxic chemicals during the
inflammatory response. Importantly, tissue inflammation associated with gastritis, hepatitis,
and colitis is an important risk factor for a variety of human cancers, such as gastric cancer,
liver cancer and cholangiocarcinoma (7). Furthermore, it is estimated that -15% of cancer
cases worldwide are attributable to infectious diseases, many of which induce chronic
inflammation (8). Although the underlying mechanism of inflammation-induced cancer is not
yet fully understood, exposure of tissues to reactive oxygen and nitrogen species is thought to
cause mutations and genetic rearrangements that contribute to tumor initiation and
progression. While NO'-induced point mutations have been studied extensively (e.g., see
references (9-11)), very little is known about the ability of NO to induce other classes of
mutations, such as sequence rearrangements that are mediated by homologous
recombination.
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Mitotic homologous recombination allows cells to repair DNA double strand breaks
by extracting missing sequence information from a sister chromatid (during S and G2 phases
of cell cycle) or from a homologous chromosome. In addition, homologous recombination
plays a critical role in restoring collapsed forks during DNA replication (for excellent
reviews of homologous recombination, see references (12-14)). Although homologous
recombination is generally highly accurate, transfer of genetic material carries with it a finite
risk, since recombination between misaligned sequences can lead to insertions, deletions,
inversions and translocations. In addition, exchanges between homologous chromosomes are
responsible for causing most spontaneous loss of heterozygosity events in mammals (15, 16).
Nearly all tumors carry sequence rearrangements that are likely the result of mitotic
homologous recombination. Consequently, whether by exposure to endogenous and
environmental recombinogens, or by inherited predisposition, conditions that lead to
increased levels of homologous recombination are associated with an increased risk of cancer
(17-19).
Very little is known about the recombinogenicity of NO' and its derivative reactive
nitrogen species in mammals. However, there are a few studies suggesting that NO' may
induce recombination in mammalian cells. For example, patients who suffer from chronic
inflammation associated with Crohn's Disease have increased levels of sister chromatid
exchanges (SCEs) in their lymphocytes (20), though it is not known to what extent NO' is
responsible for this effect. In addition, two studies have shown that mammalian cells exposed
to chemicals that give rise to NO' ('NO' donors') suffer increased levels of SCEs (21, 22),
though the NO' donors used in these studies also give rise to additional potentially
recombinogenic radical species. The observation that mammalian cells exposed to NO' have
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an increased susceptibility to loss of heterozygosity provides additional support for the
possibility that NO' induces recombination (23). Taken together, these observations suggest
that NO' may induce homologous recombination in mammalian cells. Here, we set out to
define the potential of NO to induce homologous recombination in mammalian cells, and to
explore the underlying chemistry that might be responsible for its effects.
It is well established that the recombinogenicity of a DNA damaging agent is
dependent on the types of DNA lesions that it induces. NO' reacts with oxygen and
superoxide to form N203 and ONOO-, respectively, which are the dominant reactive nitrogen
species formed under physiological conditions (Figure 2.1A). Although NO' does not directly
damage DNA, N 20 3 is a potent DNA deaminating agent, and ONOO- is a potent DNA
oxidizing agent. Most of the lesions created by N20 3 are base damages, while ONOO- attacks
both the base and sugar moities of DNA (11). For example, N203 deaminates DNA bases,
creating lesions such as uracil, hypoxanthine, and xanthine (24-27), and ONOO- oxidation of
guanine leads to 8-oxoguanine and its secondary oxidation products, 8-nitroguanine, as well
as abasic sites formed by spontaneous depurination of 8-nitroguanine (27-31). In addition to
base lesions, ONOO- also directly induces direct single strand breaks in DNA, by the
oxidative breakdown of deoxyribose (29, 32, 33).
Although double strand breaks are thought to be critical for inducing homologous
recombination, in vitro studies using purified DNA have shown that neither N20 3, nor
ONOO- efficiently creates double strand breaks by direct reaction with DNA (32, 34, 35).
However, base lesions, abasic sites, and single strand breaks can be converted into double
strand breaks by enzymatic processing (when in close proximity) or when they are
encountered by the replication fork. For example, during base excision repair (BER), single
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strand breaks may be created as repair intermediates by DNA glycosylases that have an
associated AP lyase activity or by AP endonucleases. Consequently, if DNA glycosylases
initiate BER of closely opposed lesions, double strand breaks can be formed in vitro (36).
Alternatively, DNA lesions that inhibit replication fork progression, such as BER
intermediates, are highly recombinogenic in mammalian cells (e.g., see references (37, 38)).
Indeed, previous work from this laboratory has demonstrated that DNA glycosylases promote
NO'-induced recombination in E. coli, presumably by converting BER substrates into
recombinogenic double strand breaks (39). Furthermore, studies in mammalian cells have
recently shown that glycosylases promote radiation-induced strand breaks (40).
As a first step toward revealing the underlying mechanisms of NO-induced sequence
rearrangements in mammals, we set out to reveal the chemical basis for NO'-induced
recombination in mammalian cells. Toward this end, we compared the recombinogenic
effects of the two predominant reactive nitrogen species produced under physiological
conditions: N2 0 3 and ONOO-. For example, by exposing cells to NO' and 02 gases
simultaneously in a specially designed NO' gas delivery chamber (41), the major DNA
damaging agent formed is N203. Alternatively, cells can be exposed to ONOO- using 3-
morpholinosydnonimine (SIN-1), which produces equal amounts of superoxide and NO' that
rapidly react to form ONOO-. However, in the case of the NO' delivery chamber, due to the
inevitable presence of intracellular superoxide, it is not possible to completely eliminate
formation of some ONOO-. Similarly, due to the presence 02 during SIN-1 exposure, it is not
possible to eliminate the possibility that some N20 3 is formed. Thus the NO' delivery
chamber and SIN-1, which are amenable for studies of cultured cells, provide effective
strategies for creating conditions that favor the formation of ONOO- or N203, although not
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with absolute purity. In contrast, in vitro conditions can readily be created in which plasmid
DNA is virtually exclusively exposed to either N 203 or ONOO-. Therefore, the combined
approaches of studying chromosomal recombination in cells exposed to conditions that favor
formation of either N203 or ONOO-, and studying plasmid recombination between DNA
molecules exposed to conditions that give rise to exclusively N20 3 or ONOO-, provide a
powerful strategy for elucidating the chemical nature of NO'-induced recombination in
mammalian cells.
Here, we show that exposure of mammalian cells to conditions that favor formation
of N203 is relatively weakly recombinogenic, and that N2 03-induced DNA lesions fail to
induce inter-plasmid recombination. In contrast, conditions that favored formation of ONOO-
are highly recombinogenic, both when cells are exposed and when plasmid is exposed to
ONOO and subsequently transfected into cells. By quantifying strand breaks, abasic sites,
and base lesions induced by N 203 and ONOO- in plasmid DNA, we demonstrate that
chemically-induced strand breaks and oxidative base lesions are far more recombinogenic
than deaminated base lesions, even under conditions where the quantity of N 20 3-induced
lesions exceeds that of ONOO'-induced lesions. The results of these studies contribute to our
understanding of the biological consequences of chronic inflammation and provide a
framework for delineating conditions that are most likely to lead to tumorigenic sequence
rearrangements in people.
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2.2 Experimental Procedures
Cell Culture
Mouse embryonic stem cells (J1) were maintained in DMEM containing 10% fetal
bovine serum, L-glutamine, non-essential amino acids, [-mercaptoethanol and leukocyte
inhibitory factor on gelatinized dishes without feeders. The COS-7L African Green Monkey
kidney cell line (Invitrogen) was maintained in DMEM containing 10% fetal bovine serum
and L-glutamine.
AGF Cells
Embryonic stem cells were engineered to carry a direct repeat recombination
substrate integrated at the ROSA26 locus. The design of this substrate is similar to that of the
FYDR substrate (42), except that reconstitution of full length coding sequences leads to
expression of enhanced green fluorescent protein (rather than yellow fluorescent protein).
This recombination detection system will be more fully described elsewhere (Jonnalagadda
et al., manuscript in preparation).
SIN-I Treatment of Cells
Cells were plated in complete medium 24 h prior to treatment. Cells were exposed to
the indicated doses of SIN-1 (Biomol Research Laboratories) in Dulbecco's PBS
supplemented with 25 mM sodium bicarbonate, pH 7.4, at 370 C. Exposure of cultures to air
was provided by shaking for 5 min every 10 min for 90 min, as described previously (43).
After treatment, cultures were rinsed in PBS and incubated in fresh medium.
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NO' Treatment of Cells
Cells were plated at a density of 0.5 - 2 x 106 cells per 60 mm dishes in complete
medium. After 24 h, log phase cells were exposed to 10% NO'/ 90% Ar gas mixture (BOC
Gas Co.) which was passed through 7 cm of Silastic tubing in the NO' delivery chamber, as
previously described (41). A 50% 02 / 45% N2 / 5% CO2 gas mixture (BOC Gas Co.) was
passed through a second 7 cm long tubing to maintain the 02 level in the medium. These
conditions produced steady-state levels of 02 and NO' that are approximately those that are
experienced under physiological conditions (NO' steady state levels in these experiments are
1.84 gM; physiological levels are on the order of-1 gM) (4, 44, 45). The control cells were
exposed to 100% Ar gas under the same conditions as NO' exposure. At the end of treatment,
cells were washed and incubated in fresh complete medium.
Colony Forming Assay
Following treatment with SIN-1 and NO'/0 2, cells were harvested by trypsinization,
counted and plated at a density of 100 cells/100-mm tissue culture dishes. After a week of
culture, the colonies were fixed with ethanol, stained with trypan blue, and counted.
Experiments were performed in triplicates and all experiments were performed three or more
times.
SCE Assay
J1 cells were seeded at a density of 1 x 106 per 100 mm dish for SIN-1 treatments,
and at 0.5 x 106 per 60-mm dish for NO'/O2 treatment. After 24 h, log phase cultures were
exposed to SIN-1 and NO'/0 2 as described above. After exposure, cells were washed and
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incubated in fresh McCoy's 5A media (Invitrogen) supplemented with 10 }M BrdU. After 24
hours, Colcemid (0.1 gg/ml; Invitrogen) was added to the medium for an additional 3 h.
Metaphase spreads were prepared and sister chromatids were differentially stained as
previously described (38). Experiments were performed in duplicates, and twenty metaphase
spreads were counted per data point.
Chromosomal Direct Repeat Assay
Between 0.5 and 2.5 x 105 AGF cells were seeded onto 6 well dishes for SIN-1
treatments, and onto 60 mm tissue dishes for NO/O 2 treatment. After 24 h, log phase cells
were exposed to the indicated doses of cytotoxic agents, as described above. After 72 h
(-3.25 population doublings in control cells), cells were harvested by trypsinization and
analyzed by flow cytometry to determine the frequency of fluorescent cells.
Plasmid Construction to Generate Recombination Substrates
The PstI-BamHI fragment in pCX-EGFP (gift of M. Okabe; (46)) was replaced with
a synthetic adaptor carrying NsiI, NotI, and XhoI sites to create pCX-NNX-EGFP. Full
length and truncated coding sequences were PCR amplified using primers that carry synthetic
ApoI sites and subcloned between the EcoRI sites of pCX-NNX to create pCX-NNX-A5egfp
(abbreviated as pAS5egfp) and (abbreviated as pA3egfp). The pA5egfP plasmid carries a 99 bp
deletion from the 5' end, and pA3egfp carried an 81 bp deletion from the 3' end of the open
reading frame. There are 540 bp of overlap between the deletions. Stop codons were placed
after and before these cassettes, respectively, to prevent read-through translation products.
Plasmid DNA was purified using the Qiagen plasmid purification kit. Restriction enzymes
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were from New England Biolabs. Oligonucleotides were from Amitof, Inc. (Allston, MA).
Oligonucleotide and plasmid sequences are available upon request.
ONOO-, SIN-I, and NO' treatment of plasmid DNA
ONOO- was synthesized by ozonolysis of sodium azide (47) and the concentration of
the stock solution was measured by UV immediately prior to treatment (302=1670 M-1
cmn-). Bolus exposure to ONOO- was achieved by placing a droplet of the ONOO- stock
solution on the side wall of a microcentrifuge tube containing plasmid DNA (2.5 g in 50 lIl)
in 150 mM potassium phosphate / 20 mM sodium bicarbonate buffer, pH 7.4 followed by
vigorous vortexing to mix the solutions. For SIN-i, plasmid DNA (5 jig in 100 il) was
treated in 150 mM potassium phosphate / 20 mM sodium bicarbonate buffer, pH 7.4, at 37°C
for 90 min. For NO' treatment, plasmid DNA (20 lg/ml) was exposed in the NO' delivery
chamber, under the same conditions as used for the cell exposures (see above). The NO' dose
was controlled by removing samples at various times during exposure. For all treatments,
after exposure, the DNA was recovered by ethanol precipitation, resuspended in PBS, and
quantified by UV spectrometry.
Interplasmid Recombination Assay (extracellular DNA exposure)
J1 and COS-7L cells were plated at a density of 4 x 104 cells per well in 24 well
plates. After 24 hours, 0.1 lig pA5egfp (± exposure to DNA damage), and 1 g pA3egfp
plasmids were co-lipofected into the cells by using Lipofectamine 2000 (Invitrogen) in a total
volume of 0.5 ml. To assay inhibition of EGFP expression, 0.1 g of pEGFP was treated with
the indicated doses of these agents prior to lipofection. Transfection efficiency in each
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experiment was measured by simultaneous lipofection of 0.1 fig pEGFP in three
independent samples. To keep DNA concentrations constant, 0.1 jig of damaged pLacZ
(Clontech) was used in lieu of damaged pA5egfp, and 1 gg of pLacZ was used in lieu of
pA3egfp. For all experiments, cells were trypsinized 48 h post lipofection, and analyzed by
flow cytometry to determine the frequency of fluorescent cells.
Interplasmid Recombination Assay (intracellular DNA exposure)
J1 and COS-7L cells were plated at a density of 4 x 104 cells per well in 6 well plates.
After 24 hours, 0.3 gg pA5egfp, and 0.3 gg pA3egfp plasmids were co-lipofected into the
cells in a total volume of 1 ml as described above. After 24 h, cells were treated with SIN-1
or NO/0O2 as described above. Cells were analyzed by flow cytometry 48 hours post
treatment. The transfection efficiency was tested by simultaneous lipofection of 0.3 gg
pEGFP into three independent samples.
Flow Cytometry
Pelleted cells were resuspended in OptiMEM (GIBCO/BRL) and passed through a 70
glm filter (Falcon) prior to analysis on a Becton Dickinson FACScan flow cytometer
(excitation 488 nm, argon laser; emission 580/30). Live cells were gated according to
forward and side scatter.
Quantification of DNA damage by plasmid tooisomer analysis
A plasmid nicking assay was used to quantify the DNA deoxyribose and base
damage. For lesion quantification, similar results were obtained using either the pA5egfp or
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the plasmid pSP189. The latter is a pBR-based, 4952 bp plasmid, which is similar in size to
pA5egfp (4921 bp), which allows interchangeability of the two plasmids in the nicking assay.
After ONOO-, SIN-i or NO/O 2 treatments, a portion (200 ng) of the DNA was treated with
putrescine (100 mM, pH 7.0, 1 h, 37°C) to convert all types of abasic sites to strand breaks
(48, 49). Another portion (200 ng) was kept on ice as a control for the direct strand breaks.
To quantify the oxidative base lesions formed by ONOO- or SIN-1, a third portion of the
DNA sample was treated with E. coli formamidopyrimidine-DNA glycosylase (Fpg)
(Trevigen) to convert oxidized purines to strand breaks. More than 90% of the ONOO-
guanine oxidation products in DNA are recognized by Fpg (49). Fpg treatment was
performed in a volume of 10 gL containing 200 ng of ONOO--treated DNA, 1 gL of Fpg
(-1.5 Units) and buffer containing 10 mM Tris-HCl (pH 7.5), 1 mM EDTA and 100 mM
NaCI at 37°C for 1 h. Fpg was then removed by phenol/chloroform extraction. Similarly, to
quantify nucleobase deamination products formed by NO' in the presence of 02 (e.g., N203),
plasmid DNA samples were incubated with E. coli Ung DNA glycosylase (Trevigen) and the
E. coli AlkA DNA glycosylase (Pharmingen), followed by putrescine treatment to convert
the resulting abasic sites to strand breaks. Both xanthine and hypoxanthine have been shown
to be recognized by AlkA ((50) and Dong et al., manuscript in preparation). Cross reactions
of AlkA/Ung with ONOO'-treated DNA and Fpg with N2 03-treated DNA revealed <5%
additional strand breaks, which demonstrates the specificity of these enzymes for the specific
sets of lesions caused by N203 and ONOO-. The recovered DNA was redissolved in H20 and
plasmid topoisomers were resolved by 1% agarose slab gel electrophoresis in the presence of
0.1 pg/mL ethidium bromide. The quantity of DNA in each band was determined by
fluorescence imaging (Ultra-Lum). For lesion quantification, similar results were obtained
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using either the pA5egfp or the pSP 189 plasmid (provided by Dr. M. Seidman; NIH,
Bethesda, MD), with the pSP189 plasmid used for the experiments presented in Figure 2.5.
Note that the base damage data for SIN-1 and ONOO- has been previously reported (51).
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2.3 Results
SIN-I, but not N/O, induces homologous recombination at a chromosomallv integrated
direct repeat.
To study NO'/O02 -induced homologous recombination in mammalian cells, we used
mouse embryonic stem cells that carry a direct repeat substrate that yields a fluorescent
phenotype specifically as a result of mitotic homologous recombination events (Jonnalagadda
et al., manuscript in preparation). The AGF cells carry expression cassettes for two different
truncated egfp cDNAs that are arranged in a direct repeat (Figure 2.1B; essential coding
sequences were deleted from either the 5' or the 3' end to create A5egfp and A3egfp
respectively). In this system, recombination via several different mechanisms can reconstitute
the full length EGFP sequence (e.g., gene conversion, unequal sister chromatid exchanges
and break-induced replication; (14)). Thus, recombination frequency can be readily estimated
by quantifying green fluorescent recombinant cells by flow cytometry (42, 52).
To study the effects of ONOO- and N20 3, AGF cells were exposed to various
concentrations of SIN-1 (to deliver ONOO-) or to NO' and 02 gases delivered simultaneously
via a Silastic tubing-based NO' delivery chamber to deliver N203 (referred to as 'NO/0 2'
exposure below) (41). It is well established that for most DNA damaging agents, the
frequency of recombination rises as the toxicity increases. Therefore, to compare the
recombinogenic effects of ONOO- and N203, we established conditions that induce similar
levels of cytotoxicity (Figure 2.1C). Cells were then exposed to equitoxic doses of SIN-1 or
NO/02 and were subsequently analyzed by flow cytometry to quantify fluorescent cells. As
can be seen in Figure 2.1D, SIN-1 is clearly recombinogenic, inducing recombination up to
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-3-fold. It is noteworthy that induction of recombination by SIN-1 initially increases and
then decreases as a function of dose, an observation that has also been noted by others (e.g.,
see reference (53)). In contrast to SIN-i, exposure to NO'0 2 did not lead to any detectable
increase in the frequency of recombinant cells (Figure 2.1D), even at doses that diminished
survival to below 1% (data not shown). Thus, while SIN-1 induces recombination at a
chromosomally integrated recombination substrate, NO/0 2 does not.
SIN-i is a more potent inducer of SCEs than NO02/O
The chromosomal direct repeat assay offers a rapid and effective measure of
recombination at a single locus. To assess recombination throughout the genome rather than
a single locus, we measured SCEs, which are known to result from homologous
recombination events (54). By culturing cells in the presence of BrdU for two cell cycles,
exchanges between differentially stained sister chromatids can be visualized in metaphase
spreads. For these experiments, cells were exposed to either SIN-i or NO'/0 2, cultured in
BrdU-containing media for two cell doublings, and analyzed as previously described (38). As
can be seen in Figure 2.1E, SIN-1 significantly induces SCEs (-6-fold). In addition, although
significantly less recombinogenic than SIN-i, NO'/0 2 exposure induces SCEs (-2-fold).
Although these results suggest that N203 induces homologous recombination, it is also
possible that ONOO' that is inevitably formed by reaction of NO with intracellular
superoxide is responsible for this increase in SCE levels in the NO/O 2-exposed cells.
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Creation of an inter-plasmid recombination detection assay.
To further explore the relative recombinogenicity of ONOO-- or N203-induced DNA
lesions, we developed an inter-plasmid recombination assay in which plasmids can be
exposed to pure ONOO- or to conditions that generate exclusively N20 3 prior to transfection
into the cells. For this purpose, we used plasmids that carry A3egfp and A5egfp (Figure
2.2A). A recombination event between these two plasmids can restore full length EGFP,
yielding a fluorescent phenotype. To test the efficacy of this approach, cells were transfected
with pEGFP, pA3egfp, pA5egfp, or they were cotransfected with both pA3egfp and pA5egfp.
Whereas -40% of the cells transfected with the positive control pEGFP plasmid were
significantly fluorescent, transfection with either pA5egfp or pA3egfp alone did not lead to
any detectable EGFP expression (Figure 2.2B). However, when cells were co-transfected
with pA5egfp and pA3egfp together, we observed a significant number of fluorescent cells,
indicative of inter-plasmid homologous recombination (related assays have previously been
described; e.g., see references (55, 56)).
A time course experiment revealed that the number fluorescent cells co-transfected
with pA5egfp and pA3egfp increases over time, reaching a maximal level by -48 h, which
subsequently begins to decline sometime after 72h post-transfection. This rise and fall in the
frequency of fluorescent cells likely reflects the time required to achieve maximal expression
of the EGFP protein, followed by the inevitable loss of plasmid DNA associated with
transient transfections. It is also noteworthy that the cells that carry a single copy of the
integrated substrate fluoresce following homologous recombination (which shows that a
single copy of an EGFP expression cassette is sufficient to yield a detectable fluorescent
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signal), however it is not known how many EGFP expression cassettes on extrachromosomal
DNA are required for such a signal.
In order to use this inter-plasmid assay to study the relationship between DNA
damage and recombination, it is critical to control for transfection efficiency, since cells that
receive higher quantities of plasmid have an increased chance of undergoing inter-plasmid
recombination. Under the conditions of these experiments, we found that the transfection
efficiency was highly consistent from sample to sample (less than a 10% variation among
samples; data not shown). To control for transfection efficiency, the frequencies of inter-
plasmid recombinant cells were normalized according to the percentage of fluorescent cells
transfected with the positive control vector (see Experimental Procedures).
Double strand breaks are known to be potent inducers of homologous recombination,
and it has previously been shown that double strand breaks in plasmids can be repaired by
recombining with homologous sequences available on another plasmid (55). To maximize
the sensitivity of the inter-plasmid assay for detecting damage-induced recombination, we
introduced a double strand break into pA5egfp using BamHI (Figure 2.2A), and measured
double strand break-induced recombination under various conditions. Following extensive
optimization, we found that we could increase the sensitivity of the assay to damage-induced
recombination by an order of magnitude by co-transfecting damaged pA5egip with a 10-fold
molar excess of pA3egfp (Figure 2.2C) and by transfecting cells via lipofection, as opposed
to using other transfection methods (data not shown). Given that recombination between two
copies of pA5egfp can never reconstitute full length EGFP coding sequences, conditions in
which there is a 10-fold molar excess of pA3eg increase the likelihood that recombination
events will be detectable by the appearance of a fluorescent signal.
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Inter-plasmid homologous recombination is induced when plasmid DNA is exposed to
ONOO and SIN-I. but not to NO'/O.
To study the effects of ONOO-induced DNA lesions, pA5egfp was exposed to SIN-1
or to purified ONOO- (see Experimental Procedures). To study the effects of N20 3-induced
DNA lesions, pA5egfp was exposed to N20 3 in the NO'/02 delivery chamber, as described
previously (41). The damaged pA5egfp was then mixed with undamaged pA3egfp and
transfected into mouse ES cells. Although the frequency of recombination between plasmids
could be assessed by quantifying fluorescent cells, if there are too many lesions, then even if
there is a productive recombination event, EGFP will not be expressed (e.g., due to inhibition
of transcription, concurrent mutations, or degradation of damaged plasmid). To determine the
optimal dose range, pEGFP was exposed to various concentrations of the damaging agents,
transfected into mouse cells and the proportion of fluorescent cells was assessed. The highest
dose at which no significant inhibition of EGFP expression was observed was then taken as
the upper limit for studies of recombination (Figure 2.3A). It is noteworthy that even at very
high levels of NO'/0 2 exposure, we did not observe any significant inhibition of EGFP
expression (Figure 2.3A, right). Therefore, we quantified the number of lesions created under
these exposure conditions (described in detail below), and selected an NO'/0 2 dose range that
creates a comparable number of lesions per plasmid compared to SIN-1 and ONOO-. As can
be seen in Figure 2.3B, DNA lesions induced by ONOO- significantly induced homologous
recombination (-2-fold) and DNA exposed to SIN-1 was similarly susceptible to damage-
induced recombination. However, DNA lesions created by NO'/0 2 exposure did not induce
any increase in the frequency of recombination (Figure 2.3B, right).
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Effects of ONO0-. SIN-I, and NO'/O2 on inter-plasmid homologous recombination are
conserved in diverse cell types.
A major advantage to studying damage-induced recombination using
extrachromosomal plasmids is that these experiments can be performed in different
mammalian cell types. To determine if the observed effects of ONOO-, SIN-1 and NO'/O02 on
inter-plasmid homologous recombination are similar in other mammalian cell types, we
repeated these experiments using COS-7L African green monkey kidney cells. Despite the
fact that these are very different cell types from two different species, we saw remarkably
similar dose-response curves when we assayed for inhibition of EGFP expression (Figure
2.3C). Furthermore, although there are some subtle differences in the responses of these two
cell types to damage-induced recombination (e.g., the minimal dose required to induce
recombination), overall the relative recombinogenicity of these exposures is highly similar
(Figure 2.3D).
Exposure of mammalian cells to ONO00- and SIN-1. but not to N/O0 2 induces
extrachromosomal recombination.
One of the strengths of the inter-plasmid recombination assay is that by damaging the
plasmid prior to transfection into cells, the effects of specific DNA lesions can be studied.
Another advantage of this assay is that it can be readily adapted to many different cell types.
Finally, in addition to introducing damage to the plasmids prior to transfection, the cells can
also be exposed to damaging agents post transfection to explore the possibility that
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concurrent cellular responses to damage-exposure significantly modify the effects of DNA
lesions on recombination.
We have shown above that the relative recombinogenicity of DNA lesions created by
ONOO- and SIN-1 versus NO'/O02 are similar in both mouse ES and monkey COS 7L cells
(Figure 2.3). We next asked if different cell types would respond similarly when the cells
themselves, rather than plasmid DNA, are exposed to SIN-1 and NO'/0 2. To select the
appropriate dose-range, we first established the dose dependent survival of COS 7L cells to
SIN-1 or NO'/0 2 (Figure 2.4C; note that Figure 2. 4A is the same as Figure 2.1C, and is
included here for ease of comparisons). COS 7L cells appear to be more resistant to the toxic
effects of both SIN-1 and NO' when compared to mouse ES cells (compare Figures 2. 4A and
2.4C; note the change in the dose range).
To study inter-plasmid recombination in exposed cells, we co-transfected cells with
undamaged pASegfp and pA3egfp and after 24 h (to allow time for recovery from
transfection), we exposed the cells to increasing concentrations of SIN-1 or to NO'/0 2. After
an additional 48 h, the cells were analyzed by flow cytometry (note that similar results were
observed in pilot experiments assayed either 48 h or 72 h post damage-exposure). For both
ES and COS 7L cells, exposure to SIN-1 after transfection caused a dose dependent
induction of recombination (Figures 2.4B and 2.4D). Importantly, the same dose of SIN-1
resulted in a similar fold induction in both cell types. For example, exposure to 1 mM SIN-1
induces an -2 fold increase in the frequency of recombination in both cell types, regardless
of whether the exposure occurred before or after transfection (Figures 2.3B-2.3D). Therefore,
it does not appear that cellular responses to damage-exposure dramatically alter the
magnitude of SIN-i induced inter-plasmid homologous recombination (despite the
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differences in toxicity in these cell types at the selected doses). Consistent with the previous
analysis of recombination between pA5egfp and pA3egfp (e.g., Figure 2.1D and Figure 2.3),
we did not observe any significant induction of recombination when cells were exposed to
NO'/0 2. Thus, it again appears that DNA lesions induced by ONOO- are significantly more
recombinogenic than those induced by NO'/0 2.
ONOO-induced direct single strand breaks and oxidative base lesions are recombinogenic.
Reactive nitrogen species produce three major classes of lesions: base damage, abasic
sites and single strand breaks. To gain a better understanding of how these different classes
of lesions affect homologous recombination, we used a well established plasmid-nicking
assay to quantify lesions generated when plasmid is exposed to ONOO-, SIN-i, or N203 (24,
33). Topoisomer analysis was performed to quantify single strand breaks (by direct analysis
of damaged plasmids), abasic sites (which were converted to strand breaks using putrescine),
and base lesions (which were converted to strand breaks using a combination of purified
DNA glycosylases and putrescine). The relative proportions of supercoiled, relaxed and
linear plasmid molecules were then used to calculate the number of DNA lesions (see
Experimental Procedures).
An example of an experiment in which the frequency of Fpg sensitive lesions was
estimated is shown in Figure 2.5A. In the absence of Fpg, with increasing doses of ONOO-,
there is a gradual shift from Form I (supercoiled DNA) to Form II (nicked closed-circular
DNA), which reflects the ability of ONOO- to directly induce single strand breaks. Plasmid
was then digested with purified Fpg glycosylase, which both removes damaged bases and
cleaves the backbone via its associated lyase activity (57). In the case of control undamaged
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plasmid DNA that was analyzed before and after incubation with Fpg glycosylase (Figure
2.5A, lane 1), there is very little change in the ratio of supercoiled (Form I) and nicked (Form
II) following digestion with Fpg (Fpg produced a small amount of the plasmid nicking, most
likely as a consequence of cutting at background damage). In contrast, at the highest
concentration of ONOO- (5 mM, far right lane), digestion with Fpg eliminates nearly all of
the supercoiled Form I DNA, indicating that essentially all of the plasmids had at least one
Fpg sensitive site. Importantly, it also appears that Fpg induces a small but detectable level of
double strand breaks, as indicated by the appearance of linear Form III DNA, made more
apparent by the adjustment in contrast shown in Figure 2.5B.
The ratio of Forms I and II can be used to estimate the number of lesions per million
nucleotides (although the total amount of DNA per lane can vary, depending on loading, the
ratio remains constant). Using this topoisomer approach, we estimated the levels of
chemically-induced single strand breaks, abasic sites, and base lesions. The distinction
between guanine oxidation products arising from ONOO- (49) and the nucleobase
deamination products arising from N203 (24) was achieved by differential recognition of the
lesions by Fpg and Ung/AlkA, respectively (see Experimental Procedures). We found that
ONOO- creates primarily base damage and single strand breaks, whereas SIN-1 creates
primarily single strand breaks (Figure 2.5C). In contrast, NO' exposure creates almost
exclusively base lesions, with a small number of abasic sites and an undetectable level of
single strand breaks, (Figure 2.5C), which is consistent with our published studies of N20 3-
induced DNA damage spectrum (24). It is noteworthy that base lesions and abasic sites are
masked by the presence of single strand breaks in the topoisomer assay. Thus, above 60
lesions per million nucleotides, there is more than one damage event per plasmid molecule
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on average (according to a Poisson distribution), so that the calculated levels of damage
underestimate the true level of damage (this is likely the reason for the appearance of a
plateau in base damage levels with doses of ONOO- above 0.01 mM; Figure 2.5C). This
behavior is independent of the identity of the DNA damaging agent, however, so corrective
measures are not necessary when making comparisons of different agents, as in the present
studies.
In order to gain a better understanding of the classes of lesions that lead to
recombination, we compared the quantity and quality of lesions created by the lowest
recombinogenic dose of ONOO- (0.02 mM) to those created by the highest dose of NO' (2.7
mM'min) used for the interplasmid recombination assay. Although 2.7 mM'min NO' creates
more abasic sites and many more base lesions than 0.02 mM ONOO- (Figure 2.5D), NO' was
not recombinogenic whereas ONOO- was highly recombinogenic. Importantly, NO' does not
create any detectable single strand breaks, whereas significant levels of single strand breaks
were detected at recombinogenic doses ONOO-. Note that the masking effect of single strand
breaks likely results in only a minor underestimate of the number of base lesions at 0.02 mM
ONOO-, so on a per lesion basis, ONOO- is more recombinogenic than NO'. We therefore
conclude that single strand breaks induced by deoxyribose oxidation and oxidatively
damaged bases are significantly more recombinogenic than nucleobase deamination products
in mammalian cells.
It is well established that double strand breaks induce homologous recombination in
mammalian cells (58, 59). Although DNA exposed to 0.2 mM ONOO- was highly
recombinogenic, none of the plasmid DNA appeared to have been linearized by exposure to
0.2 mM ONOO- (this dose falls between lanes 8 and 9 in the top gel in Figure 2.5A).
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However, following digestion with Fpg in vitro, double strand breaks can be detected by the
appearance of linear DNA (see lanes 8 and 9 in the lower gel of Figure 2.5A, and in 2.5B).
Intriguingly, at 1-5 mM ONOO-, digestion with Fpg essentially eliminates the supercoiled
Form I DNA, and it is around this dose range that the frequency of induced recombination
appears to decline (compare 0.2 and 2 mM ONOO- in Figure 2.5D, left), and the percentage
of cells able to express EGFP from the ONOO- treated positive control pEGFP vector starts
to plummet (Figure 2.3A and 2.3C). When DNA is transfected into mammalian cells, most of
the DNA is rapidly degraded by cytosolic nucleases (60). Furthermore, it has been shown
that whereas supercoiled plasmid yields high levels of expression from a marker transgene 72
h post lipofection, linearized DNA yields no detectable expression (61). Given that
mammalian cells harbor multiple DNA glycosylases that act on a broad range of substrates
(57, 62), it is likely that a much greater proportion of the damaged plasmid is linearized by
mammalian glycosylases following transfection, than by Fpg digestion in vitro, rendering the
DNA vulnerable to nucleolytic degradation. Taken together, these results suggest that
following transfection, mammalian DNA glycosylases create double strand breaks that both
induce homologous recombination, and render the DNA vulnerable to degradation by
exonucleases.
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2.4 Discussion
It has long been known that chronic inflammation contributes to cancer. Although it
is well established that NO' creates reactive nitrogen species that form mutagenic DNA
lesions (9, 10, 35), very few studies had investigated the possibility that NO' induces
homologous recombination events, even though homologous recombination causes sequence
rearrangements that are known to contribute to cancer (16, 18, 63). Indeed, dozens of known
carcinogens are recombinogens (17, 19). Furthermore, people who are born predisposed to
spontaneously high levels of recombination are prone to cancer (18, 19). Thus, whether
caused by exposure or by an inherited predisposition, homologous recombination events are
a form of genetic instability that can lead to cancer.
Here, we have shown that ONOO-, the product of the reaction of NO with
superoxide, causes highly recombinogenic DNA lesions. In contrast, when NO' reacts with
oxygen to form N203, the resulting DNA lesions did not induce a detectable increase in
interplasmid recombination. Therefore, NO' becomes particularly recombinogenic
specifically under conditions where it reacts with superoxide to create ONOO-. Importantly,
NO' mediates both cell signaling and inflammation, but only under conditions of
inflammation does the body simultaneously create high levels of both NO' and superoxide.
Therefore, it is likely that NO' does not significantly induce recombination when produced at
low concentrations during cell-signaling, whereas the results of the present studies show that
following reaction with superoxide, it becomes highly recombinogenic and can thus
contribute to tumorigenic sequence rearrangements.
We are primarily interested in the effects of inflammatory chemicals on genomic
stability under physiologically relevant exposure conditions. In the case of NO/O 2, it has
67
been estimated that the steady state concentration of NO' at sites of inflammation is < 1 gM
(4, 45, 64, 65). In the studies described here, cells were exposed to 1.3 jiM NO' (steady
state), which is a reasonable approximation of the level expected to be present within
inflamed tissues. In terms of ONOO-, we elected not to expose cells to pure ONOO-, because
if added to the media, the result would be a bolus exposure that does not accurately reflect
conditions during inflammation (the half life of ONOO- is - 50 ms (66)). In contrast to
ONOO-, SIN-1 makes it possible to achieve longer term exposures, since SIN- 1 decomposes
to form ONOO- at a fairly steady rate (at least during the first 90 minutes of exposure; (67)).
At 1 mM SIN-i, ONOO- is produced at a rate of-0.2 jiM/sec (67), and in the studies
presented here, 0.5 mM SIN-1 significantly induced homologous recombination at the
integrated direct repeat substrate (note that this exposure was also relatively non-toxic; see
Figs. C-1D). Although the exact concentration of ONOO- at sites of inflammation are not
yet known, the conditions used in these experiments are on par with the expected nM-gM
range of ONOO' concentrations thought to be present during inflammation (4).
Comparisons of ONOO-induced recombination (reported here) and ONOO'-induced
mutations (reported in the literature) suggest that ONOO- is similarly potent as both a
mutagen and a recombinogen. For example, at a dose of SIN-1 that kills -75% of TK6 cells,
mutations at HPRT and TK are induced by -2 fold (23, 43), whereas in the studies presented
here, a dose of SIN-1 that kills -25% of the cells induced a -3 fold increase in recombination
a single locus in the chromosomally integrated recombination substrate. These results suggest
that ONOO- may be as recombinogenic as it is mutagenic, although further studies are
required, since toxicity does not necessarily directly reflect the levels of damage. Comparing
the studies presented here to those in which exposed plasmid DNA has been used to study
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mutagenesis (thus avoiding the complexities of assessing damage levels in cells), we again
found similarities in the mutagenic and recombinogenic effects of ONOO-. Specifically, in
previous studies using extrachromosomal plasmids, 2-2.5 mM ONOO- induced a 4-9-fold
increase in point mutations, respectively (9, 33). Here, we found that 0.02 mM ONOO-
induced a 2-fold increase in interplasmid recombination in mouse ES cells, and that 2 mM
ONOO- induced a 4-fold increase in interplasmid recombination in monkey kidney cells.
Although further studies are necessary to control for cell-type effects, these comparisons
suggest that the mutagenic potential of ONOO- is on par with its recombinogenic potential.
Although double strand breaks are thought to be critical for inducing homologous
recombination, ONOO- creates oxidative base lesions, abasic sites, and single strand breaks
(4). Consistent with previous studies, in the topoisomer analysis performed here, we were
unable to detect the presence of any ONOO- or SIN- -induced double strand breaks at doses
that were highly recombinogenic. However, we have shown that Fpg can introduce double
strand breaks in ONOO--treated plasmids (Figure 2.5A) and in SIN-1 treated plasmids (data
not shown). In contrast, treatment with DNA glycosylases did not induce double strand
breaks in NO'/O02-treated plasmid (data not shown). Thus, following transfection, closely
opposed lesions on opposite strands could potentially be converted into double strand breaks
by DNA glycosylases, as was originally demonstrated for oxidative damage in vitro, and has
been recently demonstrated for radiation damage in mammalian cells (36, 40). Alternatively,
abasic sites and single strand breaks may be converted into double strand breaks during
replication, which is likely to contribute to SIN-1 induced recombination at the integrated
direct repeat. However, given that the plasmids used in these experiments do not have an
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origin of replication, the most likely cause of interplasmid recombination induced by ONOO-
are double strand breaks created by enzymatic processing in the recipient cells.
The results of these studies show that conditions that favored formation of N 203 did
not induce recombination at any of the recombination substrates, although there was an small
but significant increase in sister chromatid exchanges in cells exposed to NO/0 2. It is
certainly possible that some of the lesions induced by N203 induce SCEs that were not
detected using the engineered substrates. However, due to the inevitable presence of
superoxide in normal cells, it is also possible that NO' reacts with superoxide to form ONOO
in these cells. Nevertheless, it is clearly the case that ONOO- is significantly more
recombinogenic than N203 in all of the recombination assays, and N203 lesions failed to
induce any detectable increase in interplasmid recombination. These results were somewhat
unexpected, given that lesions created by both N 203 and ONOO- are substrates for the base
excision repair pathway, and that base excision repair intermediates have been shown to be
highly recombinogenic in mammalian cells (e.g., (37, 38)).
One major difference between ONOO- and N203 is that ONOO- can directly react
with deoxyribose to induce single strand breaks. Therefore, it is possible that chemically-
induced single strand breaks are converted into recombinogenic double strand breaks when
another single strand break is enzymatically introduced on the opposite strand by base
excision repair enzyme(s). Given that glycosylases rapidly find their targets (tl/2 = minutes
for the Aag DNA glycosylase, for example (68)), it is not difficult to imagine that a
glycosylase might find its target before a chemically-induced strand break on the opposite
strand has been repaired. Furthermore, different types of glycosylases act on ONOO--induced
guanine oxidation and nitration products (e.g., 8-nitroguanine, 8-oxoguanine and its
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secondary oxidative products) compared to N2 03-induced nucleobase deamination products
(uracil, xanthine and hypoxanthine) (49, 50) and Dong et al., manuscript in preparation). The
vast majority of ONOO-induced lesions are repaired by bifunctional glycosylases (Fpg and
Nth, and their mammalian homologs), and these enzymes have the ability to both to remove
the base lesions and to cleave the sugar-phosphate backbone (e.g., via their associated lyase
activity) (69, 70). In contrast, those glycosylases known to act on N 203-induced lesions are
monofunctional (e.g., Ung and AlkA, and their mammalian homologs; (50, 71) and Dong et
al., manuscript in preparation), so these enzymes remove the base lesions but cannot create
single strand breaks. Taken together, the observation that ONOO- is more recombinogenic
than N20 3 may be because bifunctional glycosylases can create recombinogenic double
strand breaks by cleaving across from a pre-existing chemically-induced strand break and by
enzymatic cleavage at two closely opposed base lesions.
Although deaminated bases are known to be mutagenic (27), we did not find that
EGFP expression was inhibited by exposure to NO'/0 2. At the highest dose of NO'/0 2, we
estimated that there are -2 lesions/plasmid. Given that only -15% of the plasmid sequences
code for EGFP, it is likely that copies of the plasmid that harbor undamaged coding
sequences are responsible for the observed EGFP expression. Unexpectedly, we found that
an even lower number of ONOO- lesions/plasmid inhibited EGFP expression. Following the
same logic, it seems unlikely that EGFP expression is suppressed by mutagenic damage to
coding sequences. Given that linearized plasmid DNA is highly vulnerable to degradation by
exonucleases (60, 61), one possibility is that EGFP expression is suppressed due to plasmid
loss, rather than to mutations. Thus, the observations that suppression of EGFP and induction
of recombination go hand in hand for ONOO- and SIN-1, and that NO/0 2 neither suppresses
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EGFP nor induces recombination, are consistent with a model wherein glycosylases
introduce double strand breaks that both increase the vulnerability of the DNA to
degradation, and induce homologous recombination.
One interesting result of these studies was that the relative recombinogenicity of
ONOO- and N203 is very similar in mouse embryonic cells and monkey kidney cells,
regardless of whether the DNA was exposed prior to transfection, or cells were exposed after
transfection. However, there are also some subtle differences. For example, there is a
significant difference in the doses of ONOO- required to achieve maximal induction of
recombination in embryonic cells versus kidney cells (Figure 2.3). Although there are many
possible explanations for this observation, one possibility is that embryonic stem cells have
relatively higher levels of DNA glycosylase that induce double strand breaks. If this were the
case, then glycosylase-induced double strand breaks could potentially be induced at lower
levels of adducts. Although ONOO--induced recombination is a general feature of
mammalian cells, these results show that the relative sensitivity of cells to ONOO-induced
recombination clearly is variable among different cell types.
The magnitude of ONOO--induced recombination is significant. Mammalian cells
subjected to conditions that favor formation of ONOO- are susceptible to -3-fold increase in
recombination at the integrated AGF recombination substrate, and to -6-fold increase in
SCEs. For comparison, it has been reported that phenytoin, an oxidizing agent, induces a 2-
to 3-fold increase in recombination at an analogous direct repeat substrate in CHO cells (72).
Indeed, in the SCE literature, most of the agents that induce such high levels of SCEs are
chemicals that most of us will never experience (73). Given that inflammation is unavoidable
in the lifetime of most people, and that ONOO- is highly recombinogenic, endogenously
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produced ONOO- may be one of the most significant recombinogens to which most people
are exposed. As such, ONOO--induced recombination may be an important risk factor for
tumorigenesis.
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Figure 2.1. NO'/O02 - or SIN-i-induced toxicity and homologous recombination in mouse
embryonic stem cells. (A) Schematic depicting the major reactions of NO' secreted by
activated macrophages. (B) The chromosomal direct repeat substrate. Expression cassettes
are represented by large arrows with emphasis on the coding sequences (gray) and deleted
regions (black). A5egfr and A3eg/jp expression are driven by the chicken beta-actin promoter
and cytomegalovirus enhancer. Homologous recombination can lead to the restoration of
full-length EGFP coding sequence and fluorescence expression. (C) Relative toxicity
induced by exposure to the indicated doses of NO' delivered in the gas delivery chamber or
SIN- as determined by colony forming assay. For NO' exposure, Ar gas was used as a
negative control and relative survival was normalized accordingly. Values are the mean of
three samples + SEM. (D) Relative levels of damage-induced recombination at a
chromosomally integrated direct repeat. Fold induction of fluorescent recombinant cells is
shown. Following exposure to NO/0 2 or SIN-1 (72 h), cells were analyzed by flow
cytometry. Values are the mean of three samples + SEM. (E) SCEs induced by SIN-i and
NO/0 2. SCEs per chromosome were detected by analyzing 20 metaphase chromosomes at
each dose. The results shown are mean + SD for duplicate experiments.
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Supplementary Data
Mitomycin C (MMC) is a well studied, highly recombinogenic DNA damaging agent.
Experiments conducted to measure NO/0O2- or SIN-l-induced toxicity and homologous
recombination in mouse embryonic stem cells (Figure 2.1) were conducted in parallel with
MMC as a positive control. Although this data was not included in the manuscript (Chapter
2), it provides valuable information about the relative recombinogenicity of NO'/0 2- or SIN-
1 when compared to MMC. As evident from Supp. Figure 2.1, MMC is significantly more
recombinogenic than both NO'/02 - or SIN-1 at equitoxic doses.
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Supp. Figure 2.1. NO'/0 2- or SIN-i-induced homologous recombination in comparison to
Mitomycin C (MMC)-induced homologous recombination at equitoxic doses in mouse
embryonic stem cells. First row shows the survival curves, second row shows damage
induced recombination at a chromosomally integrated direct repeat, and the third row shows
damage induced SCEs.
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Homologous recombination events are an important source of mutations that are
likely to be the underlying cause of one or more mutations in every tumor. Nevertheless, we
do not yet have an extensive understanding of what causes recombination in people.
Although exposure to toxic levels of most carcinogens is recombinogenic, most humans are
is not likely to be exposed to high concentrations of these agents. In contrast, inflammation is
a widespread pathophysiological response in humans, and it is known to contribute to cancer.
Indeed, during inflammation, the high levels of reactive oxygen and nitrogen species that are
produced by activated macrophages are highly toxic to neighboring normal cells. The major
physiologically relevant reactive nitrogen species are N 203 and ONOO', which are formed
when NO' reacts with either oxygen or superoxide, respectively. This study has shown, by
sister chromatid exchange, chromosomal direct repeat, and interplasmid recombination
assays, that ONOO- is a strong recombinogen, whereas N203 is relatively weakly
recombinogenic. Consequently, NO' has the potential of being highly recombinogenic
specifically under conditions when superoxide is present, as is the case during inflammation.
These results suggest that ONOO--induced recombination may contribute to tumorigenic
sequence rearrangements and may play an important role in inflammation-induced cancers.
Double strand breaks (DSBs) are thought to be critical for inducing homologous
recombination. In our studies, we observed that ONOO- created DNA damage induced
significant levels of inter-plasmid recombination, whereas no significant levels of inter-
plasmid recombination was detected with N203. Interestingly, neither ONOO' nor N20 3
directly induce double strand breaks. Exposure of plasmid DNA to ONOO- created
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predominantly base oxidation products and single strand breaks, while exposure of plasmid
DNA to N2 03 created base deamination products and abasic sites. Together these results
suggest that, on a per lesion basis, ONOO'-induced oxidative base lesions and single strand
breaks are significantly more recombinogenic than N20 3-induced base deamination products.
Since DSBs are thought to induce recombination, we hypothesize that ONOO- can induce
formation of double strand breaks via (1) two closely opposed chemically induced single
strand breaks; (2) a closely opposed chemically induced single strand break and an oxidative
base lesion; (3) two closely opposed oxidative base lesions (Figure 3.1). These closely
opposed oxidative base lesions could potentially be converted into a single strand break by
DNA glycosylases, leading to the formation of recombinogenic DNA double strand breaks.
These possible mechanisms proposed for the differential recombinogenicity observed
for ONOO- and N2 0 3 require further testing. For example, our studies suggest that base
oxidation products are more recombinogenic than base deamination products on a per lesion
basis. Given that both of these lesions are repaired by base excision repair (BER) pathway,
indeed, both types of lesions could enzymatically be converted into strand breaks as
intermediates of BER pathway. This raises an interesting question; what is the key factor that
accounts for the differential recombinogenicity of oxidation and deamination base products?
One major difference is the type of glycosylases that acts on ONOO-induced base oxidation
products (e.g., 8-nitroguanine, 8-oxoguanine and its secondary oxidative products) and the
type of glycosylases that acts on N2 03-induced base deamination products (uracil, xanthine
and hypoxanthine) (1, 2) and Dong et al., manuscript in preparation). The vast majority of
ONOO--induced lesions are repaired by bifunctional glycosylases (Fpg and Nth, and their
mammalian homologs). These enzymes have the ability to both to remove the base lesions
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and simultaneously cleave the sugar-phosphate backbone (e.g., via their associated lyase
activity) (Figure 3.2) (3). In contrast, glycosylases known to act on N20 3-induced lesions are
monofunctional (e.g., Ung and AlkA, and their mammalian homologs; (1, 4) and Dong et al.,
manuscript in preparation), so these enzymes remove the base lesions, but cannot create
single strand breaks (Figure 3.2). In the case of monofunctional glycosylases, generation of
nicks requires an additional step catalyzed by AP endonucleases. This difference in the action
of monofunctional versus bifunctional glycosylases could be the key factor leading to the
difference in recombinogenicity observed with ONOO-induced base oxidation products
versus N203-induced base deamination products. This hypothesis needs further testing and
one approach to test it may be possible by studying the effects of over-expression as well as
knocking down of some BER pathway enzymes that are known to play a role in the repair of
base oxidation products and base deamination products.
Replication is believed to play an important role in converting various types of
template damage into recombinogenic double strand breaks (Figurel.l). Nevertheless, the
plasmids that were used in the extrachromosomal recombination studies (Figure 2.3 and
Figure 2.4) lacked mammalian origin of replication. To address the possible effects of
replication on the recombinogenicity of ONOO- or N20 3-induced DNA lesions, we repeated
the set of experiments presented in Figure 2.3 and Figure 2.4 with plasmids carrying SV40
origin of replication. Although SV40 origin of replication replicates efficiently in SV40
transformed monkey kidney cells (COS 7L), we did not detect any effect of replication on
inter-plasmid recombination induced by ONOO- or N20 3-induced DNA lesions (data not
shown). These results are controversial to what is traditionally believed in regarding the role
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of replication in generation of recombinogenic DNA lesions, and suggests that the
extrachromosomal plasmid assay is not an ideal system to study the effects of replication.
Another interesting question that needs to be further addressed is the physiological
relevance of our findings. In this study, to dissect the effects of ONOO- and N203 on
homologous recombination in mammalian cells, we exposed cells and plasmids to each of
these chemicals. We have shown that ONOO- is significantly recombinogenic, and based on
this result we have hypothesized that during inflammation ONOO- induces recombination.
The relevance of our findings to inflammation needs to be supported with further studies.
One way to mimic inflammation in cell culture experiments would be to perform co-culture
experiments by using macrophages. Macrophages can be cultured in vitro and be stimulated
to secrete reactive oxygen and nitrogen species by using interferon-y (5). Thus, by co-
culturing mammalian cells with stimulated macrophages, we can ask if during conditions that
mimic inflammation, homologous recombination is induced in mammalian cells. Lastly, the
physiological relevance of our findings can be tested by using various mouse models for
inflammation and analyzing SCEs in the inflamed tissues, or by using the FYDR mouse that
was developed to detect recombination (6).
Given that inflammation is unavoidable in the lifetime of most people, and that
ONOO- is highly recombinogenic, this study suggests that endogenously produced ONOO-
may be one of the most significant recombinogens to which most people are exposed. Thus,
ONOO'-induced recombination may be an important risk factor for tumorigenesis in an
inflamed tissue.
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Figure 3.1. Possible mechanisms for the formation of recombinogenic double strand breaks
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strands, which could potentially be converted into double strand breaks by DNA
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abasic site (shown with an arrow head). Monofunctional glycosylases remove the damaged
base creating an abasic site (no subsequent cleavage of the sugar phosphate backbone takes
place). AP endonucleases cleave the sugar phosphate backbone 5' of the abasic site. The
DNA polymerase adds the missing nucleotide. In case of monofunctional glycosaylases, the
abasic ribose is removed by deoxyribosephosphodiesterase (dRpase). The repair is completed
by the action of ligase (7).
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4.1 Extracellular Matrix and its Components
The extracellular matrix (ECM) in which cells reside determines many of the
biological properties of the cells and the characteristics of the tissues formed (1). Although
ECM was historically thought as an inert scaffold for cell and tissues, in recent years ECM
has emerged as an important modulator of inter-cellular and intra-cellular signaling events
(e.g., see references (2-6)). The currently emerging view is one in which there is an active
interplay between the cell and ECM. According to this view, cells synthesize their ECM in a
highly regulated and specific fashion. In turn the ECM serves to modulate the signaling
events in a structurally specific manner and impinges on the functioning of the cell.
The ECM is composed of two major classes of molecules - proteins and
polysaccharides. The protein components include fibrous proteins (e.g., collagens and
elastin), which mainly provide tensile strength, adhesive glycoproteins (e.g., fibronectin,
laminin, tenascin), and proteoglycans- the core proteins with attached polysaccharides. While
glycoproteins and proteoglycans provide a hydrated gel which resists compressive forces,
they also play a major role in cellular signaling events (7). Complex polysaccharides called
glycosaminoglycans (GAGs) constitute the second major component of the ECM. GAGs are
linear polysaccharides made up of disaccharide building blocks consisting of an amino sugar
(either a glucosamine or galactosamine) and a uronic acid (either a glucuronic acid or
iduronic acid) (8). In addition to these resident components, the ECM also contains
cytokines, chemokines and growth factors (e.g., EGF, FGF, TNF, IL-2) which are involved
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in signaling events.
There are 4 main classes of GAG family of polysaccharides - hyaluronan,
chondroitin/dermatan sulfate, keratan sulfate, and heparin/heparan sulfate (7, 9). The
disaccharide repeat units, number of disaccharides that make up a chain and examples of
tissue distribution of these 4 classes of GAGs are shown in Table 4.1. It is noteworthy that
hyaluronan is considered to be the simplest class of GAGs (10). In contrast, keratan sulfate,
chondroitin/dermatan sulfate and heparin/heparan sulfate may have sulfation at various sites
of their disaccharide repeat units which adds complexity to their structure and enables them
to have structural specificities (7).
Table 4.1. The disaccharide repeat units, number of disaccharides that make up
examples of tissue distribution of the 4 main classes of GAGs.
a chain, and
Although hyaluronan is found as a free polysaccharide in the ECM, the other GAGs
are found attached to proteoglycan cores (I 6). Most proteoglycans carry between 1-3 GAG
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Main Classes Disaccharide Number of Examples of Tissue Refs.
of GAGs Repeat Unit Dissacchari- Distribution in
des Mammals
Hyaluronan Glucosamine 250 to 25,000 Skin, skeletal tissues, (10)
linked to synovidal fluid and the
glucuronic acid vitreous humor of the eye
Chondroitin/ Galactosamine Average of 40 Cartilage, brain, (11, 12)
Dermatan linked to uronic connective tissue,
Sulfate acid fibroblasts, neural cells,
endothelial cells,
lymphocytes and myeloid
cells
Keratan Sulfate Glucosamine < 50 Bone and cartilage (13)
linked to
galactose
Heparin/ Glucosamine 20 to 200 Mast cells (heparin), (14, 15)
Heparan Sulfate linked to uronic every type of cells
acid I I(heparan sulfate)
chains. Numerous growth factors and cytokines are known to bind to the GAG components
of proteoglycans (9, 17). Accordingly, GAGs on a cell's surface are critical modulators of the
signals received from the extracellular milieu. Furthermore, it is increasingly becoming clear
that the fine structure of GAGs play an important role in their binding to the signaling
molecules (18).
4.2 Heparan Sulfate Glycosaminoglycans (HSGAGs)
The most complex member of the GAG family is HSGAGs, and this results from
their structural diversity. The acronym HSGAG includes both heparin (a highly sulfated
polysaccharide commonly isolated from mast cell or mucosa) and heparan sulfate that is
present at the cell surface and the ECM. HSGAGs are characterized by a linear chain of 20-
200 disaccharide units of uronic acid linked 1,4 to an o-D-glucosamine (Figure 4.1) (9, 17,
19). HSGAGs can vary both in terms of the number of disaccharide repeat units and the
chemical modifications internal to each repeat unit. The chemical modifications that may
take place include the O-sulfation at the second carbon of the uronic acid (2-0) and the 0-
sulfation at the third and sixth carbons of the glucosamine (3-0 and 6-0), as well as N-
sulfation (N-S) or N-acetylation (N-Ac) of the second carbon of the glucosamine (Figure 4.1)
(20). Together, the four different modification sites give rise to 24 different possible
structures for a disaccharide repeat for a particular uronic acid isomer. Furthermore, there are
two variations of the uronic acid component: a-L-iduronic acid or P-D-glucuronic acid.
Altogether, these possible modifications combined with the two possible uronic acid epimers
yield 48 possible disaccharide, which makes HSGAG the most information dense and diverse
biopolymers when compared to DNA (made up of 4 bases), and proteins (made up of 20
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amino acids). For example, an HSGAG polymer made up of 5 disaccharide units can have a
total of 485 (-250 million possible sequences, whereas a penta-peptide made of 5 amino acids
can have 205 (3.2 million) different sequences or a DNA strand of 5 nucleotides can only
have 45 (1024) different sequences.
Due to this high sequence diversity of HSGAGs, understanding how the assembly of
48 building blocks is regulated by a cell to provide a functional polysaccharide and the
biological functions mediated by these specific HSGAG structures has been one of the most
challenging areas of research.
4.3 Biosynthesis and Degradation of HSGAGs
Virtually all cells express proteoglycans that carry HSGAG chains (7). Much of the
key advances in dissecting the biosynthetic pathway for HSGAGs has been made possible
through targeting the enzymes involved in HSGAG biosynthesis at a whole-organism level
(21-29).
Unlike other structurally complex charged biopolymers such as DNA, RNA or
proteins, HSGAGs do not undergo template-based biosynthesis. Instead, their biosynthesis in
mammals is regulated by a complex series of enzymatic steps initiated within the golgi
apparatus. HSGAG biosynthesis occurs in 4 key steps in mammalian cells. These steps are
(1) synthesis of the proteoglycan core; (2) synthesis of the tetrasaccharide linkage sequence;
(3) extension of the HSGAG chain by copolymerization of glucuronic acid and N-
acetylglucosamine; and (4) modification of the nascent chain by a complex series of
enzymatic steps. These steps are explained in more detail below.
The synthesis of the proteoglycan core is the first step in HSGAG biosynthesis. Some
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examples of HSGAG proteoglycans are perlecan, agrin, syndecans, betaglycans, glypicans
and serglycin (30-32). The core proteins of cell surface proteoglycans may be transmembrane
(e.g., syndecan) or GPI-anchored (e.g., glypican). These proteins range in size from lOkDa
(serglycin) to 400 kDa (perlecan). However the number of HSGAG chains attached to these
core proteins does not necessarily parallel their size. For example, while 1-3 HSGAG chains
are attached to perlecan, serglycin may have as high as 10-15 heparin chains. Except for
serglycin, most proteoglycans, irrespective of their size carry 1-3 HSGAG chains.
Proteoglycans are synthesized in endoplasmic reticulum of cells and are transported to Golgi
for subsequent polysaccharide addition (7).
HSGAGs are attached to their core proteoglycan at a serine residue via a
tetrasaccharide linkage regions consisting of serine-xylose-galactose-galactose-glucuronic
acid. Thus, the synthesis of the proteoglycan is followed by the synthesis of the
tetrasaccharide linkage sequence (Figure 4.2), which constitutes the second step in HSGAG
biosynthesis (12, 33). Xylotransferase initiates this process by using UDP-xylose as a donor.
Although many studies have been pursued to find a consensus sequence of amino acids
determining the attachment site, a perfect consensus sequence has not been found. However,
it is noteworthy to mention that a glycine residue was always found next to the carboxyl-
terminal side of the serine (34).
After the synthesis of the tetrasaccharide linkage sequence, the HSGAG chain is
elongated by alternating additions of glucuronic acid and N-acetyl-glucosamine to form
repeating P1,4-linked disaccharide units (Figure 4.2). This polymerization constitutes the
third step of HSGAG biosynthesis and is performed by two glycosyl transferases, EXT1 and
EXT2, which belong to the exostosin family of putative tumor suppressor genes. Together,
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the protein products of these genes form a stable heterodimeric complex in the Golgi and
extend the HSGAG chain (35, 36).
The last step in HSGAG biosynthesis is the modification of the nascent HSGAG
chain. The nascent chain is modified either concomitantly or independently by the sequential
activity of a series of enzymes which leads to N-deacetylation-sulfation, O-sulfation and
epimerization of some of the glucuronic acid to iduronic acid (Figure 4.3) (14, 37). The
HSGAG modifying enzymes, N-deacetylase-N-sulfotransferase, the 2-0, 3-0, and 6-0
heparan sulfate sulfotransferases, and epimerase play a key role in this modification process.
In the recent years, several tissue-specific isoforms of the biosynthetic enzymes have been
identified, giving this system an additional level of complexity (38). For example, five
isoforms of heparan sulfate 3-0 sulfotransferase and three isoforms of heparan sulfate 6-0
sulfotransferase have been identified to date (39, 40). Therefore, cell or tissue-specific
HSGAG biosynthesis might be a result of tissue-specific expression of certain enzyme
isoforms.
As a result of the four biosynthetic steps described above, a highly heterogeneous
HSGAG chain is formed. These HSGAG chains are either transported to the cell surface or
secreted into the extracellular environment. Although the regulatory factors behind the
location of the HSGAGs are not completely understood, it is believed that the proteoglycan
core is the determining factor (16). For example, while syndecan is often transported to the
cell surface, perlecan is found in the extracellular matrix.
The synthesized proteoglycans are also subjected to continuous turnover (15). While
some of these proteoglycans are shed via proteolytic degradation, others can be internalized
by endocytosis. A series of enzymes are involved in the chemical degradation of the
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endocytosed HSGAG chains in the lyzozymes (41). The long carbohydrate chain is first
cleaved into smaller polysaccharide fragments by endoglycosidases termed heparanases (42,
43). The remaining polysaccharide fragments are sequentially degraded by cleavage at the
terminal end via an endoglucuronidase (either a-iduronidase or P-glucuronidase) followed by
desulfation of this uronic acid residue via an epimer-specific sulfatase. The resultant terminal
glucosamine is next cleaved by a -N-acetylglucoaminidase, followed by desulfation and N-
acetylation of this residue by a combination of sulfatases and acetyl transferases of which
heparan-N-sulfatase, acetyl-coA:N-acetyltransferase, N-acetylglucosamine-6-sulfatase, and
N-acetylglucosamine-3-sulfatase are key players (46, 47). Interestingly, heparanase
expression has also been implicated in a variety of pathological processes including cancer
progression, angiogenesis, and development (44, 45).
4.4 Biological Functions of HSGAGs
In recent years, there has been a significant increase in the number of proteins
identified that interact with HSGAGs (17, 48). These proteins include growth factors,
cytokines, morphogens, enzymes, and modulate a variety of signaling pathways that impinge
on biological processes such as embryogenesis (49, 50), hemostasis (51), tumor-progression,
-metastasis (52, 53), and angiogenesis (54). Some known examples of HSGAG binding
proteins and their biological functions are listed in Table 4.2.
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Area Protein Effect of Interaction with HLGAGs References
Hemostasis Antithrombin Conformational change (55)
III
Growth Factors FGF Dimerization, receptor specificity (56, 57)
HGF Growth Factor sequestering
Morphogens WNT Gradient formation (29, 58)
Lipoprotein Lipoprotein Stabilization of lipoprotein lipase, (59)
Clearance lipase enhanced uptake
Cell-Cell P-selectin Modulation of leukocyte homing (60, 61)
Adhesion
Cell-Matrix Laminin Adhesion to ECM (62)
Adhesion Fibronectin Formation of Focal Adhesion points (63)
Angiogenesis VEGF Modulation of receptor-ligand (64)
interactions
Alzheimer 0-amyloid Inhibition of clearance (65)
Enzymes Heparanase, (66)
Heparinase, Substrate (67)
Sulfotase (68)
Table 4.2. Examples of HSGAG binding proteins and their biological functions.
4.4.1 Mechanisms of HSGAG Action
It is becoming increasingly clear that HSGAGs at the cell surface and in the ECM
interact with proteins primarily to (1) facilitate receptor-ligand interactions, (2) modulate
their diffusion and effective concentration and (3) act as a reservoir for signaling molecules
(18, 69). These mechanisms are described below in more detail.
HSGA Gs interact with proteins at the cell surface and ECM to mediate receptor-
ligand interactions. Several crystal structure analysis of HSGAG chains with proteins
revealed the mechanism of how HSGAGs bind to proteins to mediate receptor-ligand
interactions (55). These studies revealed that (1) proteins bind to specific units on HSGAG
chains, (2) HSGAGs may act as a platform that enables oligomerization of proteins, and (3)
HSGAGs may cause conformational changes of proteins upon binding. For example, it has
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been shown that FGF binds to a specific hexasaccharide unit within an HSGAG chain (70-
73). Thus, long HSGAG chains that carry this specific hexasaccharide unit in tandem may act
as a platform and enable oligomerization of FGF ligands. Oligomerization of the ligands
affects the kinetics and thermodynamics of receptor-ligand interactions, and is the major
mechanism of some signaling cascades. For example, it has been shown that HSGAGs
mediate FGF2 oligomerization and lead to increased receptor phosphorylation. The increased
receptor phosphorylation in turn leads to increased signaling cascades (74, 75).
HSGAGs have also been shown to cause conformational changes in the proteins upon
binding. This conformational change in turn converts the inactive form of the protein to its
active form. For example, HSGAGs bind to antithrombin III and induce a conformational
change to convert it into an active inhibitor of thrombin and factor Xa serine proteases. This
process is a critical mediator of the coagulation cascade (55) (described in more detail in
section 4.4.2).
Understanding the structure-function relationships of HSGAG-protein interactions
has been the focus of research for many years. The conformational flexibility of the
polysaccharide backbone provided by the iduronate residue was proposed to be central to the
specific binding of HSGAG oligosaccharides to a given protein (76). Unlike most other
pyranose rings, iduronate is able to adopt a range of different ring conformations such as
chair, 1C4 or 4C1, or skew-boat, 2So , thus providing the polysaccharide chain with
conformational flexibility (77, 78). The conformational changes in HSGAG that are induced
upon protein binding are reminiscent of those occurring in DNA, where, as a rule, protein
binding causes kinked DNA or DNA bending for maximum contact and specificity (1 7, 18,
79).
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HSGA Gs modulate the diffusion and effective concentration ofproteins. HSGAGs
mediate diffusion of proteins and form a gradient from the ECM to the cell surface by
providing passive resistance to free diffusion as well as by dictating diffusion and gradient
formation in a sequence specific fashion. This is best exemplified by the developmental
studies done on the common fruit fly - Drosophila (29, 50, 80). These studies have shown
that a major mechanism by which cells create a gradient for a morphogen is by expressing
specific HSGAGs on the ECM, which bind and modulate the movement of a morphogen. For
example, Wnt family of morphogens control cell proliferation and differentiation during
development, and it was found that HSGAGs have tissue-specific effects on Wnt signaling,
modulating both short and long-range functioning of the morphogen (81, 82). It was also
shown that alteration of the fine structure of the HSGAGs involved in this process abolished
gradient formation and arrested development (29, 80).
HSGA Gs act as a reservoir of signaling molecules at the cell surface and ECM. An
example for the role of HSGAGs in sequestering proteins is provided by FGF. It has been
shown that HSGAGs in the ECM, specifically in the basement membrane, bind and sequester
FGF molecules in an inactive form (69, 75). Upon external stimuli, these FGF proteins are
rapidly released by controlled digestion of the ECM, providing a rapid response without the
need for de novo protein synthesis (83, 84).
4.4.2 Effects of HSGAGs on Physiological and Pathophysiological Processes
The interaction of HSGAGs with a variety of proteins impinges on many
physiological and pathophysiological processes. Some of the well studied processes are
hemostasis, morphogenesis, tumor-progression, tumor-metastasis and angiogenesis. These
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processes and how HSGAG sequences impinge their roles in these processes are discussed
below.
HSGAGs in Hemostasis. Hemostasis is the maintenance of the hemodynamic state of
blood. In humans, a complex coagulation cascade exists to stop excessive bleeding from
ruptured blood vessels to maintain the hemodynamic state of blood. One of the key steps of
this coagulation cascade is the activation of prothrombin (factor II) to thrombin (factor IIa),
which then acts on fibrin to initiate the mesh network responsible for clot formation (69). To
maintain hemostasis, it is as important to inhibit the coagulation cascade once the bleeding
stops, as it is to initiate it. One way this can be achieved is via the inhibition of Factor IIa.
Factor IIa can be inhibited when bound by inhibitory AT-III. The inhibitory effect of AT-III
is mediated by a specific HSGAG sequence, HNA,/s,6sGHNs,3s,6sI2sHNs,6s (85). Once bound to
this highly sulfated pentasaccharide, AT-III goes through a conformational change and
inhibits many of the coagulation proteases including Factor IIa (55, 85, 86, 87). As a
summary, specific HSGAG sequences inhibit the coagulation cascade by binding to AT-III,
which subsequently inhibits factor IIa. The role of HSGAGs in modulation of coagulation
cascade exemplifies how specific HSGAG sequences impinge on important biological
functions. Importantly, highly sulfated heparin is currently being used clinically as a major
anticoagulant for a variety of pathophysiological conditions (85).
HSGAGs in Morphogenesis. Various genetic studies done with Drosophila have
shown the significance of HSGAGs in body patterning in vivo. Genetic screens for mutations
that lead to abnormal morphogenesis and body development uncovered a number of genes
involved in HSGAG biosynthesis (see Table 4.3). The normal phenotypes were recovered by
ectopic expression of the wild type HSGAG biosynthetic enzymes. Furthermore, all of these
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mutants were shown to have defective signaling pathways that are known to be critical in
development, such as Wingless, Hedgehog, and FGF signaling. These studies, combined with
cell biological and biochemical studies done to elucidate the mechanism of Wingless,
Hedgehog and FGF signaling provide convincing evidence that impaired HSGAG
biosynthesis compromises morphogenesis (88-91). Indeed, impaired GlcNAc/GlcA
biosynthesis was found to be related to Hereditary Multiples Exostoses in humans, which is a
pathologic condition that is associated with abnormal skeletal development (92).
HSGAG Mutated Defective Human Related Refs.
Biosynthetic Drosophila Pathways Homologue Pathology
Enzyme Genes
UDP-glucose sugarless Wingless UDP-Glc-DH None (81) (93)
dehydogenase (94)
N-Deacetylase- sulfateless Wingless NDST-1/2 None (80)
Sulfotransferase FGF
GlcNAc/GlcA tout-velu Hedgehog EXT-1/2/3 Hereditary (95) (92)
Polymerase EXL-1/2/3 Multiples
Exotoses
2-0 pipe Dorsal- HS2TS None (50)
sulfotransferase ventral HS3TS (96)
patterning HS6TS
Adapted from (97)
Table 4.3. HSGAG biosynthetic enzymes that are involved in morphogenesis and the
signaling pathways impinged on.
HSGAGs in Tumor Progression and Metastasis. HSGAGs have been implicated to
play a critical role in tumor onset, progression, and metastasis. It has been proposed that
HSGAGs in the basement membrane constitute a barrier to infiltration of tumor cells into
normal tissue, and that the metastatic and invasive properties of tumors are associated with
the degradation of HSGAGs (98). Consistent with this idea, it was found that many tumors
over-express an extracellular mammalian HSGAG degrading enzyme, heparanase (66, 99). It
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also appears that the metastatic potential of some tumors correlates with the expression levels
of heparanase (98) and suppression of heparanase activity has been shown to inhibit tumor
metastasis in vivo (100). It has also been proposed that HSGAGs modulate tumor cell
adhesion to the basement membrane and prevent its infiltration, and it has been shown that
exogenous addition of highly sulfated HSGAGs interfere with tumor cell adhesion to the
basement membrane and leads to tumor metastasis (101, 102). In extensive studies done in
our laboratory, tumor transplants treated with bacterial heparinase I and heparinase III, which
have distinct substrate specificities, revealed that HSGAGs play a critical role in a
structurally specific manner, in tumor onset, progression, and metastasis . While heparinase I
cleaves at the highly sulfated regions, heparinase III cleaves at the undersulfated regions (8,
103, 104). In our studies heparinase III inhibited tumor growth and suppressed the
development of lung metastasis while heparinase I promoted tumor growth and was
ineffective in preventing metastasis. . It is now established that there are specific structural
changes in tumor cell surface HSGAGs as a function of the oncogenic process (105, 106).
For example, elevated levels of 6-O-sulfation and reduced levels of 2-0- and N-sulfation
were found during progression of human colon adenoma to carcinoma (105). Upregulation of
6-0 sulfation was also found in Lewis lung carcinoma cells (107). On the contrary, 6-0-
sulfation was downregulated during malignant transformation of mouse mammary epithelial
cells (108). These studies again suggest a role for specific HSGAG structures in tumor
progression and metastasis.
HSGAGs in Angiogenesis. Angiogenesis is the process of generating new capillary
blood vessels. It is controlled by a fine balance between pro- and anti-angiogenic factors,
and is a critical process for a developing tumor to grow beyond a certain size (-3mm3) (109).
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Various studies have implicated the role of HSGAGs in the modulation of angiogenesis and
it has been shown that this modulation occurs through the structural-interactions between
HSGAGs and the angiogenic growth factors or the negative regulators of angiogenesis (54,
64, 109, 110). For example, it was shown in a chorioallantoic membrane assay that
heparinases inhibited angiogenesis (54). In another study, endostatin, a potent anti-
angiogenic molecule, was found to be an HSGAG binding protein (111). The emerging view
from these studies is that HSGAGs are potent mediators of pro- and anti-angiogenic signalling
pathways and a change in the HSGAG structure can tip the angiogenic balance to either promote or
inhibit angiogenesis.
4.5 Role of HSGAG Degrading Enzymes in Structure-Function Studies
Understanding specific structure-function relationship of HSGAGs has been a very
challenging task due to their highly heterogeneous structure and their low availability on the
cell surface and ECM. Furthermore, unlike other biopolymers (e.g. polynucleotides or
polypeptides), tools that can be used to amplify HSGAGs have yet not been developed
because of their complex biosynthesis.
Tools for the structural analysis of HSGAGs are just coming of age. One of the main
focuses of our lab has been to develop technologies based on recombinant HSGAG
degrading enzymes from Flavobacterium heparinum. Flavobacteria synthesize many
glycosaminoglycan degrading enzymes as part of their catabolic life cycle (112, 113).
Among these enzymes are heparinases, specifically, heparinase-I, heparinase-II, heparinase-
III, A4,5-glycuronidase, 2-O-sulfatase, 3-O-sultafase and N-sulfatase. Each of these enzymes
has unique substrate specificities and act on the HSGAG chain in a sequential order (8, 114).
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The reactions catalyzed by these enzymes and the order they act on the HSGAG chain is
shown in Figure 4.4. Thus, with their substrate specificities, these enzymes provide us with
invaluable tools that can be used in determination of HSGAG sequences, similar to the way
proteases are used to obtain sequence information about proteins, and restriction enzymes are
used to obtain sequence information about DNA.
The first step in the catabolic cycle of Flavobacteria is the depolymerization of the
HSGAG chains. This is catalyzed by heparinases, which cleavage the glycosidic bond by 13-
elimination (8). There are three types of heparinases, -I, -II, and -III, and all three
heparinases have distinct substrate specificities and cleave HSGAG chains at distinct sites
(115, 116). Heparinase I cleaves HSGAGs at sites with an O-sulfated L-iduronic linkage,
heparinase III cleaves at unsulfated uronic acid moiety, and heparinase II cleaves both at
sulfated iduronic and unsulfated uronic acid regions of HSGAGs. Exhaustive digestion of an
HSGAG chain with a combination of heparinases yields the disaccharide building blocks that
make up the HSGAG chain. The next step in the catabolic cycle of Flavobacteria is the
removal of the 2-0-sulfate from the disaccharide by the action of 2-0 sulfatase, followed by
the hydrolysis of the disaccharide into its monosaccharide units by A4,5-glycuronidase. This
is followed by the removal of the 6-0, 3-0 and N-sulfates from the glucosamine moiety by
the actions of 6-0, 3-0 and N-sulfatases respectively. It is yet not known whether 3-0
sulfatase acts on the glucosamine before N-sulfatase, or vice versa (8). In summary, all these
enzymes have unique substrate specificities and can be used in obtaining HSGAG sequence
information.
In addition to their role in HSGAG sequencing, HSGAG degrading enzymes also
provide us with invaluable tools that can be used to modify cell surface and ECM HSGAG
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structures in vitro and in vivo to reveal specific structure-function relationships. For instance,
heparinases from Flavobacteria has been used to reveal the role of HSGAGs in tumor
progression and metastasis, as well as in angiogenesis (53, 54).
4.6 Specific Objectives
The emerging view is that specific HSGAG sequences bind to proteins, impinge on
critical signaling pathways and modulate fundamental biological processes. It is becoming
increasingly clear that glycomics impinges on proteomics, and by doing so, it impinges on
transcriptomics and even genomics (18). Thus, a thorough understanding of the role that
HSGAGs play is a very important dimension in our understanding of biological processes in
the post-genomic era.
One of the major focuses of our lab has been to use recombinant HSGAG degrading
enzymes from Flavobacteria to (1) determine specific sequence information of HSGAG
chains, (2) to reveal the role HSGAGs play in biological processes.
Chapter 5 in this thesis describes the molecular cloning, recombinant expression and
biochemical characterization of an HSGAG degrading enzyme, A4,5 glycuronidase from
Flavobacterium heparinum. This enzyme, with its unique substrate specificity is an
invaluable addition to the repertoire of recombinant HSGAGs degrading enzymes that can be
used for sequencing of HSGAG chains.
In Chapter 6 of this thesis, the studies done to elucidate the role of HSGAGs in
differentiation of embryonic stem cells into endothelial cells are described. These studies
were conducted by using some of the HSGAG degrading enzymes described above, in
combination with other tools, and have significant implications in regenerative therapies. The
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HSGAG paradigm we discovered in ES cell differentiation opens new approaches and
strategies for tissue engineering and will enable the development of novel molecular
therapeutics.
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Figure 4.1. Heparan Sulfate Glycosaminoglycans (HSGAGs) repeat unit. HSGAGs are
extracellular and cell surface polysaccharides. They are made up of a disaccharide repeat unit
of a uronic acid (U) linked 1,4 to a glucosamine (G).There are two possibilities for the uronic
component of the disaccharide unit: Iduronic acid or Glucuronic acid. The chemical
modifications that may take place physiologically are O-sulfation at the second carbon of the
uronic acid (2-0) and the O-sulfation at the third and sixth carbons of the glucosamine (3-0
and 6-0), as well as N-sulfation (N-S) or N-acetylation (N-Ac) of the second carbon of the
glucosamine.
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Golgi Membrane
Heparan Sulfate Linkage Region Repeating Disaccharide Chain
Figure 4.2. Schematics of initiation of HSGAG biosynthesis. HSGAG biosynthesis starts by
the addition of the tetrasaccharide linkage sequence [xylose (Xyl)- galactose (Gal)- galactose
(Gal)- glucuronic acid (GlcA)] to the serine residue of a core proteoglycan. This is followed
by the addition of N-acetyl-glucosamine (GlcNAc) to the linkage tetrasaccharide. The
HSGAG chain is then extended by subsequent alternating additions of glucuronic acid and
N-acetyl-glucosamine.
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Figure 4.3. Schematics of modification of the nascent HLGAG chain. The nascent chain is
modified by the sequential activity of a series of enzymes which leads to N-deacetylation -
sulfation, epimerization, and O-sulfations. N-deacetylase-N-sulfotransferase (NDST)
converts some N-acetyl-glucosamines (GlcNAc) to N-sulfated-glucosamines (GlcNS). This
is followed by the action of epimerase which converts some glucuronic acids (GlcA) to
iduronic acids (IdoA). Lastly the 2-0, 3-0, and 6-0 heparan sulfate sulfotransferases act to
further modify the HSGAG chain. As a result, a highly heterogeneous HSGAG chain is
formed.
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Figure 4.4. HSGAG degrading enzymes from Flavobacterium heparinum. Among these
enzymes are heparinases, 2-0-sulfatase, A4,5-glycuronidase, 6-0-sulfatase, 3-0-sultafase
and N-sulfatase. Each of these enzymes has unique substrate specificities and act on the
HSGAG chain in a sequential order. The reactions catalysed by these enzymes and the
sequential order are shown. It is not exactly known whether N-sulfatase or 3-0-sulfatase acts
first.
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CHAPTER 5
Molecular Cloning, Recombinant Expression and
Biochemical Characterization of the Heparin/Heparan Sulfate
A4,5 Glycuronidase from Flavo Heparinum
Synopsis: The soil bacterium Flavobacterium heparinum produces several enzymes that
degrade heparan sulfate glycosaminoglycans (HSGAGs) in a sequence-specific manner.
Among others, these enzymes include the heparinases and an unusual glycuronidase that
hydrolyzes the unsaturated Delta4,5 uronic acid at the nonreducing end of oligosaccharides
resulting from prior heparinase eliminative cleavage. We report here the molecular cloning of
the Delta4,5 glycuronidase gene from the flavobacterial genome and its recombinant
expression in Escherichia coli as a highly active enzyme. We also report the biochemical and
kinetic characterization of this enzyme, including an analysis of its substrate specificity. We
find that the Delta4,5 glycuronidase discriminates on the basis of both the glycosidic linkage
and the sulfation pattern within its saccharide substrate. In particular, we find that the
glycuronidase displays a strong preference for 1> 4 linkages, making this enzyme specific to
heparin/heparan sulfate rather than 1 3 linked glycosaminoglycans such as
chondroitin/dermatan sulfate or hyaluronan. Finally, we demonstrate the utility of this
enzyme in the sequencing of heparinase-derived HSGAG oligosaccharides.
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CHAPTER 5
Molecular Cloning, Recombinant Expression and
Biochemical Characterization of the Heparin/Heparan Sulfate
A4,5 Glycuronidase from Flavo Heparinum
5.1 Introduction
Glycosaminoglycans (GAGs) are linear, acidic polysaccharides that exist
ubiquitously in nature as residents of the extracellular matrix and at the cell surface of many
different organisms (1). In addition to a structural role, GAGs act as critical modulators of a
number of biochemical signaling events (2) requisite for cell growth and differentiation, cell
adhesion and migration, and tissue morphogenesis. The heparan sulfate glycosaminoglycans
(HSGAGs) are a particular class of GAGs that have emerged as key players in many
different biological processes ranging from angiogenesis (3) and cancer biology (4) to
microbial pathogenesis (5). HSGAGs have also recently been shown to play a fundamental
role in multiple aspects of development (6).
HSGAGs are able to mediate these different biological events as a consequence of their
considerable structural diversity (7, 8). This chemical heterogeneity is due largely to the
differential sulfation pattern present for each disaccharide unit within the oligosaccharide
chain. Adding to this structural variability is the C5 epimerization of the uronic acid that
occurs at select chain positions. Taken together, these structural determinants impart a unique
sequence to each HSGAG chain. In turn, this sequence dictates a critical HSGAG-protein
interaction (9).
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A determination of GAG sequence, however, has been technically challenging. To
begin with, these polysaccharides are naturally present in very limited quantities, which, unlike
other biopolymers such as proteins and nucleic acids, cannot be readily amplified. Second, due
to their highly charged character and structural heterogeneity, HSGAGs are not easily isolated
from biological sources in a highly purified state. Compounding this reality has historically
been the lack of sequence-specific tools to cleave these linear polysaccharide chains in a
manner analogous to DNA sequencing or restriction mapping. Recent chemical and enzymatic
approaches have been used to cleave GAGs in a sequence-specific fashion. These HSGAG-
degradation procedures have been used in conjunction with several analytical methods such as
gel electrophoresis (10, 11) HPLC, and mass spectroscopy (12) to sequence the
polysaccharides. We have refined this GAG sequencing approach by using tandem capillary
electrophoresis/MALDI-MS analyses carried out within a bioinformatics framework (13). We
have used this method to rapidly sequence biologically important HSGAGs, including
saccharide sequences involved in modulating anticoagulation (14). The use of additional
glycosaminoglycan-degrading enzymes will increase the analytical scope of this and other
sequencing procedures.
Flavobacteria synthesize many glycosaminoglycan-degrading enzymes as an integral
part of their catabolic life cycle (15). For this reason, this particular soil bacterium has been
invaluable for identifying several enzymes potentially useful to the in vitro characterization of
glycosaminoglycan structure. The biosynthesis of many of these enzymes can be induced
several fold under growth conditions of high glycosaminoglycan content (16, 17). One of the
first such heparin-degrading enzymes purified from adapted F. heparinum2 1 cultures included
While Flavobacterium heparinum is the historical (and commonly used) taxonomy, the current scientific name
for this microorganism is Cytophaga heparina.
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the heparin lyases (i.e., heparinases) (16), which cleave large chains of heparin and heparan
sulfate into constituent oligosaccharides, each possessing a A4,5 unsaturated uronidate at the
non-reducing end. In a likewise manner, an unusual glycuronidase that specifically hydrolyzes
this unsaturated uronic acid was also identified and partially purified (18).
In this study, we report the first known molecular cloning of the A4,5 glycuronidase
from the F. heparinum genome and its subsequent recombinant expression in E. coli as a
soluble, highly active enzyme. We also present a biochemical characterization of the
glycuronidase that includes a demonstration of its kinetic equivalence to the native enzyme and
a description of its unusual substrate specificity.
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5.2 Experimental Procedures
Chemicals and reagents
Unless otherwise stated, biochemicals were purchased from Sigma Aldrich Chemical
(St. Louis, MO). Unsaturated disaccharides were purchased from Calbiochem (San Diego,
CA). Reagents for XZAP II genomic library construction and screening were obtained from
Stratagene (La Jolla, CA). Additional molecular cloning reagents were obtained from the
manufacturers listed.
Bacterial strains and growth conditions
F. heparinum (Cytophaga heparina) was obtained as a lyophilized stock from
American Type Culture Collection (ATCC, Manassas, VA), stock no. 13125. E. coli strains
included TOP10 (Invitrogen, Carlsbad CA) for PCR cloning and subcloning and BL21(DE3)
(Novagen, Madison WI) for recombinant protein expression. Bacteriophage host strains
XL1-Blue MRF' and SOLR were obtained from Stratagene.
Large-scale Purification of A4.5 glvcuronidase from Flavobacterium
The A4,5 glycuronidase was purified from a 10 liter fermentation culture essentially
as described for the Flavobacterial 2-O-sulfatase (19). Briefly, the cell pellet was harvested
by centrifugation, resuspended in 200 mL of sodium phosphate buffer, pH 7.0 and lysed by
repeated passage through an Aminco French pressure cell. The bacterial lysate was
chromatographed on a CM-Sepharose CL-6B column (17 x 3.2 cm), equilibrated with 10
mM sodium phosphate pH 6.5. A4,5 glycuronidase activity was eluted using a salt gradient of
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0 to 0.3 M NaCl. Pooled fractions were diluted in sodium phosphate pH 6.7 buffer and
applied to hydroxyapatite (Bio-Gel HTP, 16x2cm). Glycuronidase activity was eluted by
application of a 0.01 to 0.5 M sodium phosphate gradient. Pooled enzyme fractions were
desalted using Sephadex G-50M before applying to a Taurine-Sepharose CL-4B column
(14x2cm). As a final purification step, the flow-through from Taurine Sepharose
chromatography was reapplied to a CM Sepharose column and eluted by a NaCl gradient as
described. Purification to homogeneity was verified by SDS-PAGE which indicated a single
protein with an apparent molecular weight of approximately 45 kDa.
Generation of glcuronidase peptides and protein sequencing
A4,5 glycuronidase (approximately 1 nmol) was denatured in 50 gL 8M Urea, 0.4 M
ammonium bicarbonate and reduced with 5 mM dithiothreitol at 65C, cooled to room
temperature, and alkylated with 10 mM iodoacetic acid for 20 minutes. The reaction was
quenched with water. To this reaction was added 4% (w/w) of trypsin, and the digestion was
carried out at 37C overnight. The resulting peptides were separated using gradient reverse-
phase HPLC (2-80% acetonitrile in 0.1% trifluoroacetic acid) over the course of 120 minutes.
Tryptic peptides were monitored at 210 and 277nm. Peptide peaks were collected and
sequenced using an on-line Model 120 phenylthiohydantoin-derivative analyzer
(Biopolymers Laboratory, Massachusetts Institute of Technology).
Molecular cloning of the 4,5 glvcuronidase gene from F. heparinum genomic DNA
Flavobacterial genomic DNA was isolated from a 10 mL Flavobacterial culture
using the Qiagen DNeasy DNA purification kit according to the Manufacturer's instructions
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for gram-negative bacteria (approximately 2 x 109 cells per column). Following purification,
genomic DNA was ethanol precipitated and resuspended in TE buffer (10 mM Tris, pH 7.5, 1
mM EDTA) at 0.5 mg/mL. The quality of genomic DNA was confirmed
spectrophotometrically at 260/280 nm and by electrophoresis on a 0.5% agarose gel
The following degenerate primers were synthesized from peptides corresponding
initially to peaks 19 and 24:
5' GARACNCAYCARGGNYTNACNAAYGAR 3' (peak 19 forward),
5' YTCRTTNGTNARNCCYTGRTGNGTYTC 3' (peak 19 reverse);
5' AAYTAYGCNGAYTAYTAYTAY 3' (peak 24 forward);
5' RTARTARTARTCNGCRTARTT 3' (peak 24 reverse).
All four primers were screened in a PCR assay using all possible pairings (forward and
reverse). The PCR reaction conditions included 200 ng of genomic DNA, 200 picomoles for
each forward and reverse primer, 200 jpM dNTPs, 1 unit of Vent DNA Polymerase (New
England Biolabs) in a 100 pI reaction volume. 35 cycles were completed using a 52°C
annealing temperature and 2 minute extensions at 720C. A 450 bp product amplified using
primers 19 forward and 24 reverse was gel purified and subject to direct DNA sequencing
which confinned the inclusion of translated sequence corresponding to peptide peaks 19 and
24 in addition to peak 12. The same DNA was also 32 p radiolabeled by random priming using
200 CpCi 32P[dCTP] at 6000 Ci/mmole (NEN, Boston, MA), 50-100 ng of DNA and the
Prime-it II random priming kit (Stratagene) (probe 1). Unincorporated 3 2 p dNTPs were
removed by gel filtration using G-50 Quick-spin columns (Roche biochemicals, Piscataway
New Jersey).
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DNA hybridization probe 2 was initially created by PCR as described above except
using degenerate primers 26 CARACNTAYACNCCNGGNATGAAY (peak 26 forward) and
20 picomoles of reverse, non-degenerate primer 54 (TTCATGGTCGTAACCGCATG).
Direct sequencing of this PCR fragment confirmed the presence of gene sequence
corresponding to peak 26 and peak 13 peptides. A4,5 5' specific DNA probe 3 used in DNA
southern hybridizations (below) was PCR amplified from genomic DNA using primers 68
(TATACACCAGGCATGAACCC)) and 74 (CCCAGTATAAATACTCCAGGT).
Plaque hybridization screening ofF. heparinum genomic library
A X ZAP II genomic library was constructed as described (20). The amplified library
(1 x 1010 pfu/mL) was plated out at approximately 1 x 106 pfu (-50,000 pfu/plate) on 100 x
150 mm LB plates. Plaque lifts on to nylon membranes (Nytran Supercharge, Schleicher and
Schuell) and subsequent hybridization screenings were completed using standard methods
and solutions (21). DNA was crosslinked to each filter by UV-irradiation (Stratagene
Stratalinker) for 30 seconds at 1200 joules/cm3 . Hybridizations were carried at 420C using
107-108 cpm of radiolabeled probe (at approximately 0.25 ng/mL). Low stringency washes
were carried out at room temperature in 2X SSC, 0.1 % SDS; high stringency washes carried
out at 58-600 C in 0.2X SSC and 0.1% SDS. Hybridized plaques were visualized by phosphor
imaging (Molecular Dynamics) and/or 32 p autoradiography. Tertiary screens of positive
clones were completed and the recombinant phage was excised as a double-stranded
phagemid (pBluescript) using the Ex-Assist interference-resistant helper phage according to
the manufacturer's protocol (Stratagene). Recombinants were characterized by DNA
sequencing using both T7 and T3 primers.
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Creation of a flavobacterium Bgl II-EcoRI subgenomic library for isolation of the A4,5 5'
terminus
Southern DNA hybridizations were completed according to standard protocols (21)
using 32p radiolabeled probe 3. 1 gg of genomic DNA was cut with 20 units of Eco R1, Bgl
II, and Hind III individually or as double digests and the restriction products were resolved
by gel electrophoresis on a 1 % agarose gel run in 1X TAE buffer. Based on this Southern
analysis, a 1.5 kb DNA fragment containing the 5' A4,5 terminus was identified. 10 gg of
Flavobacterial genomic DNA was therefore digested with Bgl-II-Eco Ri and the DNA
resolved on a preparative gel run under identical conditions as those described for the
analytical gel. DNA ranging from approximately 1-2 kb was gel purified and ligated into
pLITMUS as a Bgl II-EcoR1 cassette. Positive clones were identified by PCR colony
screening using primers 68 and 74 and confirmed by DNA sequencing.
PCR cloning of A4.5 gene and recombinant expression in E. coli
The full-length glycuronidase gene was directly PCR amplified from genomic DNA
using forward primer 85 TGTTCTAGACATATGAAATCACTACTCAGTGC and reverse
primer 86 GTCTCGAGGATCCTTAAGACTGATTAATTGTT (with Nde 1 and Xho 1
restriction sites denoted in bold), 200 ng genomic DNA, and Vent DNA Polymerase for 35
cycles. dA overhangs were generated in a final 10 minute extension at 72°C using AmpliTaq
DNA polymerase (Applied Biosystems). PCR products were gel purified, ligated into the
TOPO/TA PCR cloning vector (Invitrogen), and transformed into One-shot TOP 10
chemically competent cells. Positive clones were identified by blue/white colony selection
and confirmed by PCR colony screening. The 1.2 kb A4,5 gene was subcloned into
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expression plasmid pET28a (Novagen) as an Nde l-Xho 1 cassette. Final expression clones
were confirmed by plasmid DNA sequencing.
For the expression of A4,5 glycuronidase beginning with M21 (A4,5A20), the forward
primer 95 TGT TCT AGA CAT ATG ACA GTT ACG AAA GGC AA (also containing an
Nde 1 restriction site near its 5' terminus) was used in place of primer 85 (above). 50 ng of
the original expression plasmid pET28a/A4,5 was used as the DNA template in PCR
reactions involving a total of 20 cycles. Otherwise, cloning was as described for the full-
length gene. Both pET28a/A4,5 and pET28aA4,5~2° plasmids were transformed into BL21
(DE3) for expression as N-terminal 6X His-tagged proteins. 1 liter cultures were grown at
room temperature (-200 C) in LB media supplemented with 40 g/mL kanamycin. Protein
expression was induced with 500 gM IPTG added at an A600 of 1.0. Induced cultures were
allowed to grow for 15 hours (also at room temperature).
Recombinant A4,5 glycuronidase purification
Bacterial cells were harvested by centrifugation at 6000 x g for 20 minutes and
resuspended in 40 mL of binding buffer (50 mM Tris-HCL, pH 7.9, 0.5 M NaCl, and 10 mM
imidazole). Lysis was initiated by the addition of 0.1 mg/mL lysozyme (20 minutes at room
temperature) followed by intermittent sonication in an ice-water bath using a Misonex XL
sonicator at 40-50% output. The crude lysate was fractionated by low-speed centrifugation
(18,000 x g; 4°C; 15 minutes) and the supernatant was filtered through a 0.45 micron filter.
The 6X-His tag A4,5 glycuronidase was purified by Ni+2 chelation chromatography on a 5
mL Hi-Trap column (Pharmacia Biotech, NJ) pre-charged with 200 mM NiSO4 and
subsequently equilibrated with binding buffer. Column washes included an intermediate step
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with 50 mM imidazole. The A4,5 enzyme was eluted from the column in 5 mL fractions
using high imidazole elution buffer (50 mM Tris-HCL, pH 7.9, 0.5 M NaCl, and 250 mM
imidazole). Peak fractions were dialyzed overnight against 4 liters of phosphate buffer (0.1M
sodium phosphate, pH 7.0, 0.5 M NaCl) to remove the imidazole.
The 6X His tag was effectively cleaved by adding biotinylated thrombin at 2
units/milligram of recombinant protein, overnight at 40C with gentle inversion. Thrombin
was captured by binding to streptavidin agarose at 40 C for two hours using the Thrombin
Capture Kit (Novagen). The cleaved peptide MGSSHHHHHHSSGLVPR was removed by
final dialysis against a 1000-fold volume of phosphate buffer.
Protein concentrations were determined by the Bio-Rad protein assay and confirmed
by UV spectroscopy using a theoretical molar extinction coefficient £=88,900 for A4,5A2 °.
Protein purity was assessed by SDS-PAGE followed by Coomassie Brilliant Blue staining.
Computational methods
Signal sequence predictions were made by SignalP VI.1 using the von Heijne
computational method (22) with maximum Y and S cutoffs set at 0.36 and 0.88, respectively.
Glycuronidase multiple sequence alignments were made from select BLASTP database
sequences (with scores exceeding 120 bits and less than 6% gaps) using the CLUSTAL W
program (version 1.81) preset to an open gap penalty of 10.0, a gap extension penalty of
0.20, and both hydrophilic and residue-specific gap penalties turned on.
129
Assay for enzyme activity and determination of kinetic parameters
Standard reactions were carried out at 30°C and included 100 mM sodium phosphate
buffer, pH 6.4, 50 mM NaCl, 500 FM disaccharide substrate and 200 nM enzyme in a 100 pI
reaction volume. Hydrolysis of unsaturated heparin disaccharides was determined
spectrophotometrically by measuring the loss of the A4,5 chromophore measured at 232 nm.
Substrate hydrolysis was calculated using the following molar extinction coefficients
empirically determined for each unsaturated disaccharide substrate: AUHNAc, 8232=4,524;
AUHNAc,6S, 8232=4,300; AUHNS, 8232=6,600; AUHNS,6S, 8232=6,075; AUHNH2,6S, 8232=4,826;
AU2 SHNs, 6 s, a232=4,433. Initial rates (Vo) were extrapolated from linear activities representing
<10% substrate turnover and fit to pseudo first-order kinetics. For kinetic experiments,
disaccharide concentration for each respective substrate was varied from 48 to 400 jiM
concentrations. Km and kcat values were extrapolated from Vo vs. [S] curves fit to the
Michaelis-Menten equation by a non-linear least squares regression.
For experiments measuring the relative effect of ionic strength on glycuronidase
activity, the NaCl concentration was varied from 0.05 to 1 M in 0.1 M sodium phosphate
buffer (pH 6.4), 200 gM AUHNS,6s and 100 nM enzyme under otherwise standard reaction
conditions. The effect of pH on catalytic activity was kinetically determined at varying
AUHNS,6S concentrations in 100 mM sodium phosphate buffer at pH 5.2, 5.6, 6.0, 6.4, 6.8, 7.2
and 7.8. Data were fit to Michaelis-Menten kinetics as described above and the relative
kcat/Km ratios plotted as a function of pH.
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Detection of A4,5 glcuronidase activity by capillary electrophoresis
200 gig of heparin (Celsus Laboratories) was subject to exhaustive heparinase
digestion as described (13) with certain modifications that included a 50 mM PIPES buffer,
pH 6.5 with 100 mM NaCI in a 100 il reaction volume. Following heparinase treatment, 25
picomoles of A4,5 glycuronidase were added to one-half of the original reaction (pre-
equilibrated at 300 C). 20 jgl aliquots were removed at 1 minute and 30 minutes and activity
quenched by heating at 95°C for 10 minutes. 20 til of the minus A4,5 control (also heated for
10 minutes) was used as the 0 time point. Unsaturated disaccharide products were resolved
by capillary electrophoresis run for 25 minutes under positive polarity mode as previously
described (12).
Molecular mass determinations by MALDI-MS
The molecular weight of both the wild type and recombinantly expressed forms of the
enzyme were determined by matrix-assisted laser desorption ionization mass spectrometry
(MALDI-MS) using a Voyager Elite time-of-flight instrument (PerSeptive Biosystems,
Framingham, MA). Prior to mass analysis, the N-terminal histidine tag of the recombinant
protein was removed. For MALDI-MS analysis, 0.5 l of an aqueous protein solution (0.1-1
mg/mL) was added to the target followed by the addition of 1 l1 of a saturated sinapinic acid
matrix solution in 50% acetonitrile/water. The sample was allowed to air dry and then placed
into the instrument. Mass spectra were collected in the linear mode using delayed extraction.
Instrument parameters were adjusted to maximize signal. All spectra were calibrated
externally using a mixture of ovalbumin and carbonic anhydrase (Sigma-Aldrich).
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5.3 Results
Molecular cloning of the A4,5 glvcuronidase gene from F. heparinum genome
To clone the A4,5 glycuronidase gene, we isolated a series of A4,5 glycuronidase-
derived peptides after a protease treatment of the purified enzyme. The native enzyme was
directly purified from fermentation cultures ofF. heparinum using a 5-step chromatography
scheme as previously described (19). The extent of purity was ultimately characterized by
reverse phase chromatography, which indicated a single major peak (Figure 5.1A). We were
able to generate a number of peptides by a limit trypsin digestion of the purified enzyme. 26
peptide fragments were resolved by reverse phase chromatography (Figure 5.1B). From these
26, at least eight peptides (corresponding to major peaks 8, 12, 13, 19, 24, and 26) were of
sufficient yield and purity and were selected for protein sequence determination (Figure
5.1C).
Based on this information, we designed degenerate primers corresponding to peaks
19, 24, and 26. These primers were used to PCR amplify A4,5 specific sequences to be used
as suitable DNA hybridization probes for screening the Flavobacterial genomic library. A
combination of two primer pairs in particular (peak 19 forward and peak 24 reverse) gave a
discrete PCR product of approximately 450 base pairs. The translation of the corresponding
DNA sequence indicated that it contained the expected amino acid sequence corresponding
to peaks 19 and 24. The peak 12 peptide also mapped to this region. We used this PCR DNA
fragment in the initial plaque hybridizations. The most 5' terminal clone obtained in this
screening included approximately one-half of the predicted gene size corresponding to the
carboxy terminus of the putative ORF. Invariably, all of the isolated clones possessed an Eco
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R1 site at their respective 5' termini. In an attempt to isolate a clone from the phage library
possessing the other half of the gene, we rescreened additional plaques, this time using a
second N-terminal specific DNA hybridization probe (probe 2) in tandem with the original
probe 1. This second strategy also failed to yield any clones with the fully-intact A4,5 gene.
Alternate approaches were taken in an attempt to obtain the 5' terminus of the
glycuronidase gene. The size of this missing region was estimated, based on the molecular
weight of the native protein, to be approximately 45 amino acids (135 base pairs). We
completed DNA southern analyses to identify potentially useful DNA restriction sites
flanking the 5' end of the A4,5 gene. This restriction mapping ultimately involved the use of
the Eco R1 site within the gene in conjunction with hybridization probe 3 (whose 3' end lies
just 5' to this restriction site) to positively bias our search for the remaining amino terminus.
Based on this refined map, we successfully isolated and subcloned an approximatelyl.5 kb
Bgl II- Eco R1 A4,5 fragment into pLITMUS. The 5' terminus of the A4,5 gene was obtained
from direct DNA sequencing of this subgenomic clone.
A summary of the full-length gene sequence (compiled from the two overlapping
cloning methods) is depicted in Figure 5.2. The A4,5 coding sequence is comprised of 1209
base pairs corresponding to an ORF that encodes a 402 amino acid protein. The predicted
molecular weight of 45,621 Daltons for the translated protein corresponds very well with an
empirical molecular mass of 45,586 Daltons for the purified Flavobacterial enzyme
determined by MALDI-MS. All of the peptides for which we obtained sequence information
map to this A4,5 ORF. Based on further primary sequence analyses, we have also identified a
likely bacterial signal sequence spanning amino acids 1-20 also possessing a putative
cleavage site between residues G20 and M21 (Figure 5.3). The presence within this
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hydrophobic amino terminus of an AXXA peptidase cleavage motif further supports this
presumption (24).
A search for related sequences in the NCBI protein database led to several
functionally related enzymes. In a multiple sequence alignment of our cloned enzyme with
select unsaturated glucuronyl hydrolases, we found a homology that generally corresponded
to upwards of 30% identity and nearly 50% similarity at the primary sequence level (Figure
5.4). This relatedness spanned most of the enzyme sequence, excluding the N-terminus.
Based on this alignment, we found several highly conserved positions within the F.
heparinum A4,5 glycuronidase that included several aromatic and acidic residues, e.g., W73,
F77, Y86, Fl 119, W162, W244, W250, Y253 W292, and Y379; D116, D174, D213, D287,
D293, D305, D371 and D378. Other invariant amino acids of possible catalytic importance
include H115, H201, H218 and basic residues R151, R211, and R246.
Recombinant expression and purification of the 414,5 glvcuronidase
Using PCR, we cloned from the F. heparinum genome both the full-length enzyme
and the "mature" enzyme lacking the N-terminal 20 amino acid signal sequence (A4,5t 20)
into a T7-based expression plasmid. Cloning into pET28a permitted the expression of the
glycuronidase as an N-terminal 6X His-tag fusion protein. Pilot expression studies focused
on the full-length enzyme. In these initial experiments, we examined several different
induction conditions such as temperature, time and length of induction, and even IPTG
concentrations. In every case, the full-length enzyme was present nearly exclusively as an
insoluble fraction. Attempts to purify the enzyme directly from inclusion bodies and then
refold the protein were not successful. Solubility was partially achieved by a combined use of
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detergents (e.g., CHAPS), increasing salt concentrations, and the addition of glycerol; the
partially purified enzyme, however, was largely inactive. Conversely, recombinant
expression of the enzyme lacking the presumed signal sequence yielded remarkably different
results. In this case, soluble recombinant expression levels routinely reached several hundred
milligrams of protein per liter of induced cells. The specific activity of this enzyme on the
heparin disaccharide AUHNAc was likewise robust (see below).
A summary of the expression and purification of A4,5620 is summarized in Figure 5.5
and Table 5.1. A two-step purification comprised of Ni+2 chelation chromatography followed
by thrombin cleavage to remove the 6X His purification tag typically yielded over 200 mg of
pure enzyme as assessed by SDS-PAGE followed by Coomassie Brilliant Blue staining.
Most notably, the specific activity of the recombinant enzyme acting upon AUHNAC far
exceeded the values reported in the literature for the wild type enzyme (18). While removal
of the 6X His tag from the N-terminus of the enzyme was unnecessary for optimal hydrolytic
activity, the presence of the histidine tag did appear to instigate protein precipitation over an
extended time period, especially at higher enzyme concentrations. This tag was, therefore
removed for all subsequent biochemical experiments. In this manner, the recombinant protein
was stable at 40C for at least two weeks during which time it remained in solution at protein
concentrations exceeding 10 mg/mL under the buffer conditions described.
A molecular mass of 44,209 Daltons was determined for the recombinant enzyme
(i.e., A4,5A0 ) by MALDI-MS. This empirically-established molecular weight is consistent
with its theoretical value of 43,956 Daltons based on its amino acid composition. This value
physically differs by 1377 Daltons in comparison to a molecular weight of 45,586 Daltons
likewise measured for the native enzyme. This mass differential is largely accounted for by
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the engineered removal in the recombinant protein of the 20 amino acid signal sequence.
However, we cannot exclude the possibility of differential posttranslational modifications
such as glycosylation largely accounting for the observed differences between the two
enzyme populations. Unfortunately, chemical blocking precluded us from determining the N-
terminal sequence of the native protein.
Biochemical conditions for optimal enzyme activity
To determine the optimal reaction conditions for A4,5 glycuronidase activity, we
analyzed initial reaction rates as a function of buffer, pH, temperature, and ionic strength
(Figure 5.6). For these experiments, we used the unsaturated, disulfated heparin disaccharide
substrate AUHNs,6s. Based on what is known about the degradation of heparin/heparan sulfate-
like glycosaminoglycans byflavobacteria (25) as well as initial biochemical characterization
of this and related enzymes (18, 26), we hypothesized that an unsaturated heparin disaccharide
would be a logical substrate for the A4,5 glycuronidase. Enzyme activity was routinely
monitored by a loss of absorbance at 232 nm, corresponding indirectly to the hydrolysis of the
uronic acid from the non-reducing end. The observed decrease in UV absorption is presumably
due to the chain opening of the unsaturated uronidate monosaccharide concomitant with keto-
enol isomerization to form the a-keto acid, resulting in the loss of the X23 2-absorbing carbon-
carbon bond (27).
Under the examined conditions, we observed a NaCl concentration-activity
dependence with optimal enzymatic activity occurring at salt concentrations between 50 and
100 mM. At concentrations exceeding 100 mM NaCl, the enzyme demonstrated a significant
decrease in activity that was sharply dependant on the ionic strength (Figure 5.6A), i.e., with
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approximately 60% inhibition occurring at 250 mM NaCl relative to 100% activity measured
at 100 mM NaCl.
The observed pH profile for the glycuronidase was bell-shaped (Figure 5.6B) with a
pH optimum of 6.4. This result is consistent with previously published results (18). In
addition, temperature titration experiments indicated that maximal enzymatic activity for the
A4,5 glycuronidase was achieved at 300 C. Interestingly, initial reaction rates were
significantly reduced at higher temperatures, especially at 420 C (Figure 5.6C). Preincubation
experiments at 30, 37, and 42°C to assess enzyme stability indicated no significant change in
enzymatic activity when the enzyme was subsequently measured under the standard 300 C
reaction conditions. The results of these experiments suggest that the observed decrease in
the enzymatic reaction rate at higher temperatures is not due to a thermal lability of the A4,5
glycuronidase, rather it reflects some intrinsic property of its catalytic function.
As a final variable for optimizing A4,5 glycuronidase in vitro reaction conditions, we
also considered any requirement for divalent metal ions, including Ca+ , Mg++, Mn, and
others. We found no evidence that any metal cofactor is either required for catalysis or
activates the enzyme to any appreciable extent.
Having established the reaction conditions for optimal A4,5 glycuronidase activity,
we next compared the specific activity of the recombinant enzyme (A4,520°) to the native
enzyme purified directly from F. heparinum. The activities of both enzyme fractions were
measured in parallel under identical reaction conditions. In this comparison, the recombinant
A4,5 possessed a 1.5-fold higher initial velocity relative to the native enzyme. These results
demonstrate that the recombinant enzyme is comparable in activity to the native form of the
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enzyme and possesses the added benefit that over 1000-fold more enzyme can be obtained
per liter of culture as compared to the wild type.
A4,5 glvcuronidase substrate specificity
Given the fact that the recombinant form of the A4,5 glycuronidase possessed similar
attributes to the native form and is undoubtedly free of contaminating HSGAG-degrading
activities, this form of the enzyme was used to characterize the substrate specificity of the
A4,5 glycuronidase using various unsaturated glycosaminoglycan disaccharide substrates.
These substrates examined included heparin, chondroitin, and hyaluronan disaccharides. In
particular, we considered the possibility of any structural discriminations pertaining to the
glycosidic linkage position (1--4 vs. 13) and relative sulfation state within the
disaccharide. For each substrate, kinetic parameters were determined based on substrate
saturation profiles that fit Michaelis-Menten assumptions (Figure 5.7). These kinetic values
are listed in Table 5.2. For the heparin disaccharides, kcat values varied significantly from
approximately 2 to 15 sec'1, while the apparent Km values for each respective disaccharide
were comparable, ranging from approximately 100 gM to 300 gaM. The heparin disaccharide
AU2 SHNs 6s was unequivocally not a substrate at any of the concentrations studied, even
following an extended incubation time spanning several hours. For those unsaturated heparin
disaccharides that were hydrolyzed under the conditions tested and for which kinetic
parameters could be determined, a highly interesting substrate preference was apparent. In
this hierarchy, the two disaccharides AUHNAc and AUHNAc,6s were clearly the best substrates.
In comparison, AUHNH2,6s and AUHNS were relatively poor substrates. The kinetic values for
AUHNS,6S fell roughly in the middle between these two boundaries.
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None of the non-heparin disaccharides were hydrolyzed under the conditions
established to measure substrate kinetics. These results indicate an unequivocal
discrimination of the A4,5 glycuronidase with regards to linkage position, with a strong
preference for 1-4 versus 1-3 linkages. At the same time, 13-containing disaccharides
were hydrolyzed slowly to varying degrees when the enzyme reactions were conducted over
a much longer time course (> 12 hours) and at considerably higher enzyme concentrations
(data not shown). After approximately 18 hours, greater than 80% of a monosulfated
chondroitin disaccharide (AUGalNAc,6s) was hydrolyzed, whereas the non-sulfated
chondroitin (AUGalNAc) and the hyaluronan disaccharide (AUH) were still present at
approximately 40% and 65%, respectively. The apparently positive effect of chondroitin 6-
O-sulfation within the galactosamine is consistent with our results for the heparin substrates
and provides further evidence for the influence of this position in dictating substrate
specificity.
Based on the clear, kinetically defined substrate specificity for the unsaturated
disaccharides, we set out to validate these results while, at the same time, investigating the
utility of the A4,5 glycuronidase as an enzymatic tool for HSGAG compositional analysis. In
this manner, the A4,5 glycuronidase could potentially be very useful in assessing the
composition of disaccharides resulting from prior heparinase treatment of heparin/heparan
sulfate. For this particular experiment, we pre-treated 200 gig of heparin with a heparinase
cocktail. This exhaustive digestion was then directly followed by a relatively short (1 minute)
or long (30 minute) A4,5 glycuronidase treatment carried out under optimal reaction
conditions. The unsaturated disaccharide products were then resolved by capillary
electrophoresis. The electrophoretic mobility profile for the A4,5 glycuronidase-treated
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saccharides were then directly compared to the untreated control (i.e., heparinase treatment
only) run under identical conditions (Figure 5.8). Seven disaccharide peaks were present in
the capillary electrophoretogram corresponding to the heparinase only control (Figure 5.8A).
A structural assignment for each one of these peaks was made based on previously
established compositional analyses. Consistent with the observed substrate specificity for the
A4,5 glycuronidase, the relative area of the peaks corresponding to 2-O-containing
disaccharides remained unchanged over the time course of the experiment (>18 hours). On
the other hand, peaks corresponding to disaccharides lacking the 2-0 sulfate were eliminated
to various extents over the course of the experiment. The relative rates of their
disappearances corresponded exactly to their substrate preference as determined in the
previous kinetic experiment. AUHNAc,6S (peak 8) was essentially hydrolyzed within one
minute; AUHNs,6s (peak 4) and AUHNS (peak 6) were hydrolyzed approximately 75 % and
50%, respectively. These two latter substrates were completely depleted by 30 minutes.
In addition to the assigned disaccharides, the A4,5 glycuronidase also acted on a
heparinase-generated tetrasaccharide (identified as peak 2 in Figure 5.8). The assignment of
Peak 2 as a tetrasaccharide was confirmed by MALDI-MS, which indicated a mass of 1036.9
Daltons that corresponds to a singly acetylated tetrasaccharide with four sulfates.
Disaccharide analysis of this tetrasaccharide further indicated that it does not contain a 2-0
sulfate at the non-reducing end. The A4,5 enzyme hydrolyzed approximately one-half of the
unsaturated starting material after one minute. The relative rate of hydrolysis for this
tetrasaccharide roughly corresponded to the rate observed for the disaccharide AUHNS (peak
6). This exciting result clearly indicates that a longer chain saccharide such as a
tetrasaccharide is in fact a substrate for the A4,5 catalyzed hydrolysis.
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5.4 Discussion
In this paper, we report the first-known molecular cloning of the A4,5 glycuronidase
gene from F. heparinum as well as its recombinant expression in E. coli as a highly active
enzyme. We also report a biochemical characterization of its substrate specificity. Such a
description provides important insight into possible structure-function relationships
underlying its unusual catalytic function. It also demonstrates that the A4,5 glycuronidase,
like the other GAG-degrading enzymes we have cloned (20, 28), cleaves oligosaccharides in
a non-random fashion. For this reason, we feel that the A4,5 glycuronidase is useful as a
complementary enzymatic tool in our PEN-MALDI method for sequencing complex
polysaccharides (13).
Our attempts to recombinantly express the intact glycuronidase in E. coli as a soluble,
active protein were unsuccessful. Several attempts to refold the protein from bacterial
inclusion bodies also failed. The most likely explanation for this insolubility points to the
presence of a very hydrophobic region within the wild-type protein sequence spanning the
first 20 amino acids. This N-terminal sequence is also predicted to comprise a cleavable
prokaryotic signal sequence with the most likely cleavage site occurring between position
G20 and M21 (Figure 5.3). Within this sequence, we also find the alanine repeat
AXXAXXAXXXXA that may serve as part of the actual cleavage recognition sequence (24).
This signal peptide would indicate a periplasmic location for the glycuronidase with the N-
terminus of the secreted (mature) protein beginning with M21. We recombinantly expressed
this mature variant (A4,520) in which the signal sequence was replaced entirely by an N-
terminal 6X His purification tag.
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Even in our initial purifications, it was evident that our cloned A4,5 glycuronidase
possessed a specific activity that far exceeded the activity rates reported for the
Flavobacterial enzyme in the early literature (18). These early studies however used only
partially purified enzyme under much different reaction conditions that included milligram
quantities of both substrate and enzyme. In a direct and more rigorous comparison between
the recombinant and native enzymes, we find that the recombinant enzyme (A4,5A20)
possessed a roughly three-fold higher specific activity relative to the native Flavobacterial
enzyme when measured under identical reaction conditions. From these results, it is clear that
the activity of cloned enzyme is not compromised whatsoever by its recombinant expression
in E. coli. Rather, the observed rate discrepancy is likely due to subtle differences in protein
purification and storage and not to any intrinsic enzymatic properties.
The recombinant A4,5 glycuronidase exhibits a sharp ionic strength dependence as
indicated by the shape of the NaCl titration curve (Figure 5.6A). These results are interesting
given both the ionic character of the disulfated heparin disaccharide used in this experiment
as well as the many ionic residues present within the enzyme that may function in substrate
binding and/or catalysis; many of these charged residues are conserved in structurally and
functionally related enzymes (Figure 5.4). From a substrate perspective, all of the unsaturated
disaccharides examined possess a negative charge (at pH 6.4) due to the C6 carboxylate of
the uronic acid. It is possible that this acid acts as a critical structural determinant, especially
given its proximity to the A4,5 bond. Charge neutralization of 6-0 sulfate (e.g., in AUHNS6S)
could possibly be another contributing factor. From the enzyme perspective, the recombinant
glycuronidase (A4,52 °0 ) does possess 47 basic residues (theoretical pI of 8.5), including
R151, R211, and R246 whose positions are invariantly conserved among the different
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glycuronidases examined. These basic amino acids may possibly interact with the uronic acid
carboxylate. At the same time, A4,5 also possesses 44 acidic residues. At least ten of these
positions are highly conserved. Charge masking of some of these ionic residues (either acidic
or basic) by increasing salt concentration might interfere with enzymatic activity. A similar
observation of this ionic strength dependency has been made for the heparinases (29).
We also observed a bell-shaped pH profile with a 6.4 optimum. The 6.4 pH optimum
generally agrees with results originally reported for the F. heparinum A4,5 as well as for
more recent results published for an unsaturated glucuronyl hydrolase purified from Bacillus
sp. GL1 (26). This result logically implicates one or more histidine residues functioning in
catalysis. While there are 11 histidines present within the primary sequence, only three
histidines (HI 15, H201, and H218) appear to be highly conserved. The precise catalytic
function of these histidines remains to be determined. Interestingly, catalytically critical
histidines also exist in all three heparin lyases (30) as well as chondroitin AC lyase (31) from
Flavobacterium heparinum. While these latter two classes of enzymes cleave
glycosaminoglycans by a somewhat different mechanism compared with the A4,5
glycuronidase (i.e., -elimination vs. hydrolysis), all three enzymes would presumably
involve acid-base catalysis viz the imidazole ring of the histidine.
We approached the question of substrate specificity from three structural
perspectives: (1) the nature of the glycosidic linkage; (2) the relative sulfation pattern of the
unsaturated disaccharide; and (3) the role of saccharide chain length (e.g., di- vs.
tetrasaccharide). As expected, our results indicate that for the recombinant A4,5
glycuronidase, there is an unambiguous preference for the 14 linkage over the 13
linkage making heparin/heparan sulfate rather than chondroitin/dermatan and/or hyaluronan
143
the best substrate. This observation agrees with earlier, published reports (23) likewise
indicating the critical importance of the 14 linkage position. It also clearly distinguishes
this particular Flavobacterial unsaturated glycuronidase from the chondroitin glycuronidase
isolated from the same bacterium; the latter enzyme has been shown to cleave only 1 -3
linked disaccharides (32). It should be noted, however, that while this linkage position is
clearly important for heparin/heparan sulfate A4,5 glycuronidase substrate discrimination, it
is not absolute. Both chondroitin and hyaluronan A4,5 disaccharides were hydrolyzed, albeit
at much slower rates and using higher enzyme concentrations than were required to
hydrolyze heparin disaccharides.
We also present a kinetic pattern of the A4,5 glycuronidase with regards to the
specific sulfation within a heparin disaccharide. First and foremost, we find that unsaturated
saccharides containing a 2-0-sulfated uronidate (AU2s) at the non-reducing end are
uncleavable by the A4,5 glycuronidase. Furthermore, the inability of a 2-0-sulfated
disaccharide to competitively inhibit the hydrolysis of non 2-0-containing disaccharide
substrates (such as AUHNAc) further suggests that the presence of a 2-0 sulfate precludes
binding of this saccharide to the enzyme. Therefore, 2-0 sulfation, along with linkage
position, is another unequivocal structural constraint. Based on these observations, it is also
clear that both in vivo and in vitro, the 2-0 position of the unsaturated uronidate must first be
desulfated if the A4,5 glycuronidase is to subsequently hydrolyze the glycosidic bond.
In considering the effect of specific sulfate groups present on the glucosamine, the
enzyme may be loosely summarized as having a graded preference for 6-0-sulfation but a
clear selection against unsubstituted or sulfated amines. We must emphasize that this
hierarchy is not an absolute distinction given the fact that the enzyme cleaved all the non 2-
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O-containing heparin disaccharides that we examined. Instead, it is based on relative kinetic
parameters (Table 5.2). This apparent substrate discrimination at the N and 6 positions of the
glucosamine appears to be somewhat contextual, especially in the case of 6-0-sulfation. That
is, while 6-0 sulfation may bestow a favorable selectivity to a saccharide substrate, this
positive effect is offset by the presence of a deacetylated amine (e.g., AUHNAc,6S VS.
AUHN,6S or AUHNS,6S)- While the exact reason for this structural discrimination needs to be
investigated, it is tempting to speculate a positive role of the acetate itself, e.g., in satisfying
an important van der Waals interaction.
We feel that the unequivocal bias the A4,5 demonstrates against 2-0-sulfated
uronidates along with a so-called "N-position" discrimination for the glucosamine can be
exploited for use of the glycuronidase as an analytical tool for the compositional analyses of
heparinase-treated oligosaccharides. In fact, we were able to predict the extent and relative
rates by which specific disaccharide species would disappear (i.e., due to the glycuronidase-
dependent loss of absorbance at 232 nm.), based entirely on our kinetically defined substrate
specificity determinations (Figure 5.8). As expected, all 2-0-sulfate containing disaccharides
were refractory to hydrolysis by the A4,5 glycuronidase. On the other hand, the remaining
disaccharides were hydrolyzed in a time-dependent fashion that corresponded to their relative
substrate specificities (i.e., AUHNA,6S> AUHNS, 6S>AUHNS)-
From this experiment, another important observation was made, namely that the A4,5
glycuronidase also hydrolyzes A4,5 unsaturated tetrasaccharides. It is also very interesting to
note that this particular tetrasaccharide is as good of a substrate as the disaccharide AUHNs.
This observation may argue against a substrate discrimination used by the enzyme that is
negatively based on increasing molecular weight (at least up to a tetrasaccharide) as was first
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reported (23). It also leaves open the possibility that the A4,5 glycuronidase interacts
predominantly with the unsaturated disaccharide unit residing at the non-reducing end. The
actual effect of oligosaccharide chain length on relative glycuronidase activity has to be more
thoroughly examined. In particular, it will be useful to address structure-activity relationships
as they pertain to internal saccharide positions.
The A4,5 unsaturated glycuronidase is an interesting and unusual enzyme whose
catalytic mechanism merits further investigation. The work presented here is foundational to
future studies relating molecular structure to this function. At the same time, its unique
substrate specificity makes this enzyme an excellent tool for characterizing HSGAG
composition and fine structure.
146
5.5 References
1. Habuchi, 0. (2000) Biochim Biophys Acta 1474, 115-27.
2. Tumova, S., Woods, A., and Couchman, J. R. (2000) Int JBiochem Cell Biol 32, 269-
88.
3. Folkman, J., Taylor, S., and Spillberg, C. (1983) Ciba Found Symp 100, 132-49.
4. Blackhall, F. H., Merry, C. L., Davies, E. J., and Jayson, G. C. (2001) Br J Cancer
85, 1094-8.
5. Shukla, D., Liu, J., Blaiklock, P., Shworak, N. W., Bai, X., Esko, J. D., Cohen, G. H.,
Eisenberg, R. J., Rosenberg, R. D., and Spear, P. G. (1999) Cell 99, 13-22.
6. Perrimon, N., and Bernfield, M. (2000) Nature 404, 725-8.
7. Lyon, M., Rushton, G., Askari, J. A., Humphries, M. J., and Gallagher, J. T. (2000) J
Biol Chem 275, 4599-606.
8. Esko, J. D., and Lindahl, U. (2001) J Clin Invest 108, 169-73.
9. Conrad, H. (1998) Heparin-binding proteins, Academic press.
10. Drummond, K. J., Yates, E. A., and Turnbull, J. E. (2001) Electrophoresis 22, 304-
10.
11. Calabro, A., Midura, R., Wang, A., West, L., Plaas, A., and Hascall, V. C. (2001)
Osteoarthritis Cartilage 9, S 16-22.
12. Rhomberg, A. J., Ernst, S., Sasisekharan, R., and Biemann, K. (1998) Proc Natl Acad
Sci USA 95, 4176-81.
13. Venkataraman, G., Shriver, Z., Raman, R., and Sasisekharan, R. (1999) Science 286,
537-42.
14. Shriver, Z., Raman, R., Venkataraman, G., Drummond, K., Turnbull, J., Toida, T.,
Linhardt, R., Biemann, K., and Sasisekharan, R. (2000) Proc Natl Acad Sci U S A 97,
10359-64.
15. Payza, A. N. a. K., E.D. (1956) J. Biol. Chem. 223, 853-858.
16. Linker, A., and Hovingh, P. (1965) JBiol Chem 240, 3724-8.
17. Dietrich, C. P. (1969) Biochem J 111, 91-5.
18. Warnick, C. T., and Linker, A. (1972) Biochemistry 11, 568-72.
19. McLean, M. W., Bruce, J. S., Long, W. F., and Williamson, F. B. (1984) Eur J
Biochem 145, 607-15.
20. Sasisekharan, R., Bulmer, M., Moremen, K. W., Cooney, C. L., and Langer, R.
(1993) Proc Natl Acad Sci U S A 90, 3660-4.
21. Current Protocols in Molecular Biology (1987), John Wiley and Sons, New York.
22. Nielsen, H., Engelbrecht, J., Brunak, S., and von Heijne, G. (1997) Protein Eng 10, 1-
6.
23. Hovingh, P., and Linker, A. (1977) Biochem J 165, 287-93.
24. von Heijne, G. (1988) Biochim Biophys Acta 947, 307-33.
25. Linker, A. (1979) Biochem J 183, 711-20.
26. Hashimoto, W., Kobayashi, E., Nankai, H., Sato, N., Miya, T., Kawai, S., and
Murata, K. (1999) Arch Biochem Biophys 368, 367-74.
27. Linker, A., Hoffman, P., Meyer, K.,Sampson, P., and Korn, E. D. (1960) J. Biol.
Chem 235, 3061-3065.
28. Pojasek, K., Shriver, Z., Kiley, P., Venkataraman, G., and Sasisekharan, R. (2001)
Biochem Biophys Res Commun 286, 343-51.
147
29. Lohse, D. L., and Linhardt, R. J. (1992) JBiol Chem 267, 24347-55.
30. Pojasek, K., Shriver, Z., Hu, Y., and Sasisekharan, R. (2000) Biochemistry 39, 4012-
9.
31. Huang, W., Boju, L., Tkalec, L., Su, H., Yang, H. O., Gunay, N. S., Linhardt, R. J.,
Kim, Y. S., Matte, A., and Cygler, M. (2001) Biochemistry 40, 2359-72.
32. Gu, K., Linhardt, R. J., Laliberte, M., and Zimmermann, J. (1995) Biochem J 312,
569-77.
148
A. 0 300
~; 225
8 150
1 75
Timc,'min.
Is.
0
a
C. r .7--
Figure 5.1. Purification of A4,5 glycuronidase from Flavobacterium and resultant proteolytic
products. A. C18 chromatogram of the purified enzyme. B. Purification of A4,5 peptides by
reverse phase HPLC following trypsinization of the native protein. C. Amino acid sequence
of select peptides isolated in B.
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Figure 5.2. A4,5 glycuronidase gene sequence. Shown here are both the coding and flanking DNA
sequences of the full length sequence. The coding sequence of 1209 base pairs contains an ORF encoding
a putative protein of 402 amino acids. Initiation and termination codons are highlighted in bold. Possible
Shine-Dalgarno (SD) sequence is boxed. Presumed signal sequence is underlined and its cleavage site
delimited by a vertical arrow. Eco R1 restriction site is double-overscored. Also shown are the degenerate
primer pairs (shown as arrows) used to PCR amplify DNA hybridization probes 1 and 2 as well as the
relative positions of purified A4,5 peptides (shaded in gray) for which direct sequence information was
obtained.
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Figure 5.3. Assignment of a putative A4,5 glycuronidase signal sequence. Theoretical signal
sequence determination using amino acids 1-65. Indices were calculated using SignalP V. 1.1
using networks trained on gram-negative bacteria. A vertical arrow indicates putative
cleavage site located between G20 and M21.
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Figure 5.4. CLUSTAL W multiple sequence alignment of A4,5 glycuronidase and select
unsaturated glucuronyl hydrolases. Protein sequences were selected from an initial BLASTP
search of the protein database. Identical amino acids are shaded in dark gray, near invariant
positions in charcoal, and conservative substitutions in light gray. Gen bank accession
numbers are as follows: Bacillus sp. (AB019619); Streptococcus pneumoniae (AE008410);
Streptococcus pyogenes (AE006517); Agaricus bisporsus (AJ271692); Bactobacillus
halodurans (AP01514).
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Figure 5.5. Recombinant A4,520 protein expression and purification. SDS-PAGE of A4,5
protein fractions at various purification stages following expression in BL21 (DE3) as a
6XHIS N-terminal fusion protein. Shown here is a 12% gel stained with Coomassie-Brilliant
blue. Lane 2, lysate from uninduced bacterial cells; Lane 3, crude cell lysate from induced
cultures; Lane 4, Ni+2 chelation chromatography purification; Lane 5, thrombin cleavage to
remove N-terminal 6X His purification tag. Molecular weight markers (Lanes 1 and 6) are
also noted.
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Figure 5.6. A4,5 glycuronidase biochemical reaction conditions. A. NaCl titration. B. Effect of
reaction temperature. Inset (B): A4,5 glycuronidase reaction rates measured at varying temperatures
by the disappearance of UV absorbance (232nm). 25C, (0); 300C, (0); 370C, (E); 420C, (A).
Relative enzyme activities in A and B were derived from initial rates and were normalized to 100%
activity represented by 100 mM NaCl and 30°C, respectively. C. pH profile. Km and kcat values for
the pH profile were extrapolated from Michaelis-Menten kinetics as described in the Methods. The
disulfated heparin disaccharide AUHNS,6s was used in all three experiments.
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Figure 5.7. Disaccharide substrate specificity. A. Kinetic profiles for heparin disaccharidesof varying sulfation. Initial rates were determined using 200 nM enzyme under standard
conditions. V vs. [S] curves were fit to Michaelis-Menten steady state kinetics using a non-linear least squares analysis. B. Lineweaver-Burke representation of the data shown in A.AUHNAc,6S (); UHNac (); UHNS,6S (A); AHNS (); AUHNH2 (); U2sHN,6S (+).
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Figure 5.8. Tandem use of heparinases and A4,5 glycuronidase in HSGAG compositional
analyses. 200 ptg heparin was exhaustively digested with heparinases I, II, and III, after
which A4,5 was added for a varying length of time. Unsaturated disaccharide products were
resolved by capillary electrophoresis. Assignment of saccharide composition shown for each
peak was confirmed by MALDI-MS. Each electrophoretogram represents varying time of
A4,5 glycuronidase treatment: A. minus A4,5 enzyme control; B. 1 minute (partial)
incubation; C. 30 minute (exhaustive) incubation.
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Purification Step Protein Yield Specific Activity Fold
(mg) (pmoles DiS/ min/ mg purification
protein)
Crude lysate 400 4.7 --
Ni+ 2 205 12.9 2.7
chromatography
Thrombin cleavage 205 13.6 2.9
Table 5.1. Purification summary for the recombinant A4,5 glycuronidase. Specific activities for
each fraction were measured using 800 ng of protein and 120 RIM of the unsulfated heparin
disaccharide (DiS) AUHNAc in a 100 [tl reaction volume. The fold purification was calculated
relative to the specific activity measured for the crude lysate.
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Disaccharide kcat (sec 1 ) Km (M) kcat/Km Relative kcat/Km
substrates
AUHNAc 15.3 + 0.9 283 + 31 0.054 0.49
AUHNAc 6S 11.7 + 0.6 107 + 15 0.110 1.0
AUHNs 4.9 + 0.4 251 + 40 0.020 0.18
AUHNS. 6s 8.8 + 0.9 334 + 57 0.026 0.24
AUHNH2 6S 2.4 + 0.2 235 + 40 0.010 0.09
AU 2sHNS N.A. N.A N.A. N.A.
Table 5.2. Kinetic parameters for heparin disaccharides. kcat and Km values were determined
from non-linear regression analyses of the Michaelis-Menten curves presented in Figure 7.
*N.A., no activity was detected forAU2sHNs.
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CHAPTER 6
Heparan Sulfate Glycosaminoglycan Modulation of
Embryonic Stem Cell to Endothelial Cell Differentiation
Synopsis: The directed differentiation of embryonic stem (ES) cells holds an immense
potential for regenerative medicine, necessitating an understanding of the mechanisms
regulating self-renewal and cell fate decisions. Although attempts have been made to
elucidate the key regulatory components of differentiation using transcriptiomic and
proteomic approaches, these fail to capture the complete complexity of this process, which
requires integration of the role of glycomics on differentiation. Heparan sulfate
glycosaminoglycans (HSGAGs) are components of the extracellular matrix and constitute
one of the major components of a cell's glycome. In the present study, we merged an
enzymatic decomposition-based analysis of HSGAGs with a transcriptomal dissection of
HSGAG biosynthesis to elucidate the role of the glycome in the differentiation of ES cells
into endothelial cells. Murine ES cells, directed to differentiate under LIF-free conditions,
progressively lost the stem cell marker, Oct-4, and acquired endothelial cells markers, such
as von Willebrand Factor, VE-Cadherin, VEGF-R2 and eNOS, as detected by flow
cytometry, confocal microscopy and real time-PCR. Compositional analysis of HSGAG
structure by capillary electrophoresis revealed an increase in the quantity of HSGAGs with
progressive differentiation, which was paralleled by an increase in the transcript levels of key
HSGAG-biosynthetic enzymes. Ablation of the HSGAG-biosynthetic machinery through
sodium chlorate-treatment, or the enzymatic decomposition of HSGAGs via treatment with
heparinases, inhibited the formation of endothelial cells, although differentiation to other cell
types did proceed as evidenced from the progressive loss of the Oct-4 signal. Reconstitution
of the HSGAG moiety in sodium chlorate-treated cells by the exogenous addition of heparin
partially recovered the formation of endothelial cells, suggesting that HSGAGs play a key
role in the differentiation of ES cells into endothelial cells. Western blot analysis of the
phospho-ERK levels suggest that HSGAGs may impinge on differentiation of ES cells into
endothelial cells possibly through the MAPK pathway. The current study, for the first time,
implicates the role of the glycome in the directed differentiation of embryonic stem cells,
which should now be integrated into the systems biology approach for a molecular
understanding of stem cell differentiation. Furthermore, the potential to regulate stem cell
differentiation by modifying HSGAGs opens up new treatment modalities for regenerative
medicine.
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CHAPTER 6
Heparan Sulfate Glycosaminoglycan Modulation of
Embryonic Stem Cell to Endothelial Cell Differentiation
6.1 Introduction
Embryonic stem (ES) cells are pluripotent cells derived from the inner cell mass of
developing blastocysts and have the unique ability to differentiate into any adult cell type (1).
The ease of maintenance of ES cells in vitro in an undifferentiated pluripotent state,
combined with their potential to differentiate into any cell type offers a unique opportunity to
understand the biological processes that govern differentiation processes, capturing a
perspective of the earliest stages of embryo development. Harnessing this potential of ES
cells holds the key to regenerative medicine, contingent upon the development of methods to
control their differentiation and expansion in vitro.
One of the attractive targets for regenerative medicine is the establishment of a viable
vasculature. The vascular system is laid down during early developmental stages, and is
fairly quiescent in the adult (2, 3). Neovascularization (the formation of new blood vessels)
can also occur in the adult, albeit in a strictly regulated manner in certain physiological
conditions, such as the reproductive cycle, tissue regeneration and wound healing (4).
However, excessive and unregulated blood vessel formation has been implicated in multiple
pathological conditions such as tumor angiogenesis and arthritis, making inhibition of
neovascularization an attractive and tractable therapeutic goal. In contrast, some pathological
conditions, such as diabetes, hypercholesterolemia and advanced age, are associated with
impaired neovascularization which results in ischemic tissue (5-7). This impaired
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neovascularization is in large part due to endothelial cell dysfunction and the promotion of
neovascularization in such conditions has significant therapeutic implications in treating
patients. One way to achieve this is via engineering of the impaired vasculature component in
vivo, or the ex-vivo regeneration and transplantation of reconstituted vascular tissue.
The essential component of the vasculature that plays a key role in neovascularization
is the endothelial cells lining the vessels. Numerous studies have attempted to regenerate the
vascular tissue by using primary endothelial cells and endothelial progenitor cells (8, 9).
However, these approaches are limited by the finite life span of primary cells, and by the low
abundance of progenitor cells in circulating blood. These limitations necessitate the
development of newer approaches for engineering of the vasculature.
Recent studies have revealed the potential for embryonic stem cells to differentiate
into endothelial cells, making embryonic stem cells an attractive resource for regenerative
therapies (10). However, the key limitation in using ES cells in regenerative therapies comes
from the fact that upon differentiation, ES cells form a heterogeneous cell mixture as a result
of their pluripotency. For example, murine ES cells were shown to give rise to multiple cell
types including endothelial, hematopoietic, smooth muscle and neuronal cells in vitro (11).
Furthermore, when injected in mice, ES cells have been shown to form teratocarcinomas and
malignant transformations (12, 13). Thus, dissection of factors that regulate the
differentiation process of ES cells is of extreme importance for developing regenerative
therapies, so that ES cells can be directed to differentiate towards a homogeneous cell
population. Among other factors, the extracellular matrix has been shown to be a critical
modulator of ES differentiation (11).
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One of the key components of the extracellular matrix (ECM) is a group of complex
sugars called heparan sulfate glycosaminoglycans (HSGAGs). HSGAGs are resident
components of the ECM and form a major part of a cell's glycome. HSGAGs interact with
numerous proteins and play a dynamic role in various cellular events such as proliferation,
morphogenesis, adhesion, migration and cell death, tumor metastasis and neovascularization
(for an extensive review, see reference (14)). Interestingly, although there are many reports
on the proteomal and transcriptomal analysis of stem cell differentiation (15), no previous
studies has been performed on elucidating the role of the glycome component in stem cell
differentiation.
In the current study, we report for the first time that the differentiation of stem cells
into endothelial cells is impinged on by the glycome, specifically the HSGAG component of
the cells. We demonstrate that modification of the HSGAG component of the ES cells, using
enzymatic or pharmacological approaches, inhibits the differentiation into endothelial cells,
albeit differentiation still proceeds as evident from the progressive loss of stem cell specific
marker. Furthermore, we have shown that HSGAG modulation impinges on the mitogen
activated protein kinase (MAPK) pathway, indicating that HSGAG modulation of ES cell
differentiation could possibly be mediated through the MAPK pathway.
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6.2 Experimental Procedures
Cell Culture
Mouse embryonic stem cells (J1) were grown in DMEM with 2mM L-glutamine
(GIBCO) adjusted to contain 100mM sodium pyruvate, 10mM nonessential amino acids and
1.5g/L sodium bicarbonate, with 15% fetal bovine serum (Hyclone) and supplemented with
100 units/mL penicillin G (Sigma), 100 gg/mL streptomycin sulfate (Sigma), 30 mM beta-
mercaptoethanol (Sigma) and 1000 units/ml murine Leukemia Inhibitory factor, LIF
(Chemicon). The cells were plated in 10cm cell culture dishes, coated with 0.1 % gelatin B
(Sigma) and grown at 37C in a 5% CO2 humidifier incubator. The culture medium was
changed every 2 days. The cells were subcultured at a split ratio of 1:10 when they reached
80% to 90% confluency, using a 0.25% trypsin-EDTA solution (Sigma). To induce
formation of embryoid bodies and differentiation into endothelial cells, J1 cells were plated
at a density of 1.25x 105 cells/ 100 mm dish, or 3x104 cells/ 6 wells, and cultured in the
absence of LIF for defined time periods. Fresh media was replenished every 2 days.
Enzymatic and Chemical Treatment of Cells
Heparinase-III (Hep-III) was prepared as described previously (16). Heparinase-I
(Hep-I) was a generous gift of Momenta Pharmaceuticals. Sodium chlorate and heparin were
purchased from Sigma and Cambrex BioWhittaker respectively. To enzymatically modify
the HSGAG -glycome signature of the cells, cells were washed with phosphate buffer saline
and incubated with Hep-I or Hep-III for 30 minutes everyday at 37 °C in serum free DMEM.
Digested HSGAG residues were removed by washing the cells, and cells were then fed with
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fresh media. In an additional experiment, cells were cultured with medium containing sodium
chlorate which blocks the sulfation of HSGAGs. In a reversal experiment, heparin was added
to the culture to overcome the chlorate-induced synthetic block. Treated cells were analyzed
for differentiation into endothelial cells between day 3- day 15. Hep-III was added to the
cells at a concentration of 2.5gg/mL, Hep-I was added at a concentration of 1.5gg/mL,
sodium chlorate at 10mM, and heparin (20gg). The concentrations of enzymes were
optimized to exhaustively cleave all cell surface HSGAGs in the given period of time. All
enzymes and chemicals were diluted in serum free DMEM.
Flow Cytometrv
Cells were harvested at defined time points during differentiation, incubated with rat
monoclonal antibody against CD16/CD32 (1:50 dilution, Pharmingen) to block Fct receptors,
and incubated further with the primary antibody against Von Willebrand Factor (vWF)
(Dako, rabbit polyclonal, added at a 1:100 dilution). An isotype-matched polyclonal
antibody IgG (Pharmingen) was used as the control. Cells were then washed twice and were
incubated with FITC-conjugated secondary antibody (Jackson ImmunoResearch) in a 1:100
dilution, washed twice and taken up in OptiMEM (GIBCO/BRL) and analysed on a Becton
Dickinson FACScan flow cytometer (excitation 488 nnm, argon laser; emission 580/30).
Confocal Microscopy
For microscopic analysis of endothelial cells, the differentiating J1 cells were fixed in
cold methanol at designated time points, blocked in goat serum, and probed overnight with a
rabbit primary antibody against vWF, an endothelial cell marker, or Oct-4, a stem cell
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marker. The sections were washed and re-probed with a goat secondary antibody coupled to
FITC. The nuclei were counterstained with propidium iodide. Images were captured using a
Leica LSM510 confocal microscope at a 512x512 pixels resolution. Fluorochromes were
excited with 488 nm and 543 nm laser lines, and the images were captured using 505-530 BP
and 565-615 BP filters at a 512x512 pixel resolution.
Real time PCR
RNA was isolated from J1 cells using TRIzol (Invitrogen) and RNAlater (Qiagen)
according to the manufacturer's protocol. Single stranded cDNA was generated via oligo-dT
primed reverse transcription, and genes serving as markers for differentiation were quantified
using an Abi Prism 7700 real-time PCR thermocycler (Applied Biosystems). Expression
levels were obtained for the marker genes Oct-4, VE-cadherin, VEGF-R2, and eNOS, with 13
-actin used as a control. PCR conditions involved denaturation for 10 min at 95C, followed
by 40 cycles of denaturation for 20 sec at 94C, and annealing and extension for 1 min at
60°C. cDNA isolated from J1 cells and primers for the described genes were mixed with
SYBR Green PCR Mastermix (Applied Biosystems) for real-time quantification according to
the manufacturers instructions. Primers used were 5'-ccaatcagcttgggctagag-3' and 5'-
ctgggaaaggtgtccctgta-3' for Oct-4; 5'-accgagagaaacaggctgaa-3 'and 5'-agacggggaagttgtcattg-
3'for VE-Cadherin; 5'-ggacagtgctccaaccaaat-3' and 5'-gttcacactgcagacccaga-3' for TIE-2;
5'-gctttcggtagtgggatgaa-3' and 5'-ggccttccatttctgtacca-3' for VEGF-R2; 5'-
tcttcgttcagccatcacag-3' and 5'-cctatagcccgcatagcgta-3' for ENOS; 5'-agccatgtacgtagccatcc-'3
and 5'-ctctcagctgtggtggtgaa-'3 for 13-Actin. The sulfotransferase primers and conditions were
chosen as described elsewhere (Kiziltepe et al., manuscript in preparation). Relative and
165
normalized levels of gene expression were obtained according to the equation: 2 -(Ct (gene) - Ct (P-
Actin)) where Ct is the cycle number at which amplification of each gene crossed an arbitrary
threshold within the exponential phase of amplification. Gene expression levels were further
normalized to expression levels prior to differentiation.
Isolation and Compositional Analysis ofHSGAGs
Cell surface HSGAG fragments were isolated from J1 cells at various stages of
differentiation. Briefly, cells were washed with PBS, and treated with trypsin/EDTA
(GibcoBRL) at 37 °C for 25 min to harvest cell surface proteoglycans. The resulting
cell/trypsin solution was boiled for 10 min to deactivate the trypsin and other proteins. The
solution was centrifuged at 4500g, the supernatant was collected and concentrated by
centrifuging in a Centriprep-3 (Amicon). The concentrated supernatant was run through
ultrafree-DEAE (Pharmacia) that had been equilibrated with 0.1 M sodium phosphate buffer,
pH 6.0, that contained 0.15 M NaCl. The bound HSGAG fragments were washed and eluted
with 0.1 M sodium phosphate buffer, pH 6.0, that contained 1.0 M NaCl. The fragments were
then concentrated and buffer-exchanged into ultra-pure water by application to a Microcon
filter (molecular weight cutoff = 3,000 Da). The samples were exhaustively digested
overnight with a mixture of Hep-I-III (1 milliunit each) in 25 mM sodium acetate and 1 mM
calcium acetate, pH 7.0. The samples were analyzed by capillary electrophoresis using a
high-sensitivity flow cell under reverse polarity with a running buffer of 50 mM
Tris/phosphate, pH 2.5. Identities of the resultant saccharides were determined based on co-
migration with known standards.
166
Western Blotting
For elucidating the biochemical pathways involved downstream of the modulation of
the cell surface sugars, protein contents of the embryoid bodies were solubilized by rapid
mixing with 3x SDS sample buffer under reducing conditions. Equivalent amounts of protein
per sample were electrophoretically resolved on 4-12% gradient polyacrylamide gels, and
transferred onto a nitrocellulose (0.22 gim) membrane. The membrane was subsequently
probed with a phosphor-ERK antibody (1:800 dilution, Cell Signaling Technologies), which
specifically detects the phosphorylated forms of ERK1 and 2. The signal was amplified using
a 1:2,000 dilution of the appropriate horseradish peroxidase-conjugated secondary antibody
(BioRad), and the immunocomplexes were visualized using enhanced chemiluminescence
detection (Amersham Life Science). The signal was normalized to the expression of total
ERK1/2, which was detected on the same blot using ERK1/2 specific antibodies (Santa Cruz,
used at a 1:200 dilution). Quantification of the luminescence signal was carried out by a
Kodak 2000R imager.
Statistical analysis
Statistical significance was tested using the Students t-test or one-way ANOVA
followed by Dunnets or Friedman's Post-Hoc test. (Graphpad Prism 3 software). P<0.05 was
considered to be significant.
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6.3 Results
ES cells differentiate significantly towards an endothelial cell population.
To optimize the conditions for efficient differentiation of ES cells into endothelial
cells in vitro, we analyzed the expression levels of ES cell specific and endothelial cell
specific markers at different stages of differentiation under different cell culture conditions.
Specifically, we tested the effects of cell density, the ECM content (i.e., gelatin, collagen,
laminin, matrigel), exogenous addition of growth factors (i.e., VEGF, FGF, HGF and insulin)
and different types of serum (i.e., Sigma FBS and Hyclone FBS). The optimal conditions that
gave a maximum of 30% differentiation into endothelial cells were achieved by plating the
undifferentiated cells onto gelatin B coated tissue culture dishes, at a concentration of
1.25x105 cells/ 100 mm dish, in the presence of 15% Hyclone FBS, 30 mM beta-
mercaptoethanol, 1 mM sodium pyruvate, and in the absence of LIF without further
passaging for 7-15 days. No effects of exogenous addition of growth factors were detected,
possibly due to the presence of sufficient levels of growth factors either coming from the
FBS or produced by the autocrine signaling of ES cells. The ES cell specific marker analyzed
was Octamer-4 (Oct-4) (17) and endothelial cell specific markers analyzed were von
Willebrand Factor (vWF) (18), vascular endothelial growth factor receptor-2 (VEGF-R2)
(19), vascular endothelial cadherin (VE-cad) (20), and endothelial cell specific nitric oxide
synthase (eNOS) (21). The flow-cytometry analysis of the expression of vWF in
differentiating ES cells showed an increase in the proportion of cells expressing detectable
levels of vWF over time (Figure 6.1A). Similarly, confocal microscopy analysis of
differentiating ES cells showed that expression levels of vWF protein increased during
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differentiation reaching a maximum between days 7-15 (Figure 6.1B). Consistently, the
expression levels of the ES cell marker, Oct-4, decreased progressively with time (Figure
6.1B). This temporally converse expression of vWF and Oct-4 indicated an efficient
differentiation of ES cells towards an endothelial cell population. Since vWF is also
expressed in megakaryocytes, although to a lesser extent (18), we confirmed our results by
analyzing the temporal transcriptomal expression of other endothelial cell-specific markers,
VEGF-R2, VE-cadherin and eNOS during differentiation. The real-time PCR results showed
a decrease in the transcript levels of Oct-4, and an increase in the transcript signals of VEGF-
R2, VE-cadherin, and eNOS, 7 days after induction of differentiation (Figure 6.1C). These
results are consistent with the results from the confocal microscopy and flow-cytometry
experiments and suggest significant differentiation towards an endothelial cell population.
HSGAG synthesis is upregulated during differentiation of ES cells.
To investigate the role of HSGAGs in the differentiation of ES cells, first we
analyzed the compositional changes in HSGAGs during differentiation. For this purpose, cell
surface HSGAGs were harvested at different stages of differentiation, normalized to cell
number and subjected to compositional analysis of the comprising disaccharide units by
capillary electrophoresis. Although there was very low levels of detectable HSGAGs on
undifferentiated cells (at day 3), there was a progressive and dramatic increase in the total
levels of sulfated HSGAGs with differentiation (Figure 6.2A).
To further confirm these results, we also investigated changes in the genetic
expression of some critical HSGAG biosynthetic enzymes during differentiation.
Biosynthesis of HSGAGs in mammals is initiated by the formation of a tetrasaccharide
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linkage (Glucuronic Acid-Galactose-Galactose-Xylose) to a proteoglycan core (22). After the
initial formation of this linkage tetrasaccharide, the alternating addition of glucuronic acid
and N-acetyl-glucosamine from their UDP-sugar nucleotide precursors forms a repeating 1,4-
linked disaccharide chain. The disaccharide chain is further modified by a series of
sulfotransferases, of which N-deacetylase-N-sulfotransferase and the 2-0, 3-0, and 6-0
heparan sulfate sulfotransferases play a key role. Tissue and substrate specific isoforms of
many of these sulfotransferases have been discovered, indicating a further level of
complexity in the biosynthesis of HSGAGs (for reviews see references (23, 24)). It is the
sulfotransferases that give HSGAGs their "signature" structure and thus these enzymes are
critical in modulating specific structure-function relationships of HSGAGs (14). We
performed real time PCR analysis for 2-0, 3-0, and 6-0 sulfotransferases, N-deacetylase-N-
sulfotransferase, and their isoforms. This analysis demonstrated that there were significantly
higher levels of all sulfotransferase transcipts as differentiation progressed with time,
supporting the results from the compositional analysis of HSGAGs (Figure 6.2B). These
results suggest a possible role for HSGAGs in differentiation of ES cells.
HSGAGs modulate differentiation of ES cells into endothelial cells.
To dissect the role of HSGAG structure in ES cell differentiation, we modified the
cell surface and extracellular HSGAG moiety of differentiating ES cells using an enzymatic
and pharmacological approach. Specifically, differentiating ES cells were incubated with
Hep -I or Hep-III for 30 minutes every day to cleave the cell surface and ECM HSGAGs at
structurally distinct sites, or cultured in media supplemented with sodium chlorate, which is a
pharmacological inhibitor of the HSGAG biosynthesis (25). Hep-I cleaves the HSGAGs at
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the highly sulfated regions, and Hep-III cleaves the HSGAGs at the undersulfated regions
(26, 27). At the end of enzymatic degradation, the medium containing the enzymes and
HSGAG fragments was replaced with fresh medium. At different time points, the
differentiation of ES cells into endothelial cells was monitored using flow cytometry,
confocal microscopy and real-time PCR. Flow cytometry analysis revealed that all the
treatments inhibited the expression of vWF factor, although to different extents (Figure
6.3A). Hep-I, which cleaves the HSGAGs at the highly sulfated regions, and sodium
chlorate, which inhibits HSGAG biosynthesis, both decreased the proportion of cells
expressing detectable levels of vWF by approximately 5 fold. Hep-III, which cleaves the
HSGAGs at the undersulfated regions, although milder, also showed an inhibitory effect by
-3 fold (Figure 6.3B).
The inhibitory effects of Hep-I, Hep-III and sodium chlorate treatments on vWF
expression were also confirmed by confocal microscopy studies (Figure 6.4A). Interestingly,
none of the treatments had significant effects on Oct-4 levels of differentiating cells (Figure
6.4B). These findings suggest that treatment with Hep-I, Hep-III or sodium chlorate does not
inhibit differentiation of ES cells, but specifically inhibit their differentiation into endothelial
cells. Most importantly, addition of heparin to sodium chlorate treated ES cells during
differentiation reconstituted conditions that favor differentiation towards endothelial cells as
detected by increased vWF staining (Figure 6.4C).
Real time PCR experiments further confirmed these findings. While there was no
effect on Oct-4 transcript levels with any of the treatments, Hep-I and sodium chlorate
treatments significantly decreased the transcript levels of VEGF-R2, VE-Cadherin and eNOS
(Figure 6.5). Hep-III treatment also decreased the transcript levels of VE-Cadherin and
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eNOS, however, surprisingly increased the transcript levels of VEGF-R2 (Figure 6.5).
Orthogonal effects of Hep-I and Hep-III in cell phenotype have also been reported elsewhere
(28) and suggests that HSGAGs modulate differentiation of ES cells into endothelial cells in
a structurally specific manner. Consistent with the confocal microscopy results, real time
PCR results also showed that addition of heparin to sodium chlorate treated ES cells
reconstituted conditions that favor differentiation towards endothelial cells as detected by
increased VEGF-R2, VE-cadherin and eNOS transcript levels.
HSGA Gs may impinge on ES cell differentiation via MAPK pathway.
The MAPK pathway is the downstream convergence point of the signaling of several
angiogenic factors such as VEGF, FGF, HGF, EGF, PDGF and angiopoietins (29). Given the
significant role of these factors in endothelial cell proliferation (for review see reference
(30)), we set out to reveal if HSGAG modulation was impinging on the MAPK pathway of
differentiating ES cells. As shown in Figure 6.6A, 6.6B, treatment of differentiating ES cells
with the HSGAG-modifying enzymes- Hep-I or Hep-III, or the pharmacological inhibitor-
sodium chlorate, inhibits the phosphorylation of ERK1/2. Interestingly this inhibition is
reversed by the addition of exogenous heparin. These results suggest that MAPK pathway is
involved in differentiation of ES cells, and HSGAGs are critical modulators of this pathway.
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6.4 Discussion
Neovascularization is involved in many physiological processes such as development,
reproduction, tissue regeneration and wound healing, and is highly regulated through an
'angiogenic switch' (3, 4). However, aberrant neovascularization underlies many
pathophysiological conditions. For example, in diabetes, hypercholesterolemia and advanced
age, dysfunctional endothelial cells and impaired neovascularization can result in ischemic
tissue (5-7). This can lead to chronic wounds and cause the loss of extremities in over 3% of
all diabetics, or result in impaired cardiovascular function in coronary artery disease'. For
such cases, endothelial cell regeneration and transplantation has potential therapeutic
implications in treating patients.
In a recent study, Levenberg et al demonstrated that embryonic stem cells exhibited
the potential to differentiate into endothelial cells, and form vessel-like structures in vitro and
in vivo (31). In the current study, we used endothelial-specific markers such as vWF, VE-
cadherin, eNOS, and VEGF-R2 to follow the differentiation of ES cells into endothelial cells
over a period of 7-15 days. Both confocal microscopy and flow cytometry analysis suggested
that the stems cells progressively differentiate into endothelial cells, which was supported by
the real-time PCR data. Consistent with earlier reports, we could observe the formation of
cord-like primordial vascular structures by confocal microscopy by day 10 (data not shown),
indicating that the embryoid bodies could serve as an interesting model to study the
molecular mechanisms of vasculogenesis and early angiogenesis.
Although differentiation of embryonic stem cells into endothelial cells is an
established concept, limited knowledge exists on the possible factors that impinge on this
differentiation process. Current studies to elucidate these factors and underlying mechanisms
American Diabetes and Heart association
173
have primarily been based on transcriptomic and proteomic approaches (15). Numerous
studies, including from our laboratory, have established that a third dimension, the glycome,
which includes the cell surface and extracellular matrix HSGAGs, also impinges on the
cellular phenotype. However, no previous studies were done on the role of HSGAGs in stem
cell differentiation, primarily owing to the complexities involved in dissecting HSGAG
structure-function relationships.
In the current study, we dissected the role of HSGAGs in ES cell differentiation into
endothelial cells. Our experiments suggest that the modulation of the HSGAG moiety of
differentiating ES cells, by either enzymatic degradation or by inhibition of their
biosynthesis, inhibits their differentiation into endothelial cells. However, despite these
modulations of the HSGAGs in the cellular microenvironment, there was still significant
decrease in the levels of the ES cell-specific marker, Oct-4. This suggests that although the
differentiation of ES cells specifically into endothelial cells is inhibited following HSGAG
modulation, the overall differentiation process is not inhibited. Intriguingly, in the current
study we detected low levels HSGAGs on the surface of undifferentiated ES cell, and there
was a progressive increase in the highly-sulfated HSGAG signal with differentiation.
Altogether, these findings suggest that although the HSGAG component of differentiating ES
cells are not critical in determining their differentiation state, they play a key role in
determining which cell lineage the differentiation process will yield. Further investigation is
necessary to determine the cell lineage that is obtained.
To dissect the possible signaling pathways impinged by HSGAGs of differentiating
ES cells, we studied the effect of the HSGAG modulation on MAPK pathway. MAPK is a
key convergence point in the signal transduction pathways of multiple angiogenic factors,
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including tyrosine kinase receptor ligands such as FGF, VEGF, HGF, EGF, PDGF and
angiopoietins (29, 32). The potential for some of these factors to promote the differentiation
of stem cells into endothelial cells is well established (33-35), and all these factors can use
HSGAGs as secondary ligand binding sites (36). Our studies showed inhibition of ERK
phosphorylation following treatment with HSGAG-degrading enzymes or sodium chlorate.
This indicates that HSGAGs are important modulators of the upstream MAPK pathway in
differentiation of ES cells into endothelial cells. It is possible that paracrine or autocrine
signaling through the growth factors, which act through the MAPK pathway, could lead to
endothelial cell enrichment as a result of differentiation. Intriguingly, in a recent study, the
inhibition of the MAPK pathway was shown to promote the self renewal of embryonic stem
cells (37), indicating a key role for the MAPK pathway in stem cell differentiation. Further
studies are warranted to dissect out the exact players in the differentiation process, such as by
using pharmacological inhibitors such as PTK787 against VEGFR or antibodies against
FGFR to selectively knock out signaling pathways.
The current study is the first to clearly dissect the role of the glycome, specifically the
role of HSGAGs, in modulating the differentiation of embryonic stem cells into endothelial
cells potentially creating the opportunity to harness the optimal HSGAG compositions for
directed differentiation, the goal for regenerative medicine.
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Figure 6.1. Embryonic stem cell differentiation into endothelial cells. The differentiation of
ES cells into endothelial cells was detected by using cell specific markers. vWF, VEGF-R2,
VE-cadherin, and eNOS were used as endothelial cell specific markers and Oct-4 was used
as ES cell specific marker. (A) Flow cytometry analysis of vWF at different stages of
differentiation. (B) Confocal images of vWF and Oct-4 staining in differentiating ES cells.
(C) Real-time PCR data of VEGF-R2, VE-cadherin, eNOS, and Oct-4 at different stages of
differentiation. The relative mRNA levels are normalized to day 3, in which no significant
differentiation was observed. Altogether, these results show that Oct-4 transcription and
expression progressively diminishes with differentiation, while that of vWF, VEGF-R2, VE-
cadherin, and eNOS increases, suggesting efficient differentiation towards an endothelial cell
population. Representative images are shown.
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Figure 6.2. Analysis of HSGAG composition and HSGAG biosynthesis during
differentiation of ES cells. (A) Capillary electrophoresis chromatograms of HSGAG
components of ES cells at different stages of differentiation. The isolated HSGAGs were
subjected to heparinase I-III digestion and analyzed via capillary electrophoresis. The signal
for di- and tri- sulfated disaccharides increased significantly upon differentiation. (B) Real
time PCR data of HSGAG biosynthetic enzymes at different stages of differentiation. The
transcription of HSGAG biosynthetic enzymes was monitored using real-time PCR. Graphs
show the relative transcriptional levels of 20-sulfotransferases (20ST), 30-sulfotransferases
(30ST), 60-sulfotransferases (60ST), N-Deacetylase-Sulfotransferases (NDST) and their
isoforms at different stages of differentiation. The transcripts of these enzymes progressively
increases as ES cells differentiate. Data from representative experiments are shown.
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Figure 6.3. Flow cytometry analysis of the effects of enzymatic or pharmacological
modification of the HSGAGs on differentiation of ES cells into endothelial cells. (A) Effects
of treatments on vWF staining at different stages of differentiation. (B) The bar plot of %
cells staining positively for vWF in the flow cytometry experiment. Extracellular degradation
of HSGAGs by heparinase I and heparinase III treatment, as well as inhibition of HSGAG
biosynthesis by sodium chlorate, inhibits differentiation of ES cells into endothelial cells.
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Figure 6.4. Confocal microscopy analysis of the effects of enzymatic or pharmacological
modification of the HSGAGs on differentiation of ES cells into endothelial cells. (A) vWF
staining. Extracellular degradation of HSGAGs by heparinase I and heparinase III treatment,
as well as inhibition of HSGAG biosynthesis by sodium chlorate, inhibited differentiation of
ES cells into endothelial cells as detected by vWF staining. (B) Oct-4 staining. Although
differentiation towards endothelial cells is inhibited, overall differentiation still did proceed
as evidenced by Oct-4 staining. (C) Reconstitution experiment by addition of heparin.
Addition of exogeneous heparin to sodium chlorate treated ES cells reconstituted conditions
that favor differentiation towards endothelial cells as detected by increased vWF staining.
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Figure 6.5. Real time PCR analysis of the effects of enzymatic or pharmacological
modification of the HSGAGs on differentiation of ES cells into endothelial cells.
Extracellular degradation of HSGAGs by heparinase I treatment, as well as inhibition of
HSGAG biosynthesis by sodium chlorate inhibited differentiation of ES cells into endothelial
cells (as detected by a decrease in VEGF-R2, VE-cadherin, and eNOS transcript levels),
albeit differentiation still took place (as detected by a concurrent decrease in Oct-4 transcript
levels). Although heparinase III treatment had effects consistent with Heparinase I in general,
it showed an orthogonal effect for VEGF-R2 transcript levels. Addition of exogeneous
heparin to sodium chlorate treated ES cells reconstituted conditions that favor differentiation
towards endothelial cells as detected by increased VEGF-R2, VE-cadherin and e-NOS
transcript levels.
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Figure 6.6. Effects of HSGAG modulation on the MAPK pathway in differentiating ES cells.
(A) Western blots performed with ERK and phospho-ERK antibodies. Western blots showed
that treatment with heparinases or sodium chlorate inhibited the phosphorylation of ERK.
This inhibition is reversed by the addition of exogenous heparin. (B) The bar plot of (A) that
shows the ratio of pERK/ERK with different treatments. These results suggest that MAPK
pathway is involved in differentiation of ES cells, and HSGAGs are critical modulators of
this pathway.
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Chapter 7
Conclusion and Future Directions
A significant part of a cell's glycome is constituted by Heparan Sulfate
Glycosaminoglycans (HSGAGs) - the resident components of the extracellular matrix. With
their 48 possible disaccharide repeat units, HSGAGs are the most information dense
biopolymers. It is becoming increasingly clear that HSGAGs impinge on critical signaling
pathways and modulate fundamental biological processes by binding and modulating the
functions of many proteins. Thus, an understanding of the role that HSGAGs play in
biological processes adds a very important dimension in our understanding of biological
processes in the post-genomic era.
Understanding specific structure-function relationship of HSGAGs has been a very
challenging task. This is primarily due to the high heterogeneity and structural diversity,
combined with the low availability of HSGAGs on the cell surface and extracellular matrix.
In addition, as a result of their highly charged character, it is difficult to isolate HSGAGs
from biological sources in a highly purified state. As a result of these technical challenges,
the development of tools to study specific structure-function relationship of HSGAGs lagged
behind that of proteins and DNA. Recently, enzymatic approaches to cleave HSGAGs in a
structurally specific fashion have been developed to reveal sequence information of
HSGAGs, in a manner analogous to the use of restriction enzymes in DNA restriction
mapping and the use of proteases in obtaining sequence information of proteins.
One of the main focuses of our laboratory has been to clone, recombinantly express
and characterize HSGAG degrading enzymes from Flavobacterium heparinum. These
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enzymes include heparinase-I, heparinase-II, heparinase-III, A4,5-glycuronidase, 2-0-
sulfatase, 3-0-sultafase and N-sulfatase (1). With their unique substrate specificities, each of
these enzymes serves as invaluable tools that can be used to obtain HSGAG sequence
information. Prior to the studies explained in Chapter 5 of this thesis, the repertoire of
HSGAG recombinant enzymes of our laboratory was limited to heparinase-I, heparinase-II
and heparinase-III. Chapter 5 describes the cloning, recombinant expression and
characterization of A4,5-glycuronidase, which is an invaluable addition to the repertoire of
recombinant enzymes that can be used for characterizing HSGAG composition and fine
structure.
The studies presented in Chapter 5 is foundational to future structure-function studies
of A4,5-glycuronidase. This enzyme is particularly suitable for crystallographic structural
studies due to the high yields of pure protein that can be obtained from bacterial cell cultures.
Further biochemical characterization of A4,5-glycuronidase is warranted to reveal the amino
acids critical for substrate binding and catalytic mechanism. Dissection of the catalytic
mechanism of A4,5-glycuronidase would make it possible to engineer variants of this enzyme
with unique substrate specificities, which can be added to the repertoire of HSGAG
degrading enzymes to expand the tools available for HSGAG sequencing. In short, A4,5
glycuronidase is an interesting enzyme whose catalytic mechanism merits further
investigation.
The ultimate goal of our laboratory is to have a broad repertoire of recombinant
HSGAG degrading enzymes with unique substrate specificities, and apply these enzymes to
the micro-sequencing of HSGAGs. With the addition of A4,5-glycuronidase, the current
repertoire includes heparinase-I, heparinase-II, heparinase-III, A4,5-glycuronidase (2-4).
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Very recently, another HSGAG degrading enzyme from Flavobacterium heparinum, 2-0
sulfotase, was added to this repertoire (5). One of the future aims of the Sasisekharan lab is to
continue expanding this Flavobacterium-derived repertoire of HSGAG degrading enzymes.
A complete repertoire would be possible by the addition of several other enzymes such as, 6-
0 sulfatase, the 3-0 sulfatase and the N-sulfatase, to the existing repertoire. A powerful
HSGAG sequencing methodology based on heparinases, MALDI-MS, and capillary
electrophoresis was previously developed (6), and each new addition of a HSGAG degrading
enzyme to the repertoire enables the further improvement of this sequencing methodology.
In addition to their role in sequencing, Flavobacterium-derived HSGAG degrading
enzymes also provide us with invaluable tools that can be used to modify HSGAGs of the
cell surface and ECM to reveal the role of HSGAGs in biological processes. For instance,
heparinases have been used to reveal the role of HSGAGs in tumor progression, metastasis
and angiogenesis (7, 8). Chapter 6 of this thesis describes studies done to elucidate the role of
HSGAGs in differentiation of ES cells into endothelial cells, which has tremendous
implications in the field of regenerative medicine. In these studies, we demonstrated that
modification of the HSGAG moiety of the ES cells, specifically by exogenous addition of
heparinases, or by inhibiting their biosynthesis, inhibited ES cell differentiation into
endothelial cells. Interestingly, differentiation still did proceed as evident from the
progressive loss of the stem cell specific marker, indicating that cells other than of the
endothelial lineage were yielded. Further investigation is necessary to determine which cell
population was obtained as a result of differentiation when the HSGAG moiety was
modified. Additionally, we showed that HSGAG modulation impinges on the mitogen
activated protein kinase (MAPK) pathway, indicating that HSGAG modulation of ES cell
187
differentiation could possibly be mediated through the MAPK pathway. The dissection of the
exact pathways impinged on by HSGAGs that modulate stem cell differentiation requires
further investigation.
Our results show that HSGAGs are critical for ES cell differentiation into endothelial
cells. Intriguingly, earlier studies from our laboratory had demonstrated that the HSGAGs are
key for the survival of endothelial cells, and there is a switch from highly sulfated to
undersulfated with an overall loss of HSGAG when the cells shift from a healthy to apoptotic
state (9). This, in context of the observation that HSGAGs play a key role in the
differentiation of stem cells to endothelial cells, raises a very interesting question: How does
HSGAG fine structure impinge on the dynamic state of endothelial cells? For example,
would inhibition of HSGAG sulfotranserases (i.e., 3-0, 2-0 or 6-0) inhibit differentiation of
ES cells into endothelial cells? If so, which sulfotransferases are critical for differentiation?
Similarly, would the inhibition of sulfotransferases induce apoptosis in an endothelial cell? If
so, which sulfotransferases are critical? These questions are very important in understanding
the effects of HSGAGs on the biology of endothelial cells and needs to be further explored.
Most importantly, questions similar to these can be asked about different types of cells as
well as distinct types of glycosaminoglycans to obtain a more global understanding of the
role of glycosaminoglycans on the biology of a cell.
Additionally, the current finding has significant implications in blood vessel
engineering. For example, by providing ES cells with the right type of HSGAG
microenvironment, it might be possible to direct their differentiation towards endothelial
cells - the essential components of blood vessels. Our results also show that enzymatic
degradation of the HSGAGs of differentiating cells or ablation of the HSGAG-biosynthetic
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machinery inhibited the formation of endothelial cells. This finding has important
implications in regeneration of tissues other than blood vessels. For example, by inhibiting
differentiation towards endothelial cells, it is possible to enrich the differentiating cell
population in other cell types (i.e., neurons, bone marrow and muscle tissue). In short, by
modulating the HSGAG moiety of ES cells, it is possible to direct differentiation towards a
more homogeneous cell population. Thus, the HSGAG paradigm we discovered in ES cell
differentiation opens new approaches and strategies for regenerative medicine and enables
the development of novel molecular therapeutics.
It is becoming increasingly clear that HSGAGs impinge on proteome, and as a result
can also affect the transcriptome (10). The studies reported in Part B of this thesis are the first
to show that differentiation of stem cells into endothelial cells is impinged on by the
glycome, specifically the HSGAG component of the glycome. Thus, this study emphasizes
the significance of the glycome as the third component after the proteome and the
transcriptome, which should now be integrated into the systems biology approach for a
molecular understanding of physiological and pathophysiological processes.
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